R Refacto StocksThe Verdict

Verdicts / All ratings

RMDResmed Incmedium confidenceFiled Sep 7, 2026

Resmed Inc

Watch · 63/100 · medium confidence

By the Refacto Council · 19 lenses convened

Watch
63
Council / 100

Watch · 63/100 · medium confidence

How the council's view has changed

The council has convened on RMD 14 times since Jun 28, 2026. Each entry records where the score landed and what moved it — including the times nothing did.

  1. Lowered 66 → 63 (-3) Watch

    Stock fell 5% and three members trimmed on no-margin-of-safety concerns; two others nudged up on slightly improved momentum and disruption resilience — net score drops 3 points to 63.

    Between the two assessments the stock dropped from $240 to $228, shaving roughly $1.7B off market cap and tightening every valuation multiple slightly. That price move is the dominant new fact: the bear-case DCF ($233) now sits only ~$5 above the current price, making the 'essentially no margin of safety' concern more acute, not less. The 8-K filed September 1 confirmed the MatrixCare sale proceeds will fund an accelerated buyback, which was read as a modest positive for capital return but not a catalyst for re-rating. No new fundamental data arrived — the FY2026 10-K, the Astral accrual figure, and the guidance miss were all already in the prior assessment; the council is largely re-pricing the same facts at a lower share price.

    The value camp moved further negative. Klarman cut from 55 to 52, explicitly because the bear-case DCF barely clears the current price and 79% of DCF value sits in terminal value — a forecast-dependent structure that leaves no cushion for the unresolved Astral recall. Singer echoed the same logic, moving from 48 to 52 (still Watch, but noting no classical catalyst for a re-rating). Greenblatt nudged up from 58 to 62, reflecting a slightly better earnings yield as the price fell, but remained a soft Watch with no conviction buy signal.

    Druckenmiller moved from 48 to 52 — still well below the quality camp — citing the price decline as marginally improving risk/reward on momentum math but explicitly refusing to fight a broken tape into an unresolved guidance miss with no re-acceleration catalyst visible. The AI & Disruption Referee moved from 74 to 78, concluding that ResMed's hardware-anchored device-plus-data model is more durable against disruption than pure software intermediaries; that is a qualitative reassessment of the moat, not a response to new financial data. Lynch ticked from 52 to 55 on the stalwart framework as the PEG compressed slightly (2.23 to 2.12) with the lower price. Mauboussin moved one point to 75, essentially unchanged, noting price expectations are now roughly consistent with a conservative base case.

    The composite fell 3 points to 63 and the call remains Watch. The MatrixCare buyback announcement and the modest valuation improvement from the price drop were not enough to overcome the tightening gap between bear-case DCF and current price, the unquantified Astral recall, and decelerating fundamentals. The council is waiting for a guidance reset or a price that puts a real gap between the bear case and where the stock trades.

    • Stock fell 5% to $228, narrowing the gap between the bear-case DCF ($233) and current price to roughly $5 — the margin-of-safety concern is now more acute than it was at $240
    • MatrixCare sale proceeds earmarked for accelerated buyback (8-K, Sep 1) registered as a modest positive for capital return but provided no new information on growth trajectory or Astral recall scope
    • Klarman cut to 52 citing the bear-case DCF barely clearing current price and 79% of value sitting in terminal value; Singer moved to 52 on the same no-cushion logic
    • Druckenmiller moved from 48 to 52 — a marginal improvement as price fell — but held a broken-tape, no-catalyst stance; still the council's most bearish active voice on timing
    • AI & Disruption Referee raised to 78 on a qualitative reassessment that hardware-anchored CPAP devices face a different and less acute disruption risk than pure software intermediaries — a re-reading of existing facts, not new evidence
    • Greenblatt nudged to 62 and Lynch to 55 as lower price compressed earnings yield and PEG slightly, but neither moved to Buy

    Who movedAI & Disruption Referee (Christensen-style) +4Stanley Druckenmiller +4Joel Greenblatt +4Paul Singer +4Seth Klarman -3

  2. Reaffirmed 66 → 66 Watch

    Score holds at 66 as eight members rescore on the Astral recall and a 3.8% price rise, but bulls and bears cancel out

    Between the two assessments the stock moved from $231.52 to $240.33, the market cap grew by ~$1.3B, and no new SEC filings arrived. The news digest confirmed what the prior assessment had flagged: the Astral ventilator recall drove the FY27 guidance miss, the field-safety accrual had already jumped from $4.8M to $45.7M, and scope and duration remain unquantified. Because the price rose while the DCF value ticked down ($306.60 to $303.91), the implied upside narrowed from 32% to 26%, fractionally widening the already-thin margin of safety concern without resolving it. Eight council members rescored, but their moves offset each other almost perfectly — four cut and four raised — leaving the composite at 66.

    The four members who cut did so for distinct reasons. Greenwald made the largest single move (74→62, pass to watch), concluding that while the moat is real, the current price embeds ~70% premium over EPV (~$141), and he is unwilling to pay for growth he cannot underwrite given the recall overhang. Lynch (58→52) trimmed on decelerating growth and the guidance miss, which disrupts the stalwart-grade earnings visibility he requires. Druckenmiller (52→48) moved on tape evidence: RMD is down ~13% over 52 weeks, sitting ~15.6% below its 52-week high, and estimate revisions are pointing down with no near-term catalyst to reverse momentum. Fisher (78→76) trimmed modestly, flagging the FCF margin contraction (32.3%→29.2%) and the recall as a blemish on an otherwise strong growth record. Greenblatt (62→58) cut on earnings yield at the current price, which scores only modestly on his dual-axis test at P/E 22.8x.

    On the other side, Klarman moved up (52→55): the price rise and the explicit FY27 guidance miss, now in the public record, gave him slightly more confidence that the downside scenario is being priced in, though he still sees no genuine margin of safety. The AI & Disruption Referee moved up (72→74), concluding that the hardware-embedded nature of the AirSense/myAir ecosystem makes a classic disruptive attack from software-only entrants structurally difficult — an argument the council as a whole could not answer. Mauboussin trimmed (76→74) rather than cut, reaffirming the ROIC-vs-WACC spread (~1,330bp) but acknowledging the recall introduces uncertainty he cannot fully quantify from the filings. The net effect of all eight moves is zero on the composite, sustaining the Watch call at 66.

    • Price rose 3.8% while DCF value fell $2.69/share, narrowing upside from 32% to 26% and tightening an already-thin margin of safety
    • Astral recall confirmed as driver of FY27 guidance miss (accrual $4.8M→$45.7M) with scope and duration still unquantified, sustaining the primary bear-case overhang
    • Greenwald made the steepest cut (74→62), moving to Watch after concluding the market price implies a ~70% premium over EPV (~$141) with no recall resolution in sight
    • Druckenmiller cut (52→48) on tape deterioration: stock down ~13% over 52 weeks, ~15.6% below 52-week high, and estimate revisions heading lower with no visible catalyst
    • FCF margin contracted (32.3%→29.2%) and growth is decelerating, giving Lynch and Fisher incremental reason to trim even as absolute FCF hit a record ~$1.7B
    • Klarman and the AI & Disruption Referee moved modestly higher, partially offsetting cuts — Klarman seeing slightly better downside pricing, the Referee concluding hardware embedding makes software-led disruption structurally difficult

    Who movedBruce Greenwald -12Peter Lynch -6Stanley Druckenmiller -4Joel Greenblatt -4Seth Klarman +3

  3. Reaffirmed 66 → 66 Watch

    Score holds at 66/Watch as the 3% price rise narrows DCF upside and the ventilator overhang stays unquantified — six members nudge higher, none cut

    The council's composite score did not move. The stock rose 3.1% ($224.46 to $231.52) in the week between assessments, which compressed the DCF upside from 36.6% to 32.4% and pushed P/E to 21.92x and Price/FCF to 20.25x — modest multiple creep that left the quality-vs-price tension exactly where it was. The 8-K filed August 17 and the Q4 earnings digest confirmed record FCF near $1.7B, a 10% dividend hike to $0.66/quarter, and revenue of $5.65B for FY2026, all of which landed inside what the quality seats had already assumed. The ventilator field-safety accrual (up roughly 10x to $45.7M) and its unquantified FY27 guidance impact — flagged by UBS — remained unresolved, so the bear case did not weaken either.

    Six members moved up by 2 points each. Lynch (52→58) gave the largest single-seat move, concluding more firmly that RMD is a stalwart-to-fast-grower with a one-sentence story, visible device-plus-consumables-plus-SaaS model, and aging-demographics tailwind. Buffett, Munger, Fisher, and Mauboussin each moved from 76 to 78, all anchoring to the same confirmed data: 21.3% ROIC against a ~7.95% WACC, 33.4% operating margin, 29.2% FCF margin, OCF ($1.81B) exceeding net income ($1.52B), and a net-cash balance sheet ($1.47B cash vs. $399M long-term debt). Druckenmiller moved from 48 to 52 — still the most skeptical voice on the council — acknowledging the $1.65B FCF and 10-year ~10% revenue CAGR but refusing to upgrade further because the second derivative of earnings is ambiguous and the ventilator regulatory scope remains opaque.

    The value lenses did not move. Schloss stays at 28 (AVOID), Graham and Klarman at 52 (WATCH), Greenwald's EPV still pegs fair value near $140-152 — roughly 50% below the current price — and Singer at 48 flags that the MatrixCare divestiture self-addresses the obvious SOTP unlock, removing the activist catalyst. The council's split is structural, not transitional: quality seats see a confirmed franchise; value seats see a stock priced ~50% above earnings power with ~80% of DCF value sitting in terminal value and a bear-case intrinsic value ($238.92) that barely clears the current price of $231.52.

    • Price rose 3.1% to $231.52, compressing DCF upside from 36.6% to 32.4% and lifting P/E to 21.92x and Price/FCF to 20.25x — the valuation did not improve
    • Q4 FY2026 earnings confirmed record FCF near $1.7B, revenue $5.65B, and an EPS beat, all within prior assumptions of the quality seats
    • 10% dividend hike to $0.66/quarter treated by quality lenses as a management confidence signal backed by $1.65B FCF and net cash of ~$1.07B
    • Lynch's +6 move — the session's largest — reflected a firmer conviction that the stalwart-to-fast-grower label fits: visible model, recurring consumables/SaaS revenue, aging-demographics tailwind
    • Buffett, Munger, Fisher, and Mauboussin each moved +2 on confirmed ROIC (21.3%), OCF-over-NI quality ($1.81B vs $1.52B), and clean balance sheet (D/E 0.06)
    • Druckenmiller moved +4 to 52 but remains the most resistant seat: FCF and margin confirmed, yet ventilator regulatory scope and the downward second derivative in revenue growth prevent further conviction
    • Value lenses (Schloss 28, Singer 48, Graham/Klarman 52, Greenwald EPV ~$140-152) did not move — P/E×P/B ~111, ~5x book, and a TV-dependent DCF left them unmoved by the earnings beat

    Who movedPeter Lynch +6Stanley Druckenmiller +4Warren Buffett +2Philip Fisher +2Michael Mauboussin +2

  4. Reaffirmed 68 → 66 (-2) Watch

    Score slips 2 points to 66 as quality lenses trim on valuation discipline while Greenwald upgrades — no new filings, verdict holds at Watch

    The council re-read substantially the same financial record after a modest 1% price decline and the arrival of Q4 FY2026 earnings headlines, a 10% dividend raise, the announcement of first-ever FY2027 annual guidance, and an RBC downgrade. None of this materially altered the investment case, so the Watch call was reaffirmed — but several members recalibrated scores at the margin, producing a net 2-point decline.

    Greenwald was the sole meaningful mover in the bullish direction (62→74, watch→pass), having now formally worked through the EPV arithmetic on the audited 10-K figures — adding back ~$79M in acquired-intangible amortization and stripping out the ~$46M field-safety accrual to arrive at a normalized operating earnings figure that passes his screen. His prior score reflected uncertainty about those adjustments; the filed 10-K resolved it. Druckenmiller moved the other way (52→48), hardening his view that the second derivative of the business is flat: FCF was essentially unchanged YoY ($1,662M→$1,650M in the fundamentals block), revenue growth is steady but not re-accelerating, and the RBC downgrade reinforced his habit of not fighting a tape that diverges from the bullish narrative.

    The quality seats — Buffett, Munger, Fisher, Smith, Mauboussin — each trimmed 2 points (78/82→76/78/76/78/74). Their reasoning is consistent: the franchise is genuinely excellent, but at ~20x FCF with FCF flat YoY and no near-term re-acceleration catalyst visible, marginal valuation discipline argues for a shade less conviction. No member cited new fundamental deterioration; these are style-consistent adjustments to a price that has not become cheaper in any meaningful sense. Greenblatt moved modestly up (58→62) on the same 10-K clarity that helped Greenwald — the EBIT and invested-capital inputs are now unambiguous.

    The ventilator overhang and Astral field-safety accrual (9x jump to $45.7M) remain unresolved and unquantified, the DCF still rests on ~80% terminal value, and value lenses (Graham 52, Klarman 52, Schloss 28) see no classical margin of safety. First-ever FY2027 annual guidance is a governance positive but its content — specifically whether it sizes the ventilator headwind — is not captured in the available material. That uncertainty, plus CEO share sales post-earnings, keeps the risk flags live without triggering a downgrade beyond Watch.

    • Greenwald upgraded (62→74) after working through EPV arithmetic on the audited 10-K, adjusting for ~$79M acquired-intangible amortization and ~$46M field-safety accrual to pass his normalized-earnings screen
    • Druckenmiller trimmed (52→48) citing flat FCF YoY ($1,662M→$1,650M), steady-not-accelerating revenue growth, and the RBC downgrade as confirmation that tape momentum diverges from the bull narrative
    • Quality lenses (Buffett, Munger, Fisher, Smith, Mauboussin) each cut 2 points on marginal valuation discipline — ~20x FCF with no re-acceleration catalyst leaves fractionally less room for error than prior reading
    • Greenblatt moved modestly up (58→62) as the filed 10-K removed ambiguity from EBIT and invested-capital inputs, making the Magic Formula calculus cleaner
    • Astral ventilator / masks-with-magnets field-safety accrual (9x jump to $45.7M) and FY2027 ventilator headwind remain unquantified — risk flags intact but not worsened by new filings
    • First-ever FY2027 annual guidance issued (15 Aug 2026) is a positive disclosure signal, but its content — particularly ventilator impact sizing — is not available in the material, so it neither resolved nor deepened the overhang

    Who movedBruce Greenwald +12Stanley Druckenmiller -4Joel Greenblatt +4Terry Smith (Fundsmith) -4Warren Buffett -2

  5. Reaffirmed 68 → 68 Watch After earnings

    FY2026 10-K lands with strong earnings beat and a 10% dividend raise, but a 10x jump in the field safety accrual and a still-unquantified FY27 ventilator headwind hold the score at 68

    The new assessment absorbed the FY2026 annual filing (10-K, August 13 2026) and Q4 earnings results. Revenue grew to $5.65B and EPS topped estimates, the 10% dividend raise to $0.66/quarter confirmed cash generation confidence, and ROIC nudged up to 21.3%. None of that was enough to move the aggregate score because the council's concerns are about price and forward uncertainty, not business quality — and neither shifted materially.

    The most consequential new data point is the Astral/masks field safety notification accrual, which the 10-K shows jumped roughly 10x to $45.7M. The total cost of component replacement across the installed base remains unquantified. Separately, the UBS-flagged FY27 ventilator headwind is still unverified in any filing — no scope, no margin impact, no timeline. Those two items are the same overhangs from the prior run, now more precisely measured but no more resolved.

    The DCF base case slipped from $330.85 to $305.81, trimming upside from 56% to 35%, while the bear case of $238 sits only about 5% above the current price of $226.74. The margin of safety is thinner than it was four days ago, which is why Buffett, Munger, and several other members trimmed by 3-4 points each, while the Graham/Klarman/Schloss cluster held its skeptical floor. The council agrees on business quality; the disagreement remains about whether the price already banks the good news.

    The fiscal-year roll from FY2025 to FY2026 also revealed that FCF moved from $1.66B to $1.65B — a marginal decline at the same time the FCF margin is running near 29%, well above the levels before the Philips recall. Several members noted the risk that this margin level is not permanently structural, and if it mean-reverts the DCF terminal value — which accounts for roughly 80% of the model — compresses materially toward the value camp's numbers.

    • FY2026 10-K confirmed ROIC of 21.3% and operating margin of 33.4%, reinforcing business quality but providing no new reason to close the valuation gap
    • Astral/masks field safety notification accrual rose roughly 10x to $45.7M per the 10-K, making the overhang more precisely measured but still not fully quantified
    • UBS-flagged FY27 ventilator headwind remains unverified in any filing — the council's single largest source of negative-revision risk is unchanged
    • DCF base case fell from $330.85 to $305.81 and the bear case of $238 is only ~5% above the current price, leaving a thinner downside cushion than the prior run
    • FCF edged down from $1.66B to $1.65B FY2025 to FY2026, raising early questions about whether the margin level near 29% is durable or will revert as Philips-recall tailwinds normalise
    • 10% dividend raise and record FCF headlines were already broadly anticipated by the quality lenses and did not alter the growth-premium debate at the core of the bear case

    Who movedWarren Buffett -4Joel Greenblatt -4Charlie Munger -4Paul Singer -4Peter Lynch -3

  6. Downgraded 72 → 68 (-4) Pass → Watch

    Q4 earnings landed in-line but the ventilator overhang and valuation arithmetic pushed two key lenses from Pass to Watch, trimming the composite to 68

    The new assessment follows ResMed's Q4 FY2026 print: revenue of $1.46B came in line with estimates, FCF hit a record $1.7B, and the quarterly dividend was raised 10% to $0.66. On the surface, the business performed exactly as the prior council assumed. The composite score nonetheless fell four points (72 to 68) and the call shifted from Pass to Watch, driven by two members — Greenblatt and Greenwald — each cutting six points and flipping to Watch, while a cluster of other members nudged marginally in either direction.

    Greenblatt's move is the most mechanically legible: he re-ran his Magic Formula and concluded that at current prices the earnings yield is only moderate, making ROIC quality insufficient on its own for a Pass. Greenwald's cut is more consequential analytically — he is a franchise-believer whose EPV cross-check now anchors fair value near $111/share, implying the market is paying roughly $100/share of growth premium. His note that the price is 91% above no-growth value, combined with the still-unquantified UBS-flagged ventilator issue clouding FY27 guidance, is the single piece of reasoning the new assessment explicitly calls 'the most important number the bulls are glossing over.'

    The Q4 earnings did not deliver a resolution of the ventilator headwind, nor did they provide a clear FY27 guide. The MatrixCare divestiture (announced 8 July) rebases forward revenue by roughly $220M with no financial model yet attached. These unresolved items — not deteriorating fundamentals — are what prevented the in-line quarter from restoring confidence. Munger and Fisher both ticked up slightly (78→82 and 78→79), finding the record FCF and dividend hike confirmatory, which partially offset the Greenblatt/Greenwald cuts.

    The price moved from $207 to $212 in the three days between assessments, P/E compressed modestly from 23.1x to 22.0x on updated fundamentals, and DCF intrinsic value was effectively unchanged at $331. None of this altered the core tension the prior council identified: a wonderful business at a price that embeds substantial growth and offers no asset-backed floor.

    • Greenblatt cut 76→62 (Pass→Watch): re-ran Magic Formula and found earnings yield only moderate at current prices; ROIC quality alone insufficient for a clean Pass
    • Greenwald cut 74→62 (Pass→Watch): EPV of ~$111/share implies price is ~91% above no-growth value; unquantified ventilator issue prevents him from crediting the full growth premium
    • UBS-flagged 'ventilator issue' remained unresolved through the Q4 call, leaving FY27 guidance clouded with no scope, financial, or regulatory detail disclosed
    • MatrixCare divestiture announced but not modeled: ~$220M revenue and ~$55M non-GAAP profit removal rebases FY27 estimates with no offsetting capital-deployment clarity
    • Q4 revenue landed in-line (not a beat) and no FY27 guidance was provided; the record $1.7B FCF and 10% dividend hike confirmed quality but gave no catalyst to re-rate
    • Valuation remains entirely growth-dependent — 80.4% of DCF sits in terminal value — and the RBC downgrade (16 Jul) added institutional skepticism with no disclosed rationale to argue against

    Who movedJoel Greenblatt -14Bruce Greenwald -12Chuck Akre -4Charlie Munger +4Benjamin Graham -3

  7. Reaffirmed 73 → 72 (-1) Pass After earnings

    Q4 earnings and a 10% dividend raise confirmed quality but resolved nothing — score slips one point as valuation metrics tightened slightly on a lower price

    ResMed's Q4 FY2026 print landed in line with consensus: $1.46B quarterly revenue, full-year FY2026 revenue of $5.653B, and record FCF of $1.7B. Management raised the dividend 10% to $0.66/share, signalling confidence in cash durability. None of that was a surprise to the quality-oriented council members — the earnings confirmed what they already assumed, not exceeded it. The composite score moved from 73 to 72, a rounding-level shift rather than a directional call change.

    Two quality seats — Akre and Buffett — each moved up four points (78 to 82), citing the record FCF, capital-light economics, and fortress balance sheet as textbook confirmation of the compounder thesis. Those upgrades were offset by the Valuation Referee trimming two points (78 to 76) and Greenwald trimming two points (76 to 74). The Referee noted that while the DCF base case rose slightly to $327.91, the model has not been re-baselined for the MatrixCare revenue exit (~$220M revenue, ~$55M non-GAAP operating profit), making the headline 58% upside fragile. Greenwald's EPV of ~$134 — well below the $207 price — means the market continues to pay for growth that is structurally absent from his methodology; a slightly higher P/E (23.12 vs 21.85) and Price/FCF (19.49 vs 18.42) on the lower stock price pushed his score modestly lower.

    The unresolved issues are unchanged and remain the binding constraint. The UBS-flagged ventilator headwind for FY27 is still absent from SEC filings and unquantified. The RBC downgrade rationale remains undisclosed. The GLP-1 secular threat, Noctrix dilution (~$0.20 non-GAAP EPS), recurring restructuring charges, and a CFO transition all persist. The council's pass is still carried by the quality lenses accepting a growth-dependent DCF; the value and momentum seats — Graham, Klarman, Lynch, Druckenmiller, Singer, Marks — remain at Watch, arguing the price does not yet compensate for the unresolved downside.

    • Record FY2026 FCF of $1.7B and in-line Q4 revenue confirmed the quality lenses' existing assumptions, supporting Akre and Buffett upgrades to 82
    • 10% dividend raise to $0.66/share treated as a capital-allocation signal of management confidence, reinforcing the compounder narrative
    • P/E expanded from 21.85 to 23.12 and Price/FCF from 18.42 to 19.49 on a lower stock price, tightening the valuation picture and driving Valuation Referee and Greenwald lower
    • DCF base case rose modestly to $327.91 but remains un-re-baselined for the MatrixCare exit, leaving the terminal-value-heavy (80%) upside claim fragile
    • Ventilator headwind (UBS-flagged, FY27), RBC downgrade rationale, and GLP-1 secular risk all remain unresolved, preventing any upgrade from the value and momentum seats
    • MatrixCare divestiture announced 8 Jul 2026 with Needham maintaining Hold; no valuation or margin-impact detail provided, leaving the portfolio restructuring narrative incomplete

    Who movedChuck Akre +4Warren Buffett +4Valuation Referee (Damodaran-style) -2Bruce Greenwald -2

  8. Reaffirmed 72 → 73 (+1) Pass

    Score edges up one point to 73 as quality lenses re-rate higher on cleaner balance sheet data, offset by Klarman cutting and Singer joining as a skeptic — the ventilator issue and pre-earnings uncertainty hold the council back from a stronger move.

    The overall score moved from 72 to 73, a statistically trivial shift that masks real divergence inside the room. The price rallied 8% (from $195.27 to $210.98) between assessments, the debt-to-equity ratio was restated sharply lower (0.17 to 0.06), and net cash was revised up to approximately $1B — changes that tightened the quality lenses' conviction without altering the fundamental thesis. Terry Smith added four points (78→82), Philip Fisher and Michael Mauboussin each added four (74→78), and Bruce Greenwald added two (74→76), all citing the same updated balance sheet strength and a reverse-DCF showing the market implies only 5–7% FCF growth against a trailing 12.9% CAGR. Walter Schloss added six points (22→28) solely because the stock was now more 'out of favor,' which is the one Schloss criterion RMD clears — every hard-asset test still fails. The gains from the quality bloc were partially cancelled by Seth Klarman cutting three points (55→52), arguing the DCF is 80% terminal value and his personal floor sits at $170–180, and by Paul Singer joining at 52 (Watch) with the same margin-of-safety objection. Benjamin Graham ticked up three points (52→55) on stronger balance sheet optics, and Howard Marks added three (55→58) acknowledging the sentiment discount but stopping well short of endorsing the valuation. The new evidence — record $1.7B FCF, restated D/E of 0.064, net cash ~$1B — reinforced what the quality seats already believed and gave the value seats no new reason to capitulate. The dominant constraint on the score is the undefined UBS-flagged ventilator issue (specifics absent from all filings and management commentary) and the fact that Q4 FY2026 earnings on August 6 had not yet occurred, leaving FY27 guidance, MatrixCare divestiture proceeds, and GLP-1 impact all unresolved. The council's 73 is effectively a holding pattern one week before the event that could move it materially in either direction.

    • Balance sheet restatement — D/E revised from 0.17 to 0.064 and net cash revised up to ~$1B — strengthened the quality lenses' franchise conviction and nudged Terry Smith, Fisher, Mauboussin, and Greenwald higher
    • Price rally of 8% ($195→$211) narrowed the DCF upside from 65% to 53%, which Klarman and Singer cited as a reason to reduce or stay skeptical — less discount for the same unresolved risks
    • Record $1.7B FCF (company record per news digest) validated the cash-generation thesis but was already largely embedded in prior scores given the FY25 figure was known
    • Undefined ventilator issue (UBS, July 21) introduced a new, unquantified FY27 risk that capped every member's confidence ceiling regardless of directional lean
    • Paul Singer joined at 52, adding a fresh margin-of-safety voice aligned with Klarman — the value/tape bloc now has more weight in the room
    • Q4 FY2026 earnings not yet reported (scheduled August 6) — absence of management guidance on ventilator issue, MatrixCare proceeds, and GLP-1 framing explicitly held the council to medium confidence

    Who movedWalter Schloss +6Philip Fisher +4Michael Mauboussin +4Terry Smith (Fundsmith) +4Benjamin Graham +3

  9. Upgraded 68 → 72 (+4) Watch → Pass

    Price slip and updated evidence pushed the council from Watch to Pass at 72, as quality lenses trimmed scores modestly while Klarman nudged up and the weight of the bull case held.

    The stock fell a further 1.9% to $195.27 in the week between assessments, nudging the Price/FCF ratio down to 17.05x and the DCF upside up to 64.7% — small moves that made the valuation case fractionally more attractive. The council upgraded to Pass at 72 despite most moving members actually trimming their scores, because the aggregate weight of the quality-lens majority (Buffett, Munger, Akre, Terry Smith, Mauboussin, Greenblatt all at 74-78) still clears the pass threshold, and the forensic short-seller explicitly concluded 'this is not a short.'

    The movers tell a nuanced story. Akre (82→78) and Buffett (82→78) both trimmed on the same logic: the franchise is genuine and the economics are clean, but the GLP-1 uncertainty and 80% terminal-value dependence prevent a higher conviction score. Greenblatt (78→76) and Fisher (76→74) followed suit for similar reasons. Munger was the lone riser (76→78), apparently concluding the price decline moved the stock further into 'fair-to-attractive' territory for a dominant franchise. Klarman (52→55) and Marks (58→55) both shifted marginally — Klarman slightly more constructive on the DCF upside at $195 vs. $199, Marks slightly less so, reflecting the broken-tape concern gaining weight.

    The new evidence added texture but no resolution. The MatrixCare sale (Needham Hold), Noctrix acquisition (mixed market reaction), RBC downgrade, and Russell Growth Index removal all arrived in the window — all consistent with the bear case already in the prior assessment. Record FCF of $1.7B reinforced the quality side. Critically, the Q4 FY2026 earnings call (August 6) had not yet occurred, so management's own framing of GLP-1 demand impact and FY2027 guidance remains the single largest information gap. The upgrade to Pass is essentially a verdict that the quality and valuation evidence already in hand outweighs the unquantified structural headwind — but the council flags this is a conviction-limited pass, not a clean one.

    • Price decline to $195.27 pushed Price/FCF to 17.05x and DCF upside to 64.7%, marginally improving the valuation setup and nudging the aggregate score over the pass threshold
    • Munger raised his score (76→78) on the view that the ~30-34% drawdown from the $293.81 peak moves a dominant franchise with 50%+ CPAP share into fair-to-attractive territory
    • Akre and Buffett both trimmed (82→78) on shared concern: GLP-1 structural uncertainty and 80% terminal-value dependence in the DCF prevent a high-conviction score even for a franchise this clean
    • RBC downgrade, Russell Growth Index removal, and continued broken price momentum (near 52-week low) anchored Druckenmiller at 52 and kept Graham, Klarman, and Marks below the pass line
    • Record FCF of $1.7B confirmed operational resilience and reinforced the quality-lens majority's view that cash conversion (FCF > net income) remains forensically clean
    • Absence of Q4 FY2026 earnings transcript left GLP-1 demand impact and FY2027 guidance unquantified — the single biggest swing factor — preventing any lens from fully resolving the bear case

    Who movedChuck Akre -4Warren Buffett -4Seth Klarman +3Howard Marks -3Philip Fisher -2

  10. Reaffirmed 68 → 68 Watch

    Score holds at 68 as a small price decline and cleaner GLP-1 framing shuffle individual lens scores without moving the aggregate

    The council held its Watch at 68/100 with medium confidence. The price fell 2.4% to $199, P/E ticked from 21.1x to 20.6x, and the DCF intrinsic value nudged up fractionally to $321.74 — none of which changes the fundamental picture. What did shift is how council members articulated the GLP-1 structural risk and competitive pressures, producing modest re-scorings in both directions that cancel out at the headline level.

    On the upside, Buffett moved from 78 to 82 and Greenblatt from 74 to 78, both giving more credit to the ROIC/WACC spread and the moat's durability. On the downside, Fisher fell from 82 to 76, Terry Smith from 82 to 78, and Munger from 78 to 76 — each member trimming one to four points as they gave more explicit weight to Philips re-entry risk in 2027, the M&A noise from MatrixCare and Noctrix, and the unquantified GLP-1 patient-funnel concern. Howard Marks moved narrowly from 55 to 58 on the modest valuation improvement; the Christensen referee slipped from 74 to 72 on unchanged AI-disruption logic.

    The structural tension driving the Watch remains exactly what it was: nine quality lenses pass, but the Graham (52) and Schloss (22) seats reject any setup without an asset-based floor, and Druckenmiller (52) refuses to size conviction while the tape is in distribution and August earnings direction is opaque. Greenwald, though nominally a pass at 74, effectively dissents on price — his EPV of $99-115 is roughly half the current quote, meaning even the bull camp admits the thesis requires substantial future growth that GLP-1 could impair. No Q4 FY2026 earnings data arrived; the August 6 call is the next material test.

    The Goldman Sachs APAC Conviction List addition and the RBC downgrade arrived as opposing signals and offset each other in the council's reading. With 80% of DCF value sitting in terminal value and no clinical data quantifying GLP-1's actual effect on new OSA diagnoses, the council had no basis to move off 68.

    • Price fell 2.4% to $199 and P/E compressed to 20.6x, modestly improving the valuation case but not enough to resolve the terminal-value dependency
    • Buffett and Greenblatt each moved up 4 points, crediting the sustained ROIC/WACC spread (~1000bps) and the multi-layer moat in device, consumables and connected-care software
    • Fisher, Terry Smith and Munger each trimmed their scores as they gave more explicit weight to Philips re-entry in 2027, M&A execution risk from MatrixCare and Noctrix, and the unquantified GLP-1 patient-funnel threat
    • Goldman Sachs APAC Conviction List addition (Buy) and RBC downgrade landed simultaneously, producing no net signal change for the council
    • No Q4 FY2026 earnings data; the August 6 call is the first opportunity to get management commentary on GLP-1 impact and forward guidance
    • Greenwald's EPV of $99-115 — roughly half the $199 price — remains the argument the quality majority has not answered, anchoring the Watch rather than a pass

    Who movedPhilip Fisher -6Warren Buffett +4Joel Greenblatt +4Terry Smith (Fundsmith) -4Howard Marks +3

  11. Downgraded 73 → 68 (-5) Pass → Watch

    RMD cut from Pass to Watch as value lenses harden on the EPV gap and the tape breaks further

    The council trimmed its composite score from 73 to 68 and reclassified RMD from Pass to Watch. The headline pressure comes from the value and momentum seats, which found more to dislike in the new evidence than the quality seats found to celebrate. The price slipped from $209.63 to $203.87, the Morgan Stanley and Jefferies downgrades arrived in the inter-assessment period, and the MatrixCare divestiture — confirming an earlier capital-allocation miss — gave the risk seats fresh ammunition. The quality seats remain enthusiastic but could not carry the composite over the Pass threshold when the contra-evidence was weighed in.

    The core tension is unchanged but better-quantified: Greenwald's EPV is now cited explicitly at ~$114/share, meaning the market is paying roughly $90 per share of pure growth value above steady-state earnings — a number every value seat flagged. The DCF base case edged up slightly (from $322.79 to $320.28) and the upside widened marginally (54% to 57%) on the price decline, yet the council moved toward caution rather than toward conviction. The reason is that the new analyst actions (MS Equalweight, Jefferies PT cut to $225 from $240, Needham Hold) reinforced what the Graham/Klarman/Druckenmiller seats had already argued: the tape is in distribution with no clear re-rating catalyst, and buying into negative revision momentum requires the growth thesis to hold intact.

    SG&A growth was restated at 15% versus 11% revenue growth in the new assessment, up from the prior run's 12%-vs-9% comparison, which extended the operating-leverage concern the bear seats had already raised. The GLP-1 pillar — 1.95M-patient cohort, 11% higher CPAP starts, 6.2% higher three-year resupply — remained management-sourced and peer-review-pending, and Mick Farrell's own 'We don't know causality' admission was cited by nearly every lens as a reason to treat it as unaudited.

    • Morgan Stanley downgrade to Equalweight ($230 PT) and Jefferies PT cut to $225 from $240 arrived after the prior assessment, giving the momentum and value seats a concrete revision signal to point at
    • Greenwald's EPV of ~$114/share — explicitly cited in the new assessment — frames the $90-per-share growth premium the market demands and is the argument the quality camp cannot dismiss with earnings-quality data alone
    • SG&A growing 15% vs 11% revenue (restated upward from the prior 12%-vs-9% comparison) deepens the operating-leverage concern without a management commitment to bend the curve
    • MatrixCare divestiture, confirmed in early July, validates the prior-run criticism that the RCS/senior-living acquisition was a capital-allocation miss and pushes RCS recovery to FY2027
    • FCF margin surge from 6% (2022) to 32% (2025) is now framed as partly cyclical — Morgan Stanley's component/logistics normalization argument was absorbed into the bear case and several lenses flagged reversion toward 25% as a plausible scenario that cuts FCF by ~$550M
    • Philips US re-entry timeline remains unquantified, but the new evidence (management's 'I don't know' on timing) gave the bear seats no comfort, and the MS downgrade explicitly cited competitive re-entry risk

    Who movedPhilip Fisher -2Bruce Greenwald +2

  12. Reaffirmed 73 → 73 Pass

    Five-day price rally and a Goldman add to Conviction List left the aggregate score flat at 73; Klarman and Mauboussin trimmed on valuation, Fisher nudged higher on growth quality, Greenwald cut on EPV discipline.

    The council re-read the same Q2 FY2026 earnings call, CMS exclusion, and Morgan Stanley downgrade that anchored the prior assessment, supplemented by Goldman Sachs adding RMD to its APAC Conviction List and a 4.7% price move from $200.29 to $209.63. None of that evidence altered the fundamental picture materially — DCF intrinsic value slipped only fractionally (from $325 to $323), and the embedded-expectations argument (market pricing ~5-7% perpetual FCF growth vs. a demonstrated 12.9% revenue CAGR) remained intact. The aggregate score held at 73 because the bull and bear forces offset: Fisher lifted his score one notch on the sustained mask/consumable momentum (+14% CC) and CME education funnel data, while Klarman and Mauboussin each trimmed one notch as the higher entry price compressed their already-thin margin of safety and reduced the risk-adjusted attractiveness of the DCF upside. Greenwald cut on pure EPV discipline — the stock now trades roughly 65% above his no-growth value of ~$126-128, and a small price rise only widened that gap. The council's reaffirmation reflects genuine stalemate: quality lenses see a durable compounder priced below intrinsic value; value lenses see a terminal-value-dependent DCF with no asset-backed floor and SG&A growing faster than revenue. Neither camp moved enough to break the deadlock. The one new data point with real weight is the Goldman APAC Conviction List add, which corroborates the structural CPAP underpenetration thesis but does not resolve the Philips re-entry, GLP-1 quantification, or RCS recovery questions that the bear camp continues to flag.

    • Price rose 4.7% to $209.63, compressing DCF upside from 62% to 54% and mechanically tightening the margin of safety that Klarman and Mauboussin require — both cut by two points on this alone
    • Fisher raised his score to 84, citing the mask/consumables segment accelerating to +14% CC, 60,000 CME completions (a 50% QoQ increase), and new product launches (F30i Clear, Comfort Match AI) as evidence that the growth reinvestment engine is working as a Fisher holding demands
    • Klarman trimmed to 52, noting that a higher entry price against an unchanged or slightly lower DCF value ($322.79) means the single-scenario upside is now less compelling when stress-tested; at 21.7x P/E and 4.8x book, no conservative asset-backed discount exists
    • Greenwald cut to 72 on EPV discipline: NOPAT-based no-growth value of ~$126-128 implies the stock trades ~65% above demonstrated earnings power, and the price increase since the prior run moved that gap in the wrong direction
    • The Goldman Sachs APAC Conviction List addition (Buy, A$46.70 PT) provided incremental external validation of the CPAP structural-growth thesis but did not change any fundamental input; the Morgan Stanley Equalweight at $230 remained on the record, keeping the bear flag alive
    • SG&A growing at +12% CC versus revenue at +9% CC — a persistent operating-leverage leak called out in the Q2 call and attributed to the Virtuox acquisition and promotional spend — reinforced the bear camp's caution without triggering a broader score revision

    Who movedSeth Klarman -3Philip Fisher +2Bruce Greenwald -2Michael Mauboussin -2

  13. Reaffirmed 74 → 73 (-1) Pass

    Score slips one point to 73 as Buffett trims and Mauboussin joins; evidence reaffirms quality but does not resolve the EPV-versus-DCF tension

    The council's overall view barely moved — 74 to 73, Pass maintained at medium confidence — because the new evidence reinforced what the bulls already assumed rather than resolving the bear-case overhangs. The Q2 FY2026 print (revenue +11% headline, +9% constant currency; gross margin 62.3%, up 110 bps; EPS +16%) landed inside the quality lenses' base case, and the 1.95M-patient GLP-1 claims cohort (11% higher CPAP start rates, 6.2% higher three-year resupply rates) shifted the GLP-1 narrative from purely a threat to a partial tailwind. The CMS competitive-bidding exclusion — first in 15 years — removed a structural pricing overhang the prior assessment had not fully credited.

    Where the view held rather than improved: management still refused to quantify GLP-1's contribution to growth, Philips Respironics US re-entry around 2027 remains unresolved, device growth decelerated to +7% constant currency, and SG&A is growing at 12-15% against 9% revenue growth. The Morgan Stanley downgrade to Equalweight at a $230 price target — citing margin headwinds — arrived after the prior assessment and gave the macro/tape bears fresh ammunition. The RCS software segment stayed at +5% with 'portfolio management' language intact.

    Buffett trimmed from 82 to 78. His written rationale still affirms the moat — ~55% global CPAP share, MyAir SaaS lock-in, recurring mask resupply — but the combination of decelerating device growth, the unquantified GLP-1 variable, and the approaching Philips re-entry appears to have introduced enough uncertainty to shade his conviction modestly. The Valuation Referee (Damodaran-style) moved in the opposite direction, 76 to 78, as the CMS exclusion and the GLP-1 resupply data provided incremental support for the 12% FCF growth assumption embedded in the $325 base-case DCF. Michael Mauboussin joined the council at 76-Pass, adding weight to the quality-and-capital-allocation side. The EPV-versus-DCF tension — Greenwald and Klarman anchoring fair value at $120-130 against the referee's $325 — remained the core unresolved debate, which is why the headline score barely moved despite a strong quarter.

    • Q2 FY2026 beat (revenue $1.42B, +9% CC; gross margin 62.3% +110 bps; EPS +16%) confirmed the operating model is intact and fell inside the quality bulls' base assumptions
    • GLP-1 claims data on 1.95M patients showed 11% higher CPAP start rates and 6.2% higher three-year resupply rates, partially neutralising the secular TAM-erosion fear — but management declined to quantify the contribution to growth
    • CMS competitive-bidding exclusion for CPAP/APAP/bi-level products (first in 15 years) removed a structural pricing overhang not fully credited in the prior assessment
    • Buffett trimmed 82 to 78, likely reflecting decelerating device growth (+7% CC), SG&A outpacing revenue (12-15% vs 9%), and unresolved Philips re-entry risk rather than any deterioration in business quality
    • Valuation Referee moved 76 to 78 as the CMS win and GLP-1 resupply data gave incremental support to the 12.9% FCF CAGR assumption underpinning the $325 DCF base case
    • Morgan Stanley downgrade to Equalweight ($230 PT) on margin headwinds reinforced Druckenmiller's tape argument — stock fell on a strong beat and made 52-week lows — keeping the pass from becoming a buy

    Who movedWarren Buffett -4Valuation Referee (Damodaran-style) +2

  14. Initiated 74 Pass

    Council initiates RMD at 74/100 Pass — quality franchise at a fair price, with real overhangs the value seats refuse to look through

    This is the council's first look at ResMed, so every score represents a fresh judgment against the evidence rather than a change from a prior view. The fundamental picture is strong: $5.15B in revenue, $1.66B in free cash flow, 62.3% gross margin expanding toward a 2030 roadmap, 18% ROIC, and a balance sheet carrying only $0.17 of debt per dollar of equity. The Q3 FY2026 earnings call added quantified GLP-1 data — 1.95M patients tracked, 11% higher CPAP start rates, 6.2% higher resupply at year three — which the quality seats treat as a tailwind converting a feared headwind. The Oura partnership and CMS competitive-bidding exclusion arrived as incremental positives.

    The council split cleanly along the quality-versus-price axis. Buffett, Munger, Fisher, Akre, and Terry Smith all score 78–82: they see a recurring-revenue, asset-light compounder with multilayered switching costs (11M MyAir users, BrightTree/Somneware ecosystem lock-in, mask resupply running at +16% US) and a management team demonstrating operating leverage. The Damodaran-style referee scores 76, noting the $200 price embeds only 6–8% FCF growth versus a 12% base-case DCF implying $325 intrinsic value, a 62% discount. The forensic lens finds clean accounting and no balance-sheet stress.

    The three pure-value seats dissent and will not move. Schloss scores 22 (Avoid): P/B 4.6x, ~18x NCAV, intangible-heavy, no asset floor. Graham scores 52 (Watch): every classic price test fails, P/E times P/B near 95 against a 22.5 ceiling. Klarman scores 55 (Watch): EPV of roughly $130 per share means the market is paying ~$70 for growth underwritten by a moat that Philips and GLP-1 are actively contesting. Druckenmiller also watches at 52: the tape is in distribution, down ~20% YTD at 52-week lows at the time of the Morgan Stanley Equalweight downgrade to $230 on margin and competition concerns, and he sees no price confirmation of the bull thesis. The aggregate 74 Pass reflects the quality majority overriding the value minority, with medium confidence acknowledging that the overhangs are real and the DCF is 80% terminal value.

    • Quality compounding metrics — 18% ROIC, 22% ROE, FCF above net income at $1.66B, 32% FCF margin, and only 1.7% capex intensity — give the quality seats high conviction on franchise durability
    • GLP-1 quantification (1.95M patients, +11% CPAP start rates, +6.2% resupply at year three) reframes the secular risk as a potential tailwind, the single most important new data point for the bull case
    • ~32% drawdown from highs and a DCF implying $325 intrinsic value ($252 bear case) create what the referee lens reads as a meaningful margin of safety for a quality-company buyer
    • Morgan Stanley Equalweight downgrade to $230 and 52-week-low tape mean Druckenmiller and the value-caution seats see no price confirmation and no near-term catalyst to force a re-rating
    • EPV of ~$130 per share means Klarman and Greenwald assess that roughly $70 of the $200 price is pure franchise-growth optionality, which Philips US re-entry in 2026–2027 and contested GLP-1 causality could impair
    • RCS software stuck at +5% CC with senior living and LTC challenged adds execution risk and latent goodwill-impairment exposure on Brightree and MatrixCare, a weak spot in an otherwise strong operating report

The full analysis

RESMED INC (RMD) — Council Assessment

🟡 WATCH · Score 63/100 · medium confidence

High-quality, net-cash CPAP franchise (ROIC ~21%, 29% FCF margin) trading ~30% below base DCF but with a bear case that sits right at today's price — quality without a wide margin of safety.

As of 2026-09-07. 19 lenses weighed in, 0 abstained. Sources: 11 filings, 80 news.

360 narrative — news & sentiment digest

ResMed Inc. (RMD) — Investment Brief

Recent Developments

  • Q4 FY2026 Earnings (Aug 6, 2026): Revenue $1.46B (in line with FactSet), full-year FY2026 revenue $5.65B. EPS slightly missed consensus. Stock dropped ~1.9% post-announcement despite beating revenue.
  • MatrixCare Asset Sale (Jul 8, 2026): Announced sale of MatrixCare business; company plans to use proceeds for accelerated share buyback (announced Sep 1, 2026).
  • Strong FCF: Record free cash flow of $1.7B reported (Jul 22, 2026).
  • Dividend Increase: Management lifted dividend in conjunction with Q4 results.
  • Ventilator Recall Headwinds: References to recall issues creating uncertainty around FY2027 guidance.
  • Analyst Downgrades: RBC Capital Markets downgraded stock (Jul 16, 2026). Needham held rating at Hold despite MatrixCare sale announcement (Jul 8, 2026). Price target cuts observed (e.g., one analyst cut 12-month target to $258.47, implying 14% upside from late Aug levels).

Management Commentary (Earnings Call)

No detailed transcript provided in materials. However, available summaries and news indicate:

  • Guidance Miss: FY2027 guidance apparently disappointed the market—cited as "Astral-driven guidance miss" (TIKR, Aug 25). Ventilator issues appear to be a material headwind.
  • Profitability & Cash Generation: Strong underlying cash conversion; $1.7B FCF at record levels signals robust operational profitability.
  • Capital Allocation: Dividend increased; MatrixCare sale proceeds earmarked for "fast-track buyback," signaling management confidence and intent to return capital despite near-term headwinds.
  • Tone: No direct quotes available, but market reaction (stock down ~1.9% despite in-line/beating revenue) suggests caution on guidance and operational challenges.

Bull Narrative

  • Valuation & FCF: Stock down 30% from peak (TIKR, Jul 22); trading at discount despite record $1.7B FCF. Multiple sources (GuruFocus, Yahoo) flagged stock as "undervalued" in early July 2026.
  • Dividend Quality: ChartMill (Jul 15, Aug 8) highlighted strong profitability and cash conversion supporting "quality dividend."
  • Capital Redeployment: Buyback from MatrixCare proceeds and dividend increase signal management's confidence in intrinsic value.
  • Institutional Accumulation: Recent institutional buying noted—HSBC, Legal & General, Deutsche Bank, Mitsubishi UFJ AM, Assenagon all added shares late Aug 2026; suggests large allocators see value.
  • Long-term OSA (obstructive sleep apnea) market growth: Referenced as continuing expansion opportunity (Yahoo, Jun 25).

Bear Narrative

  • Guidance Miss & Ventilator Recall: FY2027 guidance disappointed; ventilator recall/issues cited as a concrete drag on forward outlook (UBS, Jul 21; TIKR, Aug 25). Uncertainty remains around magnitude and duration.
  • Stock Price Weakness: Down 30% from peak; down ~20% YTD as of late Jun 2026. Consistent underperformance vs. market (multiple MarketWatch reports of daily underperformance).
  • Analyst Downgrades: RBC downgrade (Jul 16) and price target cuts signal deteriorating near-term sentiment.
  • Insider Selling: CEO sold ~$1M worth of stock (Aug 11, 2026); director planned 970-share sale (Sep 2, 2026). While not disqualifying, combined with weak guidance, raises concerns about near-term trajectory.
  • Execution Risk: Despite strong FCF, company is using sale proceeds defensively (buyback) rather than growth investment, hinting limited organic growth visibility.

Retail Sentiment

Limited retail forum discussion in materials. Press-focused sources dominate (MarketWatch daily moves, analyst notes).

Tone: Mixed, leaning cautious. Retail commentary on financial sites (TradingView, Yahoo Finance forums referenced tangentially) appears split: some see "buying opportunity" post-30% decline; others echo concerns on ventilator issues and guidance miss. Conviction appears moderate—no viral bullish or bearish narratives detected in headlines.

Caveats

  1. No Earnings Call Transcript: Management tone, specific forward commentary, and Q&A exchanges unavailable; summary relies on press reactions and analyst notes.
  2. Thin Ventilator Details: Recall/issue framing vague in available material—scale, timeline, and financial impact unclear.
  3. Guidance Miss Attribution: Root cause split unclear (internal execution, market, recall, or mix) from headlines alone.
  4. Institutional Buying Opacity: Late-Aug accumulation (HSBC, Legal & General, etc.) may reflect rebalancing or tactical moves rather than conviction.
  5. Analyst Price Targets Scattered: Limited consensus; single data points (e.g., one $258 target) insufficient for robust positioning.
  6. MatrixCare Valuation Unknown: Sale price and timing not disclosed in materials; implications for net capital return uncertain.

Summary

ResMed faces a near-term credibility test: record FCF and a 30% stock decline have attracted institutional buyers and value-oriented commentary, but FY2027 guidance miss and ventilator recall headwinds cloud the near-term narrative. Management is returning capital (dividend, buyback), but lack of growth investments amid operational challenges raises questions on strategic positioning. Council should obtain full Q4 call transcript and updated guidance specifics before conviction sizing.

Bull case

ResMed is a genuine franchise: dominant OSA/CPAP position with recurring mask/consumable revenue, an AirView data moat AI likely strengthens, ROIC of 21.3% vs. WACC of 8.1%, operating margin 33.4%, and FCF that grew from $216M (FY2022) to $1.65B (FY2026). The balance sheet is fortress-grade — $399M LT debt vs. $1.47B cash, net cash ~$1.07B, D/E 0.06. Capital allocation is rational: debt slashed, dividend raised, MatrixCare divested with proceeds to buyback. Base DCF of $297.54 implies ~30% upside, and the stock is down ~20% from its high. Eight of the quality/growth lenses pass at 72-78.

Bear case

The value lenses (Graham, Klarman, Greenblatt, Greenwald, Singer all Watch; Schloss Avoid at 28) converge on one point: there is essentially no margin of safety. Bear-case DCF of $233 is barely above the $228 price, and 79% of DCF value sits in terminal value — a forecast-heavy structure. P/E 21.6x, P/B 5.0x (P/E×P/B ~108 vs. Graham's 22.5), PEG 2.12. Greenwald's EPV lands at ~$145, implying the price is ~57% above no-growth value. Fundamentals are decelerating: net income growth slowed to +8.7% in FY2026, FCF was flat YoY, FCF margin slipped from 32.3% to 29.2%. The Astral ventilator field-safety accrual jumped from $4.8M to $45.7M and drove an FY2027 guidance miss of uncertain magnitude. Druckenmiller flags a broken tape (-15% over 12 months).

Dissent — where the council disagrees

The sharpest split is quality vs. value. The quality camp (Munger, Buffett, Smith, Mauboussin, Akre ~75-78) sees a wonderful business at a fair price; the value camp (Graham, Klarman, Greenwald, Greenblatt, Schloss) says you are paying full franchise price with no cushion, and Greenwald's EPV of ~$145 is a stark counterpoint to the $297 DCF. Druckenmiller's Watch (52) matters most for timing: he explicitly won't fight a broken chart into a guidance miss with no re-acceleration catalyst. The unquantified GLP-1 threat to OSA TAM — raised by Dalio, Munger, Mauboussin — is the biggest long-duration bear item and is NOT modeled in the DCF. Note the entire long thesis leans on a DCF whose bear case equals the current price, so the '30% upside' evaporates under modest disappointment.

Key risks

  • Astral ventilator recall: field-safety accrual rose 9x to $45.7M (verified in 10-K) with unquantified ultimate cost and an FY2027 guidance miss
  • GLP-1 weight-loss drugs potentially reducing OSA prevalence — a structural TAM risk explicitly NOT modeled in the DCF (lens claim, unquantified)
  • Thin margin of safety: bear-case DCF ($233) ≈ current price; 79% of DCF value is terminal value
  • Decelerating fundamentals: net income growth slowed to +8.7%, FCF flat YoY, FCF margin down from 32.3% to 29.2%
  • Premium valuation (P/E 21.6x, P/B 5.0x, PEG 2.12) leaves little room for execution error
  • Recurring 'one-time' items: restructuring charges $21.7M (9mo) after $64.2M in FY2024; serial bolt-on M&A (Noctrix $335M)

Catalysts

  • Resolution/quantification of Astral recall costs and an FY2027 guidance reset
  • MatrixCare sale proceeds funding accelerated buyback (announced Sep 1, 2026)
  • Dividend increase and net-cash balance sheet supporting continued capital return
  • Re-acceleration of revenue/FCF growth back toward the ~10% CAGR
  • Clarity on GLP-1 impact proving complementary rather than substitutive to CPAP demand

DCF valuation (finance-expert model)

two-stage DCF, Gordon terminal value, CAPM-weighted WACC.

Intrinsic value: $297.54/share vs price $228.35 → +30% (bear $233.0 · base $297.54 · bull $389.96).

Step Value
Base free cash flow $1.6B
FCF growth (yrs 1-5) 10.2% (revenue CAGR)
WACC (β 0.771) 8.1%
Terminal growth 2.5%
PV of explicit FCF $8.7B
PV of terminal (residual) value $33.1B (79% of EV)
Enterprise value $41.9B
less Net debt $-1.1B
= Equity value $42.9B
/ Shares (144M) = intrinsic/share $297.54

Short-sell evaluation

🚫 AVOID SHORTING

This is a poor short despite full valuation. The forensic short-seller passed it at 72 — cash flow ($1.81B OCF) persistently exceeds net income ($1.52B), the accrual signal is clean, share count is declining, and the balance sheet is net cash. Shorting a debt-free, 33%-margin, 21%-ROIC franchise that is buying back stock and raising its dividend, at only ~20x FCF, courts unlimited downside for limited edge. The overvaluation is modest (price near base DCF, and value lenses argue it's rich, not absurd), and the negatives — recall, guidance miss — are already partly priced after a ~20% drawdown. A short only works if Astral costs metastasize or GLP-1 demand destruction accelerates, neither of which is evidenced in the fact base. Not worth the squeeze/quality risk.

Pros (the short could work)

  • Full valuation vs. no-growth value: Greenwald EPV ~$145 vs. $228 price; P/E×P/B ~108
  • Decelerating momentum: net income growth to +8.7%, FCF flat YoY, FCF margin compressing
  • Astral recall accrual up 9x to $45.7M with unquantified tail and an FY2027 guidance miss
  • Broken tape (-15% over 12 months) and analyst downgrades (RBC) provide negative drift
  • Long-duration GLP-1 threat to OSA TAM could re-rate the multiple lower if it materializes

Cons (what kills the short)

  • Net-cash fortress balance sheet ($1.07B net cash, D/E 0.06) — no leverage catalyst for a break
  • Real cash generation: OCF > net income, 29% FCF margin, clean accruals (forensic lens passed at 72)
  • Durable moat, recurring consumables, and AirView data platform AI strengthens rather than erodes
  • Buybacks (shares declining ~147.5M to 144.3M) plus rising dividend create a squeeze/support floor
  • Low beta (0.77) and quality-name institutional accumulation limit downside velocity
  • Unlimited-loss asymmetry on shorting a high-ROIC compounder already ~20% off its high

Council scorecard

Lens School Stance Score Conf
Chuck Akre quality 🟢 pass 78 medium
Warren Buffett quality 🟢 pass 78 medium
AI & Disruption Referee (Christensen-style) referee 🟢 pass 78 medium
Charlie Munger quality 🟢 pass 78 medium
Terry Smith (Fundsmith) quality 🟢 pass 78 medium
Philip Fisher growth 🟢 pass 76 medium
Michael Mauboussin quality 🟢 pass 75 medium
Valuation Referee (Damodaran-style) referee 🟢 pass 74 medium
Ray Dalio risk 🟢 pass 72 medium
Forensic Short-Seller (Chanos/Einhorn-style) referee 🟢 pass 72 medium
Joel Greenblatt value 🟡 watch 62 medium
Bruce Greenwald value 🟡 watch 62 medium
Howard Marks risk 🟡 watch 58 medium
Peter Lynch growth 🟡 watch 55 medium
Stanley Druckenmiller risk 🟡 watch 52 medium
Benjamin Graham value 🟡 watch 52 medium
Seth Klarman value 🟡 watch 52 medium
Paul Singer value 🟡 watch 52 medium
Walter Schloss value 🔴 avoid 28 high

Member reasoning

Chuck Akre — 🟢 pass · 78/100 · medium confidence

ResMed passes the Akre three-legged stool test with meaningful conviction, though one leg — reinvestment runway clarity — carries a question mark from the ventilator recall/guidance miss and the MatrixCare divestiture. Leg 1 (extraordinary business): RMed is a near-monopoly in CPAP/APAP therapy for obstructive sleep apnea (OSA), a chronic, underdiagnosed condition with decades of underpenetration globally. It enjoys strong switching costs (device-physician-patient ecosystems), a recurring consumables revenue stream (masks, accessories), and embedded software via cloud-connected devices. Operating margin of 33.4% and FCF margin of 29.2% (FY2026, per fundamentals) on $5.65B revenue confirm the capital-light, high-margin franchise. ROIC of 21.3% and ROE of 23.1% (fundamentals) are well above cost of capital and achieved WITHOUT financial engineering: debt-to-equity is only 6.1% (long-term debt $399M vs. equity $6.6B per the 10-K filed 2026-08-13). This is a genuine business return, not a leverage artifact. Leg 2 (management quality/integrity): Capital allocation has been rational. Long-term debt was $1.44B in FY2023 (10-K filed 2024-08-09 shows FY2023 long-term debt ~$1.435B) and has been steadily repaid to $399M by FY2026 — demonstrating disciplined balance sheet management. The MatrixCare sale and earmarking proceeds for buyback is consistent with capital return below intrinsic value (stock 20% off 52-week high). Dividend was increased in conjunction with Q4 FY2026 results. Minor concern: CEO sold ~$1M of stock per the narrative (Aug 2026), and there are acquisition and portfolio review related expenses of $11.5M in FY2026 vs. $2M in FY2025 (10-K filed 2026-08-13), plus the Noctrix acquisition for $335M (June 1, 2026) — so M&A activity is increasing. The Noctrix deal price appears reasonable for a wearable therapeutics platform that extends the OSA franchise. Non-GAAP presentation is standard and reconciliations are transparent in the 10-K. No restatements or related-party red flags visible. Field safety notifications (masks with magnets, Astral ventilator component) are disclosed promptly and accrued properly ($45.7M field safety notification expenses in accrued liabilities at June 30, 2026 per 10-K vs. $4.8M prior year) — a meaningful jump that partially explains the FY2027 guidance miss. Integrity bar is met. Leg 3 (reinvestment runway): OSA remains vastly underpenetrated globally — hundreds of millions of undiagnosed patients. The Residential Care Software segment (though MatrixCare is being divested) and the Sleep and Breathing Health segment both present reinvestment opportunities. However, FCF grew from $216M in FY2022 to $1.65B in FY2026 (per history), but FCF was essentially flat YoY between FY2025 ($1.66B) and FY2026 ($1.65B), and FCF margin ticked down from 32.3% to 29.2% — this could reflect Noctrix acquisition costs and field safety costs, or it could indicate early margin pressure. The Astral ventilator recall creates near-term noise. Reinvestment at high rates into OSA device innovation, connected care software, and geographic expansion remains the core thesis — the runway is long if the core franchise holds. Valuation: DCF base case of $297.54/share (per valuation block) vs. current price of $228.35 implies ~30% upside. Bear case is $233 — only modestly above current price, which is the key risk. At P/FCF of ~20x and P/E of ~21.6x on a business compounding FCF at a ~10% 3-year CAGR, this is a reasonable but not cheap price for an Akre-style holding. The PEG of 2.12 is elevated, suggesting the market is paying up for quality. AI risk: ResMed's connected-device platform (cloud-connected CPAPs feeding data to myAir and to physicians) could be enhanced significantly by AI-driven adherence coaching and sleep diagnostics — this is a tailwind, not a threat. AI is unlikely to disintermediate the core hardware/consumables revenue. However, GLP-1 weight-loss drugs (not explicitly in the fact base but a known market risk) could reduce OSA prevalence over time — this is the key unmodeled risk in the DCF. Confidence is medium rather than high because: (1) no earnings call transcript to assess management tone; (2) FY2027 guidance specifics unknown; (3) Astral recall magnitude/duration unclear; (4) GLP-1 impact on TAM not addressed in filings. Overall: two-and-a-half legs are clearly intact; the half-leg hesitation is on reinvestment-at-high-rates visibility given near-term headwinds. Score 78.

Key points

  • ROIC of 21.3% and ROE of 23.1% achieved with only 6.1% debt-to-equity — genuine business economics, not leverage (fundamentals, 10-K filed 2026-08-13)
  • FCF compounded from $216M (FY2022) to $1.65B (FY2026) — per-share FCF growth is the engine of value creation (fundamentals history)
  • Capital-light franchise: capex only $156M on $5.65B revenue (2.8% capex intensity), FCF margin 29.2% (FY2026, fundamentals)
  • Balance sheet strength: long-term debt reduced from ~$1.44B (FY2023) to $399M (FY2026); $1.47B cash; net cash position of ~$1.07B (valuation assumptions)
  • DCF intrinsic value $297.54/share vs. $228.35 market price = ~30% margin of safety; bear case $233 provides thin but positive cushion (valuation block)
  • Noctrix acquisition ($335M, June 1, 2026) extends OSA wearable therapeutics franchise — appears strategically coherent (10-K filed 2026-08-13)
  • Global OSA underpenetration provides multi-decade reinvestment runway; AI-enhanced adherence tools are a tailwind for the connected-device platform
  • MatrixCare sale + buyback acceleration demonstrates management willingness to prune non-core assets and return capital rationally

Red flags

  • Field safety notification accrual jumped from $4.8M to $45.7M YoY (10-K filed 2026-08-13) — Astral ventilator recall is a material near-term headwind of uncertain duration and financial magnitude
  • FY2026 FCF flat vs. FY2025 ($1.65B vs. $1.66B) and FCF margin declined from 32.3% to 29.2% — early sign of margin pressure or one-time costs worth monitoring (fundamentals history)
  • Restructuring charges of $21.7M in 9 months ended March 2026 for workforce actions (10-Q filed 2026-05-01) — suggests operational re-organization risk
  • CEO insider sale of ~$1M in Aug 2026 (narrative) combined with FY2027 guidance miss signals near-term uncertainty
  • PEG of 2.12 and P/FCF ~20x: not cheap; thin margin of safety in bear-case DCF ($233 vs. $228 current price) leaves little room for error
  • GLP-1 weight-loss drug adoption could structurally reduce OSA TAM over a 5-10 year horizon — not modeled in DCF assumptions and not addressed in available filings
  • No earnings call transcript available — management tone, FY2027 guidance specifics, and recall response details unverified

Warren Buffett — 🟢 pass · 78/100 · medium confidence

ResMed is a high-quality medical device franchise with durable competitive characteristics that fit squarely within the Buffett quality lens. The business is understandable — it makes CPAP/sleep therapy devices and related masks/accessories for obstructive sleep apnea, plus software for residential care. The economics are excellent: ROIC of 21.3%, ROE of 23.1% (fundamentals block), operating margins of 33.4% (10-K filed 2026-08-13: GAAP revenue $5.65B, operating income $1.89B), and FCF margins expanding dramatically from 6% in FY2022 to ~29-32% by FY2025-2026 (history block). This FCF surge reflects real earnings quality — operating cash flow of $1.81B versus capex of only $156M (fundamentals), yielding ~$1.65B owner earnings. The balance sheet is conservative: long-term debt of only $399M (10-K 2026-08-13), cash of $1.47B, resulting in net cash of approximately $1.07B (valuation block: net debt = -$1.07B). Debt-to-equity of 0.06 (fundamentals) is essentially negligible. Revenue has grown at a 10.2% 3-year CAGR (fundamentals). The moat appears real: ResMed dominates the global CPAP/sleep therapy market with sticky device-and-mask ecosystems, recurring consumable mask revenue, and proprietary cloud-connected device data (AirSense platform) creating switching costs for patients, providers, and payors. The DCF intrinsic value of ~$297/share (valuation block) implies ~30% upside to the current $228.35, with a bear-case of $233 providing modest but real margin of safety. At 21.6x P/E and 20x price-to-FCF, the price is not cheap but is fair for this quality tier — a wonderful business at a fair price. Capital allocation is rational: dividend increase, share buyback from MatrixCare proceeds, and selective tuck-in acquisitions (Noctrix Health for $335M per 10-K 2026-08-13). Near-term headwinds include ventilator recall issues (Astral field safety notification; accrued field safety expenses jumped from $4.8M to $45.7M per 10-K 2026-08-13), which creates FY2027 guidance uncertainty and is a watch item. CEO share sales ($1M, per narrative) and the FY2027 guidance miss are modest red flags but not disqualifying. On AI disruption: AI likely enhances ResMed's moat by improving diagnostic algorithms, patient adherence monitoring, and payors' data requirements — all areas where ResMed's connected-device data advantage deepens. AI is not a near-term commoditizing threat to CPAP hardware or consumable masks.

Key points

  • Exceptional FCF conversion: $1.65B FCF on $5.65B revenue (29% FCF margin), with operating cash flow of $1.81B vs. capex of only $156M (fundamentals, 10-K 2026-08-13) — true owner earnings with minimal maintenance capex drag
  • ROIC of 21.3% and ROE of 23.1% (fundamentals) achieved with near-zero leverage (D/E = 0.06), exactly the high-returns-without-debt profile Buffett prizes
  • Conservative balance sheet: net cash position of ~$1.07B (valuation block), long-term debt only $399M vs. $1.81B annual operating cash flow — self-funding through any reasonable downturn
  • Revenue 3-year CAGR of 10.2% compounding on a $5.65B base; net income grew from $779M in FY2022 to $1.52B in FY2026 (history block) — consistent, non-cyclical earnings growth
  • Recurring consumables (masks/accessories) create predictable re-order economics; operating lease revenue as lessor of $103M in FY2026 (10-K 2026-08-13) adds a recurring layer
  • DCF intrinsic value ~$297/share vs. $228.35 current price implies ~30% upside; bear case of $233 provides thin but positive margin of safety (valuation block)
  • Rational capital allocation: dividend increase, MatrixCare divestiture with proceeds earmarked for buyback, tuck-in acquisition of Noctrix Health at $335M (10-K 2026-08-13)
  • AI likely reinforces the moat: connected-device data platform (AirSense ecosystem) deepens switching costs as AI-driven adherence tools become payor requirements

Red flags

  • Astral ventilator field safety notification: accrued expense jumped from $4.8M (June 2025) to $45.7M (June 2026) per 10-K 2026-08-13 — a 9x increase signaling a material liability; full cost and timeline unclear from available filings
  • FY2027 guidance miss attributed to Astral-driven headwinds (narrative); earnings visibility temporarily impaired — inconsistent with the predictability I require
  • Goodwill and intangible asset base from acquisitions is substantial (developed technology and customer relationships balances in 10-Q 2026-05-01); acquired intangibles amortization ~$78M/year (10-K 2026-08-13) — requires monitoring for impairment
  • CEO sold ~$1M of stock in August 2026 (narrative) concurrent with weak guidance — minor but worth noting alongside institutional accumulation
  • SG&A as a percentage of revenue ticked up to 19.8% in FY2026 from 19.3% in FY2025 (10-K 2026-08-13), modest margin pressure; acquisition and restructuring charges in recent years add earnings noise
  • Bear-case DCF of $233 provides very thin margin of safety (~2%) at current price — not the 'fat pitch' I prefer; stock needs to stay near current levels or dip for a truly comfortable entry
  • $21.7M restructuring charges in first nine months of FY2026 (10-Q 2026-05-01) for workforce reduction — suggests some operational adjustment still underway

AI & Disruption Referee (Christensen-style) — 🟢 pass · 78/100 · medium confidence

ResMed's core business is hardware-anchored medical devices (CPAP/BiPAP, ventilators, masks) combined with a cloud-connected data platform (AirSense/myAir/AirView ecosystem) that monitors patient adherence and outcomes. The obsolescence question here is fundamentally different from a pure software or knowledge-work intermediary: the primary 'job' is to physically treat obstructive sleep apnea and respiratory disease by delivering pressurized air through a device strapped to a patient's face. AI cannot replace that physical therapeutic function. There is no disintermediation risk to the core hardware revenue from LLMs or generative AI in any meaningful 3-10 year horizon. The more interesting question is the data and software layer — ResMed's AirView platform monitors 10+ million patients and generates proprietary adherence, efficacy, and physiological data at scale. This proprietary longitudinal dataset is a genuine moat that AI makes MORE valuable, not less: better predictive adherence algorithms, tele-monitoring optimization, payer/provider reporting, and remote care coordination all improve with more data and better models. This is the compounding-moat scenario, not the commoditization scenario. The Residential Care Software segment (now partly exited via MatrixCare sale per the narrative) did carry more AI disruption risk — care coordination software is a knowledge-work workflow product where AI-native competitors (well-funded health-tech startups, or Epic/Oracle bundling) could commoditize. The MatrixCare divestiture (noted in the narrative, July 2026) actually REDUCES that exposure, though the 10-K excerpt confirms the Noctrix acquisition (June 1, 2026 per 10-K filed 2026-08-13) moves ResMed further into wearable therapeutics — a hardware-plus-data direction that AI strengthens rather than threatens. Key AI tailwinds: (1) AI-driven resupply optimization and adherence intervention (ResMed's existing data flywheel gets more valuable); (2) AI-assisted therapy titration reducing in-lab sleep study dependency expands the addressable patient pool (more devices needed, not fewer); (3) Remote patient monitoring reimbursement trends favor connected device makers. Key residual risks: (1) The Residential Care Software segment still exists post-MatrixCare and competes in a space where AI-native entrants and EHR incumbents (Epic, Oracle Health) could bundle workflows more cheaply — this is the segment where hyperscaler/platform capture is a real threat; (2) AI-assisted diagnostic tools (Apple Watch, Whoop, smartphone-based sleep scoring) could theoretically reduce the perceived need for full polysomnography and CPAP prescription pipelines if they become 'good enough' for mild OSA, compressing the addressable market at the margin; (3) Generic/commodity CPAP hardware from Asian manufacturers (already a price pressure vector) could be further enabled by AI-optimized manufacturing and direct-to-consumer channels, eroding ASPs on devices. Management's AI framing: the fact base does not include earnings call transcripts, so direct management commentary on AI strategy is unavailable — this limits confidence. The narrative references 'OSA market growth' broadly but no specific AI strategy language. This is a data gap, not evidence of denial. On balance, ResMed is a medical device company with a strong proprietary data moat that AI amplifies rather than erodes, with the most exposed software segment being divested. The Christensen-style disruption risk is LOW for core device revenue and MODERATE for the remaining software/SaaS segment. The falsifiable bear case: watch for (a) Apple/Samsung/Google launching AI-native sleep apnea screening that captures the mild-OSA market and reduces CPAP prescription rates materially; (b) Epic or Oracle bundling residential care software at near-zero marginal cost, collapsing ResMed's software take-rates; (c) AI-native direct-to-consumer CPAP companies (bypassing traditional DME/prescription channel) gaining share. The falsifiable bull case: (d) ResMed's AirView data enables AI-driven care models that attract new payer contracts or expand into chronic disease management, raising ARPU; (e) AI-assisted auto-titrating devices reduce the need for costly in-lab titration, expanding the diagnosed-and-treated population. Current evidence tilts toward the bull case on the core business.

Key points

  • Core therapeutic value is physical device delivery of pressurized air — AI cannot replicate or disintermediate this function on any 3-10 year horizon
  • Proprietary AirView/myAir platform monitors 10M+ patients; longitudinal adherence and physiological data is a compounding moat that AI makes MORE valuable, not less
  • MatrixCare divestiture (narrative, July 2026) reduces exposure to the most AI-vulnerable segment — care coordination SaaS where Epic/Oracle/AI-native entrants could commoditize
  • Noctrix acquisition (10-K filed 2026-08-13, closed June 1, 2026) moves ResMed deeper into wearable therapeutics — hardware-plus-data direction aligned with AI tailwind
  • AI-assisted auto-titration and remote monitoring reimbursement trends structurally expand the addressable OSA patient pool, benefiting device volumes
  • Revenue CAGR of ~10% (fundamentals) and FCF margin expansion to 29-32% over FY2022-2026 show no current evidence of pricing/take-rate compression consistent with commoditization

Red flags

  • Residential Care Software segment (still present post-MatrixCare) competes in knowledge-work workflows where EHR incumbents (Epic, Oracle Health) could bundle AI-native capabilities at near-zero marginal cost — hyperscaler/platform capture risk is real here
  • Apple Watch, Whoop, and smartphone sleep-scoring AI could commoditize mild-OSA screening at the margin, potentially reducing CPAP prescription conversion rates for the largest addressable cohort over 5-10 years
  • No earnings call transcript available — cannot verify whether management has an honest, funded AI strategy or is treating it as pure marketing veneer; this is a genuine evidence gap
  • Astral ventilator recall (field safety notification expenses of $45.7M accrued per 10-K filed 2026-08-13) and FY2027 guidance miss (narrative) create near-term uncertainty that masks whether any demand softness has an AI/competitive component
  • Generic CPAP hardware competition (AI-optimized Asian manufacturing, direct-to-consumer channels) could pressure device ASPs even if ResMed retains the data/software premium

Charlie Munger — 🟢 pass · 78/100 · medium confidence

ResMed is precisely the kind of business Munger prizes: a durable, understandable franchise with a genuine moat, high returns on capital, and earnings that convert robustly to free cash flow. The company dominates the CPAP/sleep-apnea device market through a combination of proprietary hardware, a cloud-connected data ecosystem (AirView/myAir), and deep payer/physician relationships that create real switching costs. The unit economics are simple: sell a device, attach a recurring mask/consumable stream, and collect data that entrenches the clinical workflow. The moat is identifiable and has been durable across multiple years of data in the fact base.

On returns: ROIC of 21.3% and ROE of 23.1% (fundamentals block) substantially exceed the 8.1% WACC, and this has been sustained across the multi-year history. FCF margins have exploded from 6% in FY2022 to 29% in FY2026 (history table), which is not a one-year artifact — the FY2025 FCF margin was 32.3%. Operating income of $1.89B on $5.65B revenue (33.4% operating margin, 10-K FY2026) is the kind of unit economics Munger respects. Owner earnings — operating cash flow of $1.81B less $156M capex = roughly $1.65B — are real and largely match reported FCF.

Balance sheet is clean. Long-term debt of $399M against $1.47B cash (10-K FY2026) leaves the company in a net cash position of roughly $1.07B. Debt-to-equity is 0.06. This balance sheet survives any plausible downturn.

Accounting quality is acceptable. Non-GAAP adjustments are disclosed and reconciled (10-K FY2026). The main adjustments — acquired intangibles amortization and field safety notification costs — are real charges but disclosed transparently. FCF conversion from net income is strong (FCF of $1.65B vs net income of $1.52B for FY2026), which is the signature of honest earnings. The one note of caution: field safety notification accruals jumped from $4.8M to $45.7M between FY2025 and FY2026 (accrued expenses table, 10-K FY2026) — the Astral ventilator component replacement issue is a real cost and a real operational risk, not a phantom. The masks-with-magnets issue is a separate but smaller liability.

Management capital allocation has been rational: debt was reduced from $1.44B (FY2023) to $399M long-term (FY2026) while FCF grew; dividends were increased; the MatrixCare sale (narrative) and planned buyback suggest willingness to exit non-core assets and return capital rather than empire-build. The Noctrix acquisition at $335M (10-K FY2026) is modest relative to FCF and plausibly adjacent. I note with mild concern that CEO sold ~$1M of stock (narrative, Aug 2026) coinciding with the guidance miss — not disqualifying but worth watching.

Valuation: The two-stage DCF yields $297.54 intrinsic value vs $228.35 market price — roughly 30% upside in the base case. The bear-case DCF is $233, barely above current price, which means at current price the stock is priced near the bear scenario. P/E of 21.6x and price-to-FCF of 20x for a 21%+ ROIC, ~10% revenue CAGR business is not cheap but is not expensive for the quality. A 5% FCF yield on a business reinvesting at 20%+ incremental returns is a reasonable entry. Revenue CAGR of 10.2% (3-year, fundamentals block) used in the DCF is plausible given OSA market underpenetration — estimated diagnosis rates remain low globally.

AI/disruption lens: AI is a tailwind for ResMed, not a threat. Remote patient monitoring, adherence analytics, and device-generated sleep data are areas where ResMed's existing AirView platform already operates. AI could enhance clinical decision support and deepen the data moat. The risk of AI commoditizing hardware is real but modest in the 3-5 year window — FDA clearance requirements and clinical validation create high barriers. The larger AI risk is if a tech giant entered remote monitoring at scale, but ResMed's installed base and payer integrations create substantial switching costs.

Inversion test: How does this go to zero or permanently impair capital? (1) A dominant new therapy (GLP-1 drugs reducing OSA prevalence) could shrink the addressable market — this is the most serious structural risk but OSA severity and comorbidities suggest PAP therapy remains necessary even for patients losing weight; the market likely grows even if patient mix shifts. (2) The Astral/ventilator recall worsens dramatically and generates massive liability — possible but the $45.7M accrual (10-K FY2026) and the company's FCF capacity suggest it is manageable. (3) Regulatory reimbursement changes — always a risk for medical device companies, not unique to ResMed. None of these answers 'yes, capital can be permanently destroyed with high probability.'

What holds the score below 85: (1) FY2027 guidance miss (narrative) creates genuine uncertainty about near-term earnings power — the market is pricing in real risk; (2) the field safety notification cost jump ($45.7M accrual) is a tangible operational issue whose full scope is unclear from the fact base — I am missing the full Q4 call transcript; (3) at 20x FCF the stock is fair but not obviously cheap — the margin of safety is moderate, not wide; (4) GLP-1 drug competition is a genuine long-term uncertainty on the TAM that I cannot fully dismiss.

Key points

  • ROIC of 21.3% and ROE of 23.1% (fundamentals block) substantially exceed WACC, sustained over multiple years — clear evidence of durable excess returns
  • FCF margins expanded from 6% (FY2022) to 29-32% (FY2025-2026 history table) — genuine operating leverage, not accounting alchemy
  • Balance sheet extremely clean: LT debt $399M vs cash $1.47B (10-K FY2026), debt-to-equity 0.06 — no refinancing risk
  • Owner earnings (OCF $1.81B minus capex $156M = ~$1.65B) closely match reported FCF — earnings are real
  • Two-stage DCF base case $297.54 vs $228.35 market price implies ~30% upside; bear case $233 means current price is near a pessimistic scenario
  • Revenue CAGR of 10.2% (3-year) is plausible given chronic OSA underdiagnosis globally — reinvestment runway exists
  • Capital allocation improving: debt reduced from $1.44B (FY2023) to $399M LT (FY2026) while FCF grew; dividend raised; MatrixCare sold rather than retained
  • AI is a tailwind via AirView remote monitoring platform — data ecosystem deepens switching costs rather than being commoditized away

Red flags

  • Field safety notification accrual jumped from $4.8M to $45.7M (10-K FY2026 accrued expenses table) — Astral ventilator issue is a real cost whose full scope is unclear without Q4 transcript
  • FY2027 guidance disappointed the market (narrative) — 'Astral-driven guidance miss' suggests this headwind persists into the forward year
  • CEO sold ~$1M of stock in August 2026 coinciding with weak guidance (narrative) — minor but noted
  • GLP-1 drugs reducing OSA severity/prevalence represent a genuine long-term TAM risk that is not quantifiable from the fact base
  • Non-GAAP reliance is moderate — amortization of acquired intangibles adds back $78M+ annually (10-K FY2026 segment D&A table); legitimate but bears watching if acquisition pace accelerates
  • At 20x FCF the margin of safety is moderate rather than wide — the stock is priced for the business being good, leaving limited room for execution disappointment

Terry Smith (Fundsmith) — 🟢 pass · 78/100 · medium confidence

ResMed is exactly the kind of business Fundsmith would scrutinize closely: a dominant medical-device franchise with recurring consumable revenues (masks, accessories), essential healthcare demand tied to obstructive sleep apnea and respiratory care, and demonstrably high returns on invested capital. The quality case is strong but carries some Fundsmith-style reservations around acquisitiveness, non-GAAP reliance, field safety notification charges, and near-term guidance uncertainty from ventilator issues. On balance, the business clears the quality bar comfortably, and the current price offers a meaningful margin of safety relative to the DCF intrinsic value — though not a screaming bargain.

ROCE/ROIC: The fact base reports ROIC of 21.3% and ROE of 23.1% for FY2026 (fundamentals block). Operating margin is 33.4% (FY2026 10-K: GAAP income from operations $1.887B on revenue $5.653B). These are sustained — the FY2025 10-K shows similar margins — placing ResMed well above a 20% ROCE threshold across multiple years. Smith's first test: pass.

Cash conversion: FCF of $1.650B versus net income of $1.523B for FY2026 (fundamentals). FCF margin 29.2%. Free cash flow is tracking above reported net income — textbook quality cash conversion. Capex is light at $156M on $5.65B revenue (~2.8%), confirming asset-light characteristics. Smith's cash-conversion test: pass.

Margins: Operating margin 33.4%, net margin 26.9%, FCF margin 29.2%. These are durable and high. The mask/accessory consumable cycle creates repeat-purchase revenue — highly Fundsmith-friendly. The Sleep and Breathing Health segment drives the core; Residential Care Software (MatrixCare, being divested per narrative) was the more questionable piece and is being shed.

Balance sheet: Debt has been rapidly reduced. Long-term debt fell from $1.435B (FY2023 10-K) to $700M (FY2024) to $660M (FY2025) to $399M (FY2026 fundamentals). Cash stands at $1.469B, giving net cash of approximately $1.07B (valuation block: net_debt = -$1.07B). This is now a net-cash business — a green flag for Smith who fears leverage.

Capital allocation concerns: The 10-K (filed 2026-08-13) discloses the $335M acquisition of Noctrix Health (June 1, 2026), a wearable therapeutics company. Smith is skeptical of serial acquisitions. The narrative also references the VirtuOx acquisition (FY2025) and the MEDIFOX DAN acquisition referenced in earlier filings. There is a pattern of bolt-on M&A which adds goodwill and acquired intangibles (amortization of acquired intangibles was $78M in FY2026 per the 10-K segment note). The company relies partly on non-GAAP metrics to back out these amortization charges and acquisition-related costs — a classic Fundsmith red flag. However, since FCF comfortably exceeds GAAP net income, the cash backing is real; the non-GAAP presentation is more cosmetic than masking a cash-generation problem here.

Field safety notifications: The 10-K (2026-08-13) discloses two active field safety notification accruals — $45.7M for masks-with-magnets and an Astral ventilator component replacement program. These are real costs and the Astral issue is reportedly behind the FY2027 guidance miss (narrative). This is a quality/execution demerit and adds near-term earnings uncertainty.

Valuation: The DCF intrinsic value is $297.54/share versus current price $228.35, implying ~30% upside (valuation block). P/E of 21.6x, price-to-FCF of 20.0x, FCF yield of ~5%. For a business growing revenue at ~10% CAGR (3-year, fundamentals) with 33% operating margins and net-cash balance sheet, a 20x FCF multiple is not cheap but is defensible. Smith would ask: is the reinvestment runway long enough to justify holding? Given global OSA underdiagnosis rates and the recurring consumable stream, yes — though the ventilator recall risk and M&A pattern are modest valuation headwinds.

AI disruption: AI is more enabler than threat for ResMed. The company's AirSense platform already uses cloud connectivity and data analytics for patient adherence and remote monitoring — an AI-augmented moat. AI-driven OSA diagnosis tools (apps, wearables) could theoretically reduce CPAP device volumes long-term, but given that devices and masks are reimbursed through established healthcare channels with regulatory approval requirements, disruption is slow. Near-term AI impact: neutral to mildly positive (better adherence data, stronger physician integration).

Summary: ResMed is a high-quality compounder — strong ROIC, exceptional margins, excellent cash conversion, asset-light, now net-cash — that fits the Fundsmith template well. The demerits (M&A pattern, non-GAAP reliance, field safety notifications, FY2027 guidance uncertainty) prevent a higher score but do not undermine the core quality thesis. The price offers ~30% upside to DCF base case with a bear-case of $233, suggesting limited downside to intrinsic value. A pass, not a high-conviction one.

Key points

  • ROIC of 21.3% and operating margin of 33.4% for FY2026 (10-K filed 2026-08-13) — sustained high returns on capital clearing the Fundsmith 20%+ threshold
  • FCF of $1.650B exceeds GAAP net income of $1.523B in FY2026; capex only ~2.8% of revenue — textbook asset-light cash conversion
  • Long-term debt reduced from $1.435B (FY2023) to $399M (FY2026); net cash position of ~$1.07B — balance sheet has been meaningfully de-risked
  • Recurring consumable revenue (masks, accessories) provides repeat-purchase, non-cyclical demand stream — exactly the Fundsmith-preferred revenue model
  • DCF intrinsic value of $297.54 vs. $228.35 current price (~30% upside); price-to-FCF of ~20x is reasonable for this quality profile
  • MatrixCare divestiture and accelerated buyback signal management willingness to optimize portfolio and return capital

Red flags

  • Serial bolt-on M&A: Noctrix ($335M, June 2026), VirtuOx (FY2025), MEDIFOX DAN — recurring acquisition activity adds goodwill/intangibles and management complexity (10-K 2026-08-13)
  • Non-GAAP earnings presentation backs out ~$78M amortization of acquired intangibles plus acquisition costs — Smith distrusts adjusted metrics even when FCF confirms underlying cash generation
  • Active field safety notifications: $45.7M Astral ventilator accrual and masks-with-magnets liability (10-K 2026-08-13) — execution risk and FY2027 guidance headwind
  • Insider selling: CEO sold ~$1M of stock (Aug 2026 per narrative) — minor but directionally cautious signal alongside guidance disappointment
  • FY2027 guidance miss attributed to Astral ventilator issues (narrative) — near-term earnings uncertainty reduces confidence in near-term compounding

Philip Fisher — 🟢 pass · 76/100 · medium confidence

ResMed passes the Fisher growth lens on most criteria but with meaningful caveats on near-term execution headwinds. The core franchise — dominant position in CPAP/sleep-disordered breathing devices, a recurring mask/accessory revenue stream, and a growing digital health/SaaS layer — fits Fisher's template of a company with a visible multi-year runway rooted in R&D-driven product expansion and an expanding addressable market (obstructive sleep apnea remains massively underdiagnosed globally). Revenue CAGR of ~10.2% over three years (per fundamentals block) is solid for a medical device company of this scale. FCF conversion has improved dramatically — FCF margin expanded from 6% in FY2022 to ~29-32% in FY2024-2026 (per the historical table in fundamentals), signaling genuine operating leverage rather than financial engineering. Operating margin of 33.4% (fundamentals, FY2026) is best-in-class for the sleep/respiratory segment and indicates strong pricing power and cost discipline. However, Fisher's bar demands candor about headwinds: the Astral ventilator field safety notification, the masks-with-magnets recall costs, and an FY2027 guidance miss (per the narrative) are exactly the kind of operational stumbles Fisher scrutinized for management character. The fact that accrued field safety notification expenses jumped from $4.8M to $45.7M (10-K filed 2026-08-13, Note 7) is a material increase that needs watching. The MatrixCare divestiture is a positive signal — pruning non-core software to refocus on the core sleep/breathing franchise — but using proceeds for buybacks rather than organic reinvestment raises a mild Fisher flag about long-term reinvestment philosophy. R&D spend is not broken out in the excerpts available, which limits confidence. The Noctrix Health acquisition ($335M, completed June 1, 2026 per 10-K filed 2026-08-13) for clinically validated wearable therapeutics is consistent with Fisher's criterion of management seeking new markets before current ones mature. Balance sheet is conservatively leveraged: long-term debt of $399M vs. $1.47B cash (fundamentals, FY2026), D/E of 0.06, giving ample firepower. AI risk is real but manageable — AI could enhance ResMed's digital health data platform (AirView has millions of connected patients) rather than commoditize it, at least over a 3-10 year horizon; the data moat from remote monitoring becomes MORE valuable as AI analytics improve. The primary Fisher risk is the current guidance credibility problem and whether management communicates transparently about recall scope and duration — no transcript was available to assess candor directly, which is a key evidence gap.

Key points

  • Revenue CAGR of ~10.2% over 3 years (fundamentals block) with FCF margin expanding from 6% (FY2022) to ~29% (FY2026), per the historical fundamentals table — this is genuine operating leverage, not accounting noise
  • Operating margin 33.4% (FY2026, fundamentals) signals best-in-class competitive position in sleep/respiratory, consistent with Fisher's margin defense criterion
  • Noctrix Health acquisition ($335M, June 1, 2026; 10-K filed 2026-08-13) — wearable therapeutics expanding addressable market; Fisher rewards pre-emptive R&D/M&A before core matures
  • Balance sheet fortress: $1.47B cash, LT debt only $399M, D/E 0.06 (fundamentals, FY2026); no dilutive equity risk, enabling long-term reinvestment
  • MatrixCare divestiture and refocus on core sleep/breathing health is strategically coherent with Fisher's emphasis on companies with deep franchise competency rather than conglomerates
  • AI/digital health tailwind: ResMed's AirView connected-device platform with millions of patients becomes MORE valuable with AI analytics — data moat reinforces, not erodes, competitive position over 3-10 years
  • DCF intrinsic value $297.54/share vs. $228.35 price = 30% upside (valuation block), with bear case $233 suggesting limited downside near current price — margin of safety exists even under conservative assumptions
  • Institutional accumulation in late August 2026 (HSBC, Legal & General, Deutsche Bank, Mitsubishi UFJ AM; per narrative) corroborates independent external validation of franchise quality — Fisher's scuttlebutt analog

Red flags

  • Field safety notification accrual surged from $4.8M to $45.7M (10-K filed 2026-08-13, Note 7 on Astral ventilators) — material step-up in recall costs; scale and duration of resolution unclear from available filings
  • FY2027 guidance miss attributed to Astral-driven headwinds (narrative/TIKR Aug 25) — without a transcript, impossible to assess whether management communicated this proactively and candidly (critical Fisher criterion on integrity)
  • R&D spend as a percentage of revenue not available in the excerpts — cannot verify the productive R&D criterion that is central to Fisher's framework; this is a key evidence gap
  • Buyback-focused capital deployment from MatrixCare proceeds (narrative) rather than organic reinvestment signals possible limits to high-return internal reinvestment opportunities — mild concern for a Fisher-style compounder
  • CEO sold ~$1M of stock Aug 11, 2026 (narrative) concurrent with guidance disappointment; not disqualifying alone but directionally negative on management confidence signal
  • SG&A as % of revenue ticked up to 19.8% in FY2026 from 19.3% in FY2025 (10-K filed 2026-08-13, MD&A table) — small but worth monitoring for cost discipline trend
  • Restructuring charges of $21.7M in first nine months of FY2026 (10-Q filed 2026-05-01) for workforce severance — suggests ongoing organizational churn inconsistent with Fisher's ideal of stable, excellent employee relations

Michael Mauboussin — 🟢 pass · 75/100 · medium confidence

ResMed earns a 'pass' through the Mauboussin lens primarily because ROIC clearly exceeds WACC, the moat sources are concrete and mechanistically defensible, and the current price embeds expectations that appear roughly consistent with a conservative-to-base case scenario — not a right-tail demand. The key reservation is near-term uncertainty around the Astral ventilator recall, FY2027 guidance disappointment, and a residual value that constitutes ~79% of the DCF (per the valuation block), meaning the terminal value does enormous lifting and any moat erosion has outsized consequences.

ROIC vs. WACC Scorecard: The fact base shows ROIC of 21.3% (fundamentals block) against a WACC of 8.12% (valuation block), yielding a spread of approximately 1,300 basis points. Operating margin of 33.4% and FCF margin of 29.2% (FY2026, 10-K filed 2026-08-13) confirm this is not a thin-spread, commodity-like business. ROE of 23.1% corroborates. The spread has been widening: FCF margin moved from 6.1% in FY2022 to 32.2% in FY2025 before settling at 29.2% in FY2026 (fundamentals history block), a structurally improving trajectory rather than cyclical luck. However, I must note that part of this FCF improvement likely reflects normalization of working capital and capex post-supply-chain disruption; the base rate says high-ROIC spreads mean-revert, so I weight the persistence question heavily.

Moat Concreteness: Three mechanisms are identifiable from the filing evidence:

  1. Switching costs (high): CPAP/APAP therapy is titrated to individual patients, data is captured on ResMed's AirSense/AirView cloud platform (referenced across 10-K filings), and switching devices disrupts compliance data continuity for physicians and payers. The SaaS/connected-device architecture creates genuine procedural switching costs — not just brand loyalty.
  2. Scale economies and intangibles (moderate-to-wide): The Sleep and Breathing Health segment generates D&A of $112M (FY2026, 10-K) with $5.65B in revenue, suggesting substantial fixed-cost leverage. Patent/IP barriers in sleep diagnostics and respiratory care are standard in medtech; the 10-K references intangible amortization of ~$78M/year implying significant acquired IP, though the useful-life schedule (2–40 years per 10-K, 2026-08-13) is wide.
  3. Regulatory and reimbursement moat (narrow-to-moderate): Third-party reimbursement is noted as a key variable (10-K and 10-Q alike), which cuts both ways — it creates barriers to new entrants (who must navigate the same reimbursement landscape) but also creates payer-concentration risk and pricing exposure. The Residential Care Software segment (now being divested via MatrixCare sale per narrative) added customer-relationship switching costs in care-coordination workflows, though that moat is being exited.

Overall moat rating: Wide, but with a stable-to-slightly-eroding trajectory given: (a) GLP-1 drugs (Ozempic/Wegovy class) as a potential long-run demand headwind for OSA — not quantified in the fact base but a known structural question; (b) Astral recall uncertainty creating near-term volume uncertainty in ventilators (narrative); (c) MatrixCare divestiture removes one switching-cost layer, though it simplifies capital allocation.

Expectations Investing — What's Priced In? The DCF intrinsic value is $297.54/share vs. current price of $228.35 (valuation block), implying ~30% upside at base. The base case uses ~10.2% FCF growth (revenue CAGR) and an 8.12% WACC with 2.5% terminal growth. Working backwards from the current price: at $228.35, the market is roughly pricing in FCF growth closer to 6–7% annually or a somewhat higher discount rate — neither assumption requires heroic optimism. The bear case at $233 (valuation block) is almost exactly the current price, suggesting the market is already pricing in near-bear conditions. For the base case to fail, FCF growth would need to sustain below the revenue CAGR of the past 3 years (10.2%) — plausible given GLP-1 headwinds and recall, but not the median outcome. P/FCF of 19.97x (fundamentals) on a business with 21%+ ROIC and 33% operating margins is not demanding by historical medtech standards. P/E of 21.6x with 27% net margins implies an earnings yield of 5.9% — modestly above the WACC, providing some margin of safety.

Distribution of Outcomes:

  • Bull (25% weight): GLP-1 uptake proves complementary rather than substitutive to CPAP, ventilator recall resolved quickly, MatrixCare sale proceeds accelerate buyback at attractive prices, FCF grows 12–15%, stock reaches $350–400.
  • Base (50% weight): Steady 8–10% revenue/FCF growth, OSA market continues expanding, recall costs manageable (~$45.7M field safety expense already accrued per 10-K 2026-08-13), stock converges toward $280–310.
  • Bear (25% weight): GLP-1 drugs meaningfully reduce new CPAP patient starts over 5 years, ventilator recall drags FY2027 more than anticipated, payer pressure on reimbursement rates, FCF growth decelerates to 3–5%, stock range $170–230.

The fat left tail is GLP-1 structural displacement — the fact base does not quantify this and I cannot assert a number, but it is the single most important outside-view question for the moat's 10-year trajectory.

Capital Allocation: The shift from debt repayment (long-term debt dropped from $1.44B in FY2023 to $399M in FY2026 per 10-K 2026-08-13) to buybacks and dividend growth reflects disciplined capital allocation as the balance sheet healed. The Noctrix Health acquisition ($335M, June 2026 per 10-K 2026-08-13) for wearable sleep therapeutics is early-stage and small relative to FCF — a plausible adjacency bet, not empire-building. MatrixCare divestiture (narrative) removes a subscale SaaS segment that was generating ROU asset impairments and restructuring charges. These moves are consistent with ROIC-focused management, not value-destructive empire-building. Insider selling (CEO ~$1M, per narrative) is minor relative to FCF and not disqualifying.

Skill vs. Luck: The FCF ramp from $216M (FY2022) to $1.65B (FY2026) is partially supply-chain normalization and partially the structural benefit of competitors (Philips) having a major recall that gifted ResMed market share — outside-view, some of this was luck. However, the operating margin expansion from pre-COVID levels to 33%+ suggests genuine scale and operating leverage that is unlikely to fully reverse.

AI and Technology Disruption: AI is potentially both a threat and an opportunity. As a risk: AI-assisted diagnostics could reduce referral pathways that funnel patients to CPAP/APAP therapy (disintermediation of the diagnostic chain). As an opportunity: ResMed's AirView connected platform and patient data assets could be enhanced by AI-driven compliance coaching, early-warning deterioration signals, and physician workflow integration — deepening switching costs. On balance, AI appears modestly net-positive over 3–10 years through the connected-device/data moat, but the GLP-1 question is a larger structural threat than AI displacement specifically.

Key points

  • ROIC of 21.3% vs. WACC of 8.12% = ~1,300bp spread; FCF margin expanded from 6% (FY2022) to 29% (FY2026) per fundamentals history — wide and improving ROIC-WACC spread, the primary criterion
  • Concrete moat mechanisms: procedural switching costs (AirView data continuity), scale/IP intangibles (~$78M amortization/yr), and reimbursement-channel barriers — not just adjective-based brand claims
  • Current price of $228.35 is near the DCF bear case of $233, implying market has already priced in near-worst scenario; base case intrinsic value $297.54 provides ~30% upside without requiring heroic growth assumptions
  • P/FCF of ~20x on 29% FCF margins and 21%+ ROIC is not demanding; expectations embedded in current price require only ~6–7% FCF growth vs. 10.2% trailing CAGR
  • Capital allocation improving: long-term debt reduced from $1.44B (FY2023) to $399M (FY2026); MatrixCare divestiture removes subscale SaaS drag; Noctrix acquisition ($335M) is adjacency bet, not empire-building
  • Field safety expenses accrued: $45.7M (FY2026, 10-K 2026-08-13) vs. $4.8M (FY2025) for masks/Astral recall — material but bounded cost; key question is whether ventilator recall extends into FY2027 volume guidance miss

Red flags

  • GLP-1 drug structural risk to OSA patient incidence is the single largest unquantified tail risk to the moat's 10-year durability — not addressed in the fact base, cannot be sized, but must be acknowledged
  • Terminal value constitutes 79.1% of DCF equity value (valuation block) — entire investment thesis rests on moat persistence assumptions that are inherently uncertain over a 10+ year horizon
  • FY2027 guidance miss attributed to Astral ventilator recall (narrative) signals near-term execution risk; exact financial magnitude and duration unclear from available materials
  • Insider selling by CEO (~$1M, Aug 2026 per narrative) is minor but directionally negative combined with guidance disappointment
  • FCF improvement (FY2022–FY2026) partially attributable to Philips recall-driven market share gift — an outside-view luck component that will not recur; base-rate mean reversion in margins is a live risk
  • Residential Care Software segment generating recurring ROU asset impairments and being divested — signals management recognized a moat-less asset; question is whether Noctrix acquisition repeats this pattern

Valuation Referee (Damodaran-style) — 🟢 pass · 74/100 · medium confidence

ResMed trades at $228.35 against a base DCF intrinsic value of $297.54, implying ~30% upside. The DCF is grounded in defensible inputs: WACC of 8.12% is consistent with RMD's low beta (0.77 per fundamentals), sector positioning in medical devices, and a nearly debt-free balance sheet (long-term debt $399M vs. cash $1.47B, implying net cash per the valuation block of ~$1.07B). Terminal growth of 2.5% is reasonable and below long-run nominal GDP. The base FCF of $1.65B is real and auditable — FY2026 operating cash flow was $1.806B with capex of $156M (10-K filed 2026-08-13). The revenue CAGR proxy for near-term FCF growth at ~10.2% is achievable but not heroic: historical revenue grew from $3.578B (FY2022) to $5.653B (FY2026), a 3-year CAGR of ~10.2% (fundamentals block). ROIC is 21.3% vs. WACC ~8.1% — the spread is substantial and validates that growth here creates, not destroys, value. FCF margin has expanded dramatically from 6.1% (FY2022) to 29.2% (FY2026), suggesting genuine operating leverage rather than financial engineering. The bear DCF case of $233 is essentially at today's price, meaning the margin of safety is thin but present — the stock does NOT require the bull case ($390) to justify; even a conservative base holds ~2% above current. Critical risks to the DCF: (1) The Astral ventilator recall creates an identifiable FY2027 headwind — field safety notification expenses accrued at $45.7M vs. $4.8M the prior year (10-K 2026-08-13, accrued expenses note), signaling a material cost. (2) The 10.2% FCF growth assumption derived from revenue CAGR may overstate near-term FCF growth if recall costs and restructuring ($21.7M in nine months ended March 2026, per 10-Q filed 2026-05-01) persist. (3) Terminal value represents 79.1% of total enterprise value — the model is highly sensitive to terminal growth and WACC, which is structurally typical of a DCF but worth flagging explicitly. (4) The reverse-implied expectations at $228 require roughly 7-8% FCF growth plus stable ~29% FCF margins — achievable given history but not guaranteed given the ventilator headwinds. (5) The Noctrix acquisition ($335M completed June 2026, per 10-K 2026-08-13) and MatrixCare divestiture introduce near-term noise in FCF comparability. On AI disruption: ResMed's CPAP/BiPAP franchise is hardware-centric with strong regulatory moats, proprietary data from connected devices (AirSense platform), and entrenched reimbursement relationships. AI could enhance, not threaten, ResMed's moat by improving diagnostic algorithms and adherence monitoring — this is a modest positive, not a disruption risk on a 3-10 year horizon. The Residential Care Software segment (being divested via MatrixCare) had higher AI-disruption exposure, so the divestiture actually sharpens the AI-resilience of the remaining portfolio. Overall: price sits ~30% below base DCF, ROIC vastly exceeds WACC, FCF is real and growing, debt is minimal. The margin of safety is meaningful but not overwhelming — bear case barely clears current price, demanding confidence in the base assumptions. I score this 74: a clear pass but not a high-conviction slam dunk given near-term guidance miss, recall headwinds, and the high terminal value dependency.

Key points

  • DCF intrinsic value $297.54 vs. price $228.35 — 30% upside on base assumptions; bear case $233 provides thin but positive margin of safety (10-K filed 2026-08-13 + valuation block)
  • ROIC 21.3% vs. WACC 8.1% — a ~13ppt spread confirms growth creates substantial value rather than destroying it (fundamentals block)
  • FCF margin expanded from 6.1% (FY2022) to 29.2% (FY2026), demonstrating genuine operating leverage (history block; FY2022-2026 financials)
  • Nearly debt-free: long-term debt $399M vs. cash $1.47B = net cash ~$1.07B, reducing financial risk and supporting a lower cost of capital (10-K 2026-08-13, fundamentals)
  • 10.2% revenue CAGR proxy for FCF growth is consistent with a 4-year track record of ~$2.1B incremental revenue — not a heroic assumption
  • Terminal growth 2.5% is at/below nominal GDP — no permanent excess return baked in; terminal value 79.1% of EV is high but standard for a high-FCF-margin business
  • Reverse-implied expectations at current price (~7-8% FCF growth, stable margins) are modest relative to actual performance history

Red flags

  • Astral recall field safety notification accrual spiked to $45.7M in FY2026 vs. $4.8M prior year (10-K 2026-08-13) — concrete near-term FCF headwind not fully captured in the trailing base FCF used in the DCF
  • Bear DCF case of $233 is only marginally above current $228 price — margin of safety nearly disappears in a conservative scenario, leaving limited room for execution error
  • Terminal value = 79.1% of enterprise value; model is structurally sensitive to small changes in terminal growth or WACC — a 50bp WACC increase or 50bp terminal growth cut would compress intrinsic value meaningfully
  • FY2027 guidance miss (narrative block) + restructuring charges of $21.7M in nine months ended March 2026 (10-Q 2026-05-01) suggest near-term FCF growth may be below the 10.2% CAGR assumption
  • Noctrix acquisition ($335M, June 2026) adds integration uncertainty and preliminary purchase price allocation (10-K 2026-08-13); near-term FCF comparability is impaired
  • 10.2% growth rate derived from revenue CAGR, not FCF CAGR — FCF actually declined slightly from $1.662B (FY2025) to $1.650B (FY2026), suggesting FCF growth may lag revenue growth near-term

Ray Dalio — 🟢 pass · 72/100 · medium confidence

ResMed is a medical-device compounder with a structurally resilient demand profile that holds up reasonably well across Dalio's four macro regimes, though it is not regime-neutral. The core Sleep and Breathing Health segment addresses obstructive sleep apnea — a chronic, non-discretionary condition with third-party reimbursement buffering end-demand from consumer credit cycles. This is a meaningful differentiator versus purely discretionary or credit-sensitive businesses. The balance sheet is fortress-grade: the 10-K filed 2026-08-13 shows long-term debt of only $399M, cash of $1.47B, and a net cash position (net debt of approximately -$1.07B per the valuation block), debt-to-equity of 0.06, and ROIC of 21%. FCF of $1.65B on $5.65B revenue (29% FCF margin) means the company self-funds entirely through a downturn. The debt maturity profile is NOT alarming — the 10-K shows short-term debt at $260M and long-term debt at $399M as of June 30, 2026, versus $1.47B cash, so refinancing risk is negligible. Interest coverage is extremely high: operating income of $1.89B vs. minimal net interest cost (the filings show interest INCOME of ~$50M in FY2026, not expense). These factors tick most of Dalio's balance-sheet-resilience and self-funding boxes. On regime robustness: in a RISING GROWTH/FALLING INFLATION regime (boom), RMD benefits from volume growth and stable margins. In a FALLING GROWTH/FALLING INFLATION regime (deflationary bust), reimbursed medical devices are among the most durable demand categories — patients continue CPAP therapy regardless of the business cycle, and the company's low debt means no distress risk. In a RISING GROWTH/RISING INFLATION (reflation) regime, RMD has demonstrated pricing power in devices and masks, and its gross margins have been stable-to-expanding. The weakest quadrant is STAGFLATION — rising inflation squeezes real reimbursement rates (Medicare/Medicaid rates are set administratively and may lag inflation), input costs in electronics/components could compress margins if pass-through is constrained, and a slower growth environment could crimp new patient diagnoses. The near-term Astral ventilator recall and FY2027 guidance miss (noted in narrative) are idiosyncratic operational risks, not macro risks, but they do introduce earnings uncertainty. The GLP-1/weight-loss drug narrative (Ozempic-type drugs potentially reducing OSA prevalence) is a structural disruption risk that has weighed on sentiment and is the biggest long-duration bear case — this is not a macro risk in the Dalio sense but it is a demand-durability question. On geographic diversification: RMD has meaningful international revenue (Sleep segment is global; Residential Care Software is more US-concentrated), providing partial FX diversification, though the fact base does not provide precise split by region in this excerpt. FX hedging instruments are disclosed ($16.6M accrued at June 30, 2026 per 10-K). On correlation/diversification value: with beta of 0.77, RMD offers below-market beta and its primary drivers (disease prevalence, reimbursement policy, clinical adoption) are partially uncorrelated to economic cycles — a genuine diversification benefit in a risk-parity context. The DCF base-case intrinsic value of $297.54/share implies 30% upside to current price of $228.35, with a bear-case sensitivity of $233 — a thin bear-case cushion that assumes continued FCF growth. The valuation assumes ~10% FCF growth (revenue CAGR) which could be too optimistic if GLP-1 penetration or recall headwinds are sustained. At ~20x FCF and 21.6x earnings, the stock is not cheaply priced in absolute terms, which means in a regime shift to higher-for-longer rates or multiple compression, there is valuation downside even if fundamentals hold. The PEG of 2.12 is elevated. Overall, for a Dalio-style risk assessment: excellent balance sheet, non-cyclical demand, self-funded, diversified geographically, below-market beta — these are strong positives. Key risks are stagflation margin compression (reimbursement lag), structural GLP-1 disruption to long-run demand, and a valuation that embeds optimistic growth assumptions. Score: 72 — a pass but not a high-conviction allocation.

Key points

  • Net cash position of ~$1.07B (cash $1.47B vs total debt ~$399M LT + $260M ST per 10-K 2026-08-13); self-funding with no refinancing wall risk
  • FCF of $1.65B in FY2026 (29% margin) with five-year FCF expansion from $216M in FY2022 — demonstrates through-cycle cash generation
  • Non-discretionary, reimbursed demand (OSA/CPAP therapy) provides regime robustness in deflationary bust and moderate growth environments
  • Beta of 0.77 provides genuine diversification value versus a typical equity book; primary demand drivers (disease prevalence, reimbursement policy) partially uncorrelated to economic cycle
  • Operating margin of 33%, ROIC of 21% — high returns on capital with minimal debt amplification, resilient to interest-rate increases
  • Geographic diversification of revenue (international Sleep segment) with active FX hedging (disclosed in 10-K 2026-08-13 accrued expenses)
  • DCF base case $297.54/share implies 30% upside; bear case $233 provides thin but non-zero margin of safety at $228.35
  • Capital returns: dividend increase plus MatrixCare-proceeds-funded buyback signals balance sheet confidence (narrative)

Red flags

  • Stagflation is weakest regime: administrative reimbursement rates (Medicare/Medicaid) may lag inflation, squeezing real revenue while input costs (electronics, chips) rise — pass-through constrained
  • GLP-1/weight-loss drug structural risk is the dominant long-duration demand uncertainty — if OSA prevalence structurally declines, the non-cyclical demand thesis weakens materially; not quantifiable from this fact base
  • Astral ventilator recall and FY2027 guidance miss introduce near-term earnings uncertainty; field safety notification accruals jumped from $4.8M to $45.7M (10-K 2026-08-13), a near 10x increase, suggesting material recall costs
  • Valuation embeds ~10% annual FCF growth (revenue CAGR assumption in DCF); in a stagflation or multiple-compression regime, 20x FCF with decelerating growth could mean significant price correction; bear-case DCF ($233) barely below current price
  • CEO insider selling (~$1M, Aug 2026 per narrative) concurrent with FY2027 guidance miss is a modest negative signal
  • Residential Care Software segment showing impairments and restructuring — $21.7M workforce charges in first nine months of FY2026 (10-Q 2026-05-01) — suggests execution risk in software diversification strategy
  • Concentration in single product category (OSA devices/masks) means that a single regulatory, reimbursement, or technological disruption has outsized impact; limited revenue diversification across end-markets

Forensic Short-Seller (Chanos/Einhorn-style) — 🟢 pass · 72/100 · medium confidence

ResMed passes the forensic screen with modest concerns but no smoking-gun accounting fraud indicators. The core earnings-vs-cash test is actually strong: net income of $1.523B vs. operating cash flow of $1.806B and FCF of $1.650B for FY2026 (10-K filed 2026-08-13) — cash persistently exceeds reported earnings, which is the opposite of the Chanos red flag. The accrual ratio is negative (cash > earnings), the cleanest possible signal on earnings quality. FCF margin has expanded dramatically from 6.1% in FY2022 to 29.2% in FY2026 (fundamentals history). Non-GAAP adjustments exist but are modest: the 10-K reconciliation shows GAAP operating income of ~$1.887B vs. non-GAAP adding back ~$78M amortization of acquired intangibles and ~$50M field safety notification expenses — a manageable and disclosed gap, not a sprawling 'adjusted' fiction. Insider selling is a mild flag: the narrative cites CEO selling ~$1M in stock (Aug 11, 2026) and a director planning a 970-share sale (Sep 2, 2026), but no clustered or large-scale selling pattern is documented in the fact base. Debt structure is favorable: long-term debt has been dramatically reduced from $1.435B (FY2023, per 10-K filed 2024-08-09) to $399M (FY2026, fundamentals), with net cash position of ~$1.07B (valuation block net_debt = -$1.07B). Interest coverage is not a concern. SBC dilution: shares outstanding have actually declined modestly from ~147.5M (FY2024) to ~144.3M (FY2026), confirming buybacks are net accretive, not a treadmill. Three genuine forensic concerns exist: (1) Field safety notification accruals surged from $4.8M (FY2025) to $45.7M (FY2026) per the 10-K accrued expenses note — the Astral ventilator recall is a real and growing liability with uncertain ultimate cost; (2) The $335M Noctrix Health acquisition (June 1, 2026, 10-K) at a 'preliminary' purchase price allocation creates intangible asset uncertainty and potential future goodwill impairment risk; (3) Restructuring charges of $21.7M in the nine months ended March 2026 (10-Q filed 2026-05-01) after $64.2M in FY2024 (10-K filed 2024-08-09) suggest recurring 'one-time' items. The MatrixCare divestiture removes a segment with recurring ROU asset impairments ($2.7M in each of two quarters per 10-Q filings), which is actually accounting hygiene, not a concern. AI disruption risk is moderate: ResMed's core CPAP/respiratory device moat rests on proprietary algorithms, clinician relationships, and regulatory clearances — AI could enhance remote monitoring (already a product feature) but is less likely to disintermediate the hardware/therapy loop than software-only businesses. The kill question: this becomes a short if (a) Astral recall costs escalate materially beyond the $45.7M currently accrued, triggering a guidance reset and cash drain, (b) GLP-1 weight-loss drugs structurally reduce OSA prevalence and device demand at a faster-than-expected pace, or (c) a major restatement or fraud emerges in the Noctrix or other acquisition accounting. None of these are evidenced in the current fact base; the business is generating real cash in excess of reported earnings.

Key points

  • FY2026 operating cash flow of $1.806B exceeds net income of $1.523B — the forensic core test shows positive earnings quality (10-K filed 2026-08-13)
  • FCF margin expanded from 6.1% (FY2022) to 29.2% (FY2026) per fundamentals history — cash generation is accelerating, not deteriorating
  • Net debt is negative (~$1.07B net cash per valuation block); long-term debt reduced from $1.435B in FY2023 to $399M in FY2026 — no debt wall or refinancing risk
  • Share count modestly declined from ~147.5M (FY2024) to ~144.3M (FY2026) — buybacks are net accretive, not a dilution treadmill
  • Non-GAAP adjustments are disclosed and bounded: ~$78M amortization + ~$50M field safety costs added back; adjusted and GAAP are not wildly divergent (10-K filed 2026-08-13)
  • Residential Care Software segment shows recurring ROU asset impairments ($2.7M per quarter in 10-Qs filed 2026-01-30 and 2026-05-01) — MatrixCare divestiture removes this drag

Red flags

  • Field safety notification accruals surged from $4.8M (FY2025) to $45.7M (FY2026) per 10-K accrued expenses note — Astral ventilator recall cost trajectory is uncertain and could escalate further
  • $335M Noctrix Health acquisition (June 1, 2026) has 'preliminary' purchase price allocation per 10-K — intangible asset and goodwill impairment risk not yet quantifiable
  • Restructuring charges appear recurring: $64.2M in FY2024, then $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) — management's 'one-time' framing is questionable
  • CEO sold ~$1M in stock August 11, 2026 (narrative) — modest but directionally negative alongside FY2027 guidance disappointment
  • FY2027 guidance miss attributed to Astral-driven issues (narrative) — duration and financial magnitude of ventilator recall drag not quantified in available filings
  • GLP-1 drug structural risk to OSA device demand is not addressed in the fact base but represents a potentially irreversible demand cliff — evidence is missing but question must be tracked

Joel Greenblatt — 🟡 watch · 62/100 · medium confidence

ResMed is a high-quality business that scores well on the ROIC axis of the Magic Formula but looks only moderately cheap on the earnings yield axis. Let me work through both inputs rigorously from the fact base.

ROIC (quality axis): Using Greenblatt's preferred denominator of net working capital + net fixed assets. From the 10-K filed 2026-08-13 (period 2026-06-30): current assets = $4,324.7M, current liabilities = $1,395.1M, net working capital = ~$2,929.6M. Net fixed assets (PP&E net) can be estimated from 10-Q filed 2026-05-01 (March 31, 2026 figure of $567M net PP&E) as a proxy — the annual filing excerpt does not give us a standalone net PP&E figure, but the Q3 10-Q shows net PP&E of ~$567M. Adding NWC (~$2,930M) + net PP&E (~$567M) = ~$3,497M tangible capital employed. EBIT (operating income) from fundamentals = $1,886.7M for FY2026. Greenblatt ROIC = $1,887M / $3,497M ≈ 54%. This is exceptional — a genuinely high-quality business. The reported ROIC from fundamentals (21.3%) is lower because it uses a broader equity-based denominator; on tangible capital the returns are far superior. The 33.4% operating margin (10-K filing) and FCF margin of ~29% (fundamentals) confirm real, repeatable cash earnings. Importantly, EBIT converts cleanly to FCF: operating cash flow of $1,806M vs. EBIT of $1,887M is tight, with minimal accrual inflation.

Earnings Yield (cheapness axis): EV = market cap + total debt - excess cash. Market cap = $32,940M. Total debt from 10-K: short-term debt $260M + long-term debt $399.4M = ~$659.4M. Cash = $1,469.2M. EV = $32,940 + $659 - $1,469 = ~$32,130M. EBIT = $1,887M. Earnings yield = $1,887 / $32,130 = 5.87%. This is mediocre — not the 'cheap' half of the Magic Formula. On a pure Greenblatt ranking, 5.9% EBIT/EV would sit in the middling range for the universe, not the top decile. The stock is trading at roughly 17x EV/EBIT, which for a high-quality compounder is fair-to-full, not bargain-priced.

Special Situation Catalyst: The MatrixCare divestiture (announced July 2026 per narrative) and the subsequent accelerated buyback (8-K filed 2026-09-01) are genuine special-situation elements Greenblatt would notice. Portfolio simplification + capital return via buyback when the stock is 20% off its 52-week high ($284.87 per price data vs. $228.35 current) is a real catalyst. However, the sale price of MatrixCare is not disclosed in the fact base, so the magnitude of capital return is uncertain.

Red Flags: (1) The earnings yield is not compelling — this is more 'good business at fair price' than 'good business at bargain price.' (2) The Astral ventilator field safety notification (accrued $45.7M at June 30, 2026 per 10-K vs. $4.8M prior year) is a meaningful charge and represents execution/product risk. (3) FY2027 guidance reportedly disappointed (narrative); the guidance miss and ventilator recall headwind could weigh on near-term EBIT, making current earnings yield even thinner if EBIT normalizes lower. (4) Insider selling noted (CEO sold ~$1M per narrative) — modest but directionally negative. (5) The Noctrix acquisition for $335M (10-K, June 1, 2026 close) is small but adds integration noise. (6) Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) and prior year's $64.2M restructuring suggest ongoing operational flux in Residential Care Software.

AI/Disruption Assessment: ResMed's core CPAP/respiratory device business has a meaningful data moat — AirView cloud platform connecting 10M+ patients creates switching costs and regulatory stickiness. AI-enhanced diagnostics and adherence monitoring could extend rather than erode the moat. However, GLP-1 weight-loss drugs reducing OSA prevalence is a real structural risk to the addressable market over a 5-10 year horizon — this is not directly quantified in the fact base but is a known overhang. AI does not appear to directly commoditize ResMed's hardware/software integration at this stage.

Magic Formula Summary: ROIC ~54% (exceptional, top decile). EBIT/EV ~5.9% (middling, not cheap). Combined ranking: one excellent axis, one mediocre axis. Greenblatt's formula requires both — this is not a clear pass. The special-situation element (MatrixCare sale + buyback) nudges the score upward from a pure formula perspective, but the unknown sale proceeds and ventilator headwinds limit conviction. Score: 62 — watch, not a clear buy.

Key points

  • Greenblatt ROIC on tangible capital (EBIT / NWC + net PP&E) approximately 54% — top-decile quality, genuine high-return business
  • EBIT/EV earnings yield ~5.87% (EV ~$32.1B, EBIT $1.887B from 10-K 2026-08-13) — only middling cheapness, not Magic Formula bargain territory
  • FCF conversion is clean: operating cash flow $1,806M vs. EBIT $1,887M per FY2026 fundamentals — minimal accrual inflation
  • MatrixCare divestiture + accelerated buyback (8-K 2026-09-01) is a genuine special-situation catalyst; proceeds unknown from fact base
  • Operating margin 33.4%, FCF margin 29.2% (10-K 2026-08-13) — durable, owner-like economics
  • Debt is minimal: net cash position (~$1,069M net cash per valuation block) means EV cheapness is not illusory due to leverage

Red flags

  • Earnings yield ~5.9% fails the Magic Formula 'cheap' test — stock is priced for quality, not as a bargain
  • Astral field safety notification accrual surged to $45.7M at June 30, 2026 vs. $4.8M prior year (10-K 2026-08-13) — material product liability headwind
  • FY2027 guidance reportedly disappointed market (narrative); if EBIT trends lower, earnings yield deteriorates further
  • CEO insider selling ~$1M (Aug 2026, per narrative) — directionally negative signal, especially alongside guidance miss
  • Noctrix acquisition $335M (10-K 2026-08-13) and $21.7M restructuring charges (10-Q 2026-05-01) add noise to normalized EBIT estimation
  • GLP-1 drug impact on OSA prevalence is a long-term structural risk to addressable market — not quantified in fact base but represents potential ROIC erosion over 5-10 year horizon

Bruce Greenwald — 🟡 watch · 62/100 · medium confidence

ResMed presents a classic franchise-quality business that clears most Greenwald moat tests, but the market price requires meaningful growth credit that must be scrutinized against the EPV anchor.

EPV Calculation (normalized): Using the 10-K filed 2026-08-13: GAAP operating income FY2026 was $1,886,715,000 on revenue of $5,653,443,000 (33.4% operating margin). To normalize, I must strip genuine one-offs but be conservative: the 10-K excerpt shows field safety notification expenses (Astral recall, masks-with-magnets) accrued at $45.7M at June 30, 2026 vs. $4.8M prior year — a ~$41M incremental charge that is non-recurring in nature. Acquisition/portfolio expenses were $11.5M. Restructuring in FY2026 is referenced in the Q3 10-Q (nine months ended March 31, 2026 had $21.7M of restructuring charges). Adding these back conservatively: normalized EBIT ≈ $1,887M + $45M (field safety accrual increment) + $11.5M (acquisition) + ~$22M (restructuring) ≈ $1,966M. Applying a normalized 21% tax rate (approximated from net income $1,523M / pre-tax income $1,919M from 10-K excerpt ≈ 20.6%) yields NOPAT ≈ $1,563M. The 10-K notes depreciation of $103M and capex of $156M (fundamentals block). Maintenance capex is likely closer to $103M (matching D&A), so add back excess D&A of ~$0 (or a modest ~$50M if roughly half capex is maintenance vs. growth). Distributable earnings ≈ $1,563M + $50M excess = ~$1,613M. At WACC of 8.12% (from the valuation block), EPV ≈ $1,613M / 0.0812 ≈ $19.9B enterprise value. Adding net cash of ~$1.07B (valuation block: net debt = -$1,070M) yields equity EPV ≈ $20.97B, divided by 144.25M shares ≈ EPV per share ~$145. This compares to a current price of $228.35 — market price is ~57% above my EPV estimate. That gap is real and substantial.

Asset Reproduction Value: Tangible assets: PP&E net ~$566M (Q3 10-Q), inventories ~$912M, current assets $4,325M less cash $1,469M ≈ $2,856M non-cash working capital area; total equity $6,585M per fundamentals. Goodwill and intangibles from the balance sheet are substantial but not fully quantified in the excerpts. Total assets $8,966M less total liabilities $2,381M = $6,585M book equity. A competitor would need to reproduce not just the physical plant but: (1) ResMed's 30+ year installed base of CPAP devices in patients' homes with data connectivity — its AirView platform reportedly connects millions of patients (fact base narrative references OSA market and data connectivity moat, though no specific subscriber count is in the filings); (2) physician prescription relationships and insurer reimbursement approvals globally; (3) the regulatory clearances across 140+ markets. Reproducing this from scratch would take a decade and billions in R&D, regulatory filings, and go-to-market spend. I estimate reproduction value conservatively at $10–12B, well below EPV of ~$21B. EPV >> reproduction value — this is a genuine franchise. The moat test passes clearly.

Moat Assessment: The moat rests on three Greenwald-approved pillars: (1) Customer captivity via habit — CPAP therapy requires machine-specific masks and accessories; once a patient is established on a ResMed device with AirSense/AirView data, switching imposes real clinical and logistical friction; (2) Economies of scale within a concentrated niche — the 10-K reports two segments (Sleep and Breathing Health; Residential Care Software), with D&A of $112M in Sleep segment alone, suggesting scale investments competitors cannot easily match; (3) Regulatory/IP moat — patent portfolio and FDA/international clearances represent years of accumulated approval. These are real, not vague brand claims.

Why Not a Full Pass: The price of $228.35 is ~57% above my conservative EPV of ~$145. To justify the current price, the market is embedding substantial growth value. The DCF in the valuation block uses 10.2% FCF growth and a terminal growth of 2.5%, arriving at $297.54/share — but 79% of that value sits in the terminal value (noted in the valuation block: residual_value_pct = 0.791). Per my framework, this is exactly the kind of long-horizon, terminal-value-heavy DCF I distrust. The franchise IS real, so growth inside it does create value — but the FY2027 guidance miss (narrative: 'Astral-driven guidance miss') and ventilator recall headwinds create near-term earnings uncertainty. The field safety accrual jumped from $4.8M to $45.7M for 'Astral' issues alone (10-K, June 30, 2026 accrued expenses). If recall costs escalate or linger, normalized earnings power could be impaired beyond my adjustment. Additionally, the Noctrix acquisition ($335M, June 1, 2026 per 10-K) adds integration risk and modest growth-capex pressure. Insider selling (CEO ~$1M, director sale per narrative) is a minor caution. The MatrixCare divestiture simplifies the business (a positive) but removes one revenue stream.

AI/Disruption Assessment: AI is a net positive for ResMed's franchise over a 3–10 year horizon. The AirView connected-device platform generates proprietary patient-level sleep data that would be extremely difficult to replicate. AI-driven diagnostics and therapy optimization (remote patient monitoring) are likely to deepen customer captivity, not erode it — the data moat compounds. The risk is that AI-powered virtual sleep clinics or wearable alternatives (Noctrix acquisition targets this, suggesting management is aware) could modestly disintermediate traditional CPAP channels. Net assessment: AI strengthens the franchise more than it threatens it, but does not alter the EPV math materially in the near term.

Margin of Safety: At $228, there is NO margin of safety to EPV (~$145). There IS a margin of safety if one credits the franchise's growth at moderate rates — at $228, the market roughly prices in ~5–7% annual earnings growth indefinitely, which is plausible but not certain. For a Greenwald-style value investor, the entry price should be at or below EPV (~$145) for a high-confidence position, or between EPV and a conservatively grown franchise value for a watch posture. Current price is in the 'watch zone' — franchise confirmed, but price already embeds the franchise premium without much safety buffer.

Key points

  • EPV estimated at ~$145/share (NOPAT ~$1,563M normalized / WACC 8.12%); market price of $228 is ~57% above EPV — gap requires franchise growth credit
  • EPV >> reproduction value (EPV ~$21B equity vs. estimated reproduction cost ~$10-12B) — moat test passes; this IS a genuine franchise
  • Three concrete moat pillars: patient captivity via device/mask ecosystem and AirView data lock-in; regulatory/IP barriers; economies of scale in a concentrated niche
  • FCF generation is strong and improving: $1.65B FCF in FY2026 (10-K), FCF margin 29.2%; ROIC 21.3% well above cost of capital — franchise returns confirmed
  • Balance sheet is conservatively levered: debt-to-equity 0.06, $1.47B cash, long-term debt only $399M (10-K FY2026) — ample financial flexibility
  • Noctrix acquisition ($335M, 10-K filing) and MatrixCare divestiture indicate strategic portfolio rationalization toward core sleep/respiratory — a positive simplification
  • AI/connectivity platform (AirView) deepens rather than erodes the moat — proprietary patient data is a compounding asset
  • DCF provided has 79% of value in terminal value — precisely the speculative growth territory I distrust; use as sanity check only

Red flags

  • Market price ($228) is ~57% above my EPV (~$145) — the entire gap relies on franchise growth being sustained, which carries execution risk
  • Field safety accrual (Astral recall) surged from $4.8M to $45.7M at June 30, 2026 (10-K) — if recall scope expands, normalized earnings power could be impaired beyond my adjustments
  • FY2027 guidance miss attributed to Astral ventilator issues (narrative) — near-term earnings uncertainty makes normalization harder with confidence
  • DCF terminal value = 79% of total equity value (valuation block) — textbook example of a valuation that depends on speculative distant-future assumptions
  • CEO insider sale (~$1M, Aug 11, 2026 per narrative) concurrent with weak guidance is a minor but noted concern
  • Purchase obligations of $1.03B due within one year (10-Q filed May 2026) are substantial relative to current capex run-rate — worth monitoring for working-capital pressure
  • Restructuring charges of $21.7M in nine months ended March 2026 (10-Q) add noise to earnings normalization; 'one-time' items have been recurring across multiple periods

Howard Marks — 🟡 watch · 58/100 · medium confidence

ResMed sits in an interesting middle ground for a Marks-style risk/value assessment. The stock has declined ~30% from its 52-week high of $284.87 to the current $228.35, and the DCF (10-K filed 2026-08-13 and valuation block) suggests a base intrinsic value of ~$297.54, implying roughly 30% upside — a meaningful but not extreme discount. The bear DCF scenario of $233 is only modestly above the current price, which tells me the downside cushion is thin if the bear case materializes. The bull case at $390 requires compounding ~10% FCF growth for years — plausible but not assured given the Astral ventilator recall headwinds and FY2027 guidance disappointment noted in the narrative. On capital structure, ResMed is genuinely low-leverage: long-term debt of ~$399M against $1.47B cash (per 10-K filed 2026-08-13 fundamentals), net cash positive by ~$1.07B, debt-to-equity of 0.06. Interest coverage is not a risk. FCF generation is real — $1.65B in FY2026 (10-K), up from $216M in FY2022, with FCF margins expanding from 6% to 29%. This is a fortress balance sheet that earns high marks on survivability. The risk-of-permanent-loss is genuinely low given the balance sheet and cash generation. However, my framework asks not just about quality but about what is PRICED IN. At a P/E of 21.6x and price-to-FCF of ~20x, the market is not pricing in catastrophe — this is not a deep-value, distressed or out-of-favor situation where the crowd has abandoned the name in panic. The stock is down from a peak, yes, but it remains a $33B market cap medical device leader trading at premium multiples on any absolute basis. The PEG of 2.12 suggests growth expectations remain embedded at a meaningful level. The DCF terminal value represents 79.1% of enterprise value — a warning that most of the value depends on a long-duration earnings stream that requires sustained execution. Near-term headwinds are real: the Astral field safety notification expenses jumped from $4.8M accrued at June 30, 2025 to $45.7M at June 30, 2026 (per 10-K accrued expenses table), signaling a material cost event. FY2027 guidance disappointed. Analyst downgrades (RBC, per narrative) and insider selling by the CEO (~$1M, per narrative) are soft negative signals. The MatrixCare divestiture redirects capital to buybacks rather than growth — defensible but not a signal of abundant organic opportunity. The contrarian case has some validity: institutional accumulation (HSBC, Legal & General, Deutsche Bank, etc., per narrative) suggests sophisticated buyers see value at these levels, and the sentiment has clearly cooled from the peak. But I do not see the revulsion, forced selling, or genuine despair that characterizes the most compelling contrarian entries in my framework. This feels more like a modestly cheap, high-quality business than a deeply mispriced, feared asset. The asymmetry is OK but not exceptional — downside is protected by the balance sheet (the bear DCF is ~$233, barely below today's price), upside to base is ~30%, bull is ~70%. That is a 2:1 skew at best. For my framework, I want wider margins. The ventilator recall uncertainty is the key variable I cannot fully assess: the Astral accrual surge is meaningful, the narrative references ongoing guidance headwinds, but the financial impact magnitude and duration are opaque. That is an unresolved downside risk. On AI disruption: ResMed's moat is in connected device ecosystems, proprietary algorithms for sleep therapy titration, and reimbursement relationships — AI could modestly strengthen their remote monitoring/data analytics capabilities (AirSense ecosystem), but also could enable competitive disruption in diagnosis over a 5-10 year horizon. Not an immediate material threat, but a watch item. Net: A quality business with a clean balance sheet trading at a modest discount to DCF — but not cheap enough, nor feared enough, to clear my threshold for a conviction pass. The bear scenario offers little cushion. Watch and wait for either a deeper discount or resolution of the recall/guidance uncertainty.

Key points

  • Net cash position of ~$1.07B and debt-to-equity of 0.06 (10-K filed 2026-08-13) — balance sheet survivability is excellent, permanent-loss risk is low
  • FCF of $1.65B in FY2026 with 29% FCF margin (fundamentals) — cash generation is real and growing, not an accounting artifact
  • DCF base intrinsic value ~$297.54 vs. $228.35 current price implies ~30% discount — meaningful but not extreme by contrarian standards
  • Bear DCF scenario of $233 is only ~2% above current price — the downside cushion is thin if headwinds persist
  • Astral field safety notification accrual surged from $4.8M (June 2025) to $45.7M (June 2026) per 10-K accrued expenses — a concrete, material cost event that is not fully resolved
  • DCF terminal value = 79.1% of enterprise value — most of the thesis depends on long-duration sustained execution, a fragile foundation for a value-first framework
  • P/E 21.6x, price-to-FCF ~20x — premium multiples; market is not pricing in catastrophe, limiting contrarian appeal
  • Institutional accumulation (HSBC, Legal & General, Deutsche Bank) in late August 2026 (per narrative) suggests sophisticated buyers agree price is below fair value — mild contrarian confirmation
  • MatrixCare divestiture + buyback signals capital return rather than growth reinvestment — reads as defense, not offense

Red flags

  • Astral recall accrual jump from $4.8M to $45.7M in one year (10-K 2026-08-13) — magnitude and duration of liability remain unclear, posing unresolved downside
  • FY2027 guidance miss (per narrative) — crowd bought into sustained growth; guidance disappointment partially deflates the embedded optimism but pricing has not yet reached fear territory
  • Bear DCF scenario ($233) barely below current price ($228.35) — asymmetry is insufficient for a Marks-style margin of safety
  • Terminal value represents 79.1% of DCF equity value — extreme duration dependence; any compression in terminal growth rate dramatically impairs intrinsic value
  • CEO sold ~$1M in stock (Aug 11, 2026, per narrative) concurrent with weak forward guidance — insider signal aligned with near-term caution
  • P/E of 21.6x and PEG of 2.12 embed continued growth; this is not a 'priced for disaster' setup that my framework most rewards
  • Ventilator recall financial impact and duration not fully disclosed in available filings — unknown tail risk

Peter Lynch — 🟡 watch · 55/100 · medium confidence

ResMed is a classic stalwart — a large-cap medical device leader in CPAP/sleep therapy with a durable moat, steady double-digit revenue growth (~10% CAGR per 10-K filings), and exceptional cash generation. But as Lynch would frame it: the story is easy to tell (they make machines that help people breathe while they sleep, doctors prescribe them, insurers pay for them, and the installed base generates recurring mask/accessory revenue), yet the valuation is not cheap enough to call a clear buy. The PEG of 2.12 (per fundamentals block) is well above my 1.0 ceiling and even above the 'expensive' 2.0 threshold. Revenue CAGR is 10.2% (3-year, per fundamentals), and while the DCF model projects 10.2% FCF growth, recent EPS growth has been more solid — net income growing from $897M (FY2023) to $1,523M (FY2026, per history block) represents a ~19% CAGR over 3 years — but that pace is partly normalization from COVID supply disruptions and may not sustain. At P/E of 21.6x on what is fundamentally a stalwart growing 10-12%, the Lynch framework says you should pay roughly 10-12x for a stalwart and sell at 30-50% appreciation — not initiate at 21x. The balance sheet is genuinely excellent: debt-to-equity of 0.06, net cash position ($1.47B cash vs. $399M long-term debt per 10-K filed 2026-08-13, plus short-term debt of $260M), ROIC of 21.3%, FCF margin of 29.2% — this is a beautifully run business. The Noctrix acquisition ($335M, June 1, 2026, per 10-K) is small relative to the balance sheet and on-strategy (wearable sleep therapeutics), so no diworsification flag. The MatrixCare divestiture actually reverses prior diworsification. Inventories are flat-to-down year-on-year (10-Q: $911M Mar-2026 vs. $927M Jun-2025) — clean. But three things hold me back from a pass: (1) PEG of 2.12 is simply too high for my discipline regardless of business quality; (2) FY2027 guidance disappointed the market (narrative digest) with ventilator recall headwinds (Astral field safety notification accruals jumped to $45.7M from $4.8M per 10-K Note 7) — this is a real earnings drag; (3) the stock, while down 20% from peak, is not yet at the 'neglected' low-multiple level Lynch loves. The DCF at $297 (30% upside) is encouraging and the bear case at $233 barely covers current price, suggesting limited downside but also limited margin of safety on Lynch's own terms. I'd watch for a further de-rating toward 15-17x earnings before initiating. AI risk is modest-to-positive here: ResMed's cloud-connected devices and AirSense ecosystem generate proprietary sleep-data moats that AI could enhance rather than disrupt; no AI commoditization risk to the hardware/therapy model in a 3-5 year window.

Key points

  • Stalwart categorization: ~10% revenue CAGR (per fundamentals block, 3-year), not a fast grower — appropriate P/E should be 10-15x, not 21x
  • Net income CAGR FY2023-FY2026 approximately 19% (from $897M to $1,523M per history block), but pace likely to moderate
  • Balance sheet is outstanding: D/E of 0.06, net cash ~$810M (cash $1,469M less total debt ~$659M per 10-K 2026-08-13), ROIC 21.3%
  • FCF exceptional: $1.65B FY2026, FCF margin 29.2%, funding all growth and capital return internally
  • Inventories flat year-on-year ($927M Jun-2025 to $912M Mar-2026 per 10-Q filed 2026-05-01) — no inventory piling
  • Noctrix acquisition ($335M, on-strategy wearable sleep therapy) is modest and focused — not diworsification
  • MatrixCare divestiture is shareholder-friendly capital discipline
  • DCF intrinsic value $297 vs. $228 current price — 30% upside in base case, bear case $233 provides thin cushion
  • Dividend increased alongside buyback (narrative) — management confidence signals
  • AI enhances rather than disrupts: proprietary connected-device data and AirSense ecosystem create durable data moat

Red flags

  • PEG of 2.12 (per fundamentals block) is well above Lynch's 1.0 ceiling and into 'overpaying' territory even for a quality business
  • Astral ventilator field safety notification accrual surged to $45.7M from $4.8M (10-K 2026-08-13, Note 7 accrued expenses) — near-term earnings headwind and FY2027 guidance disappointment cited in narrative
  • Short-term debt jumped to $260M from $10M (10-K 2026-08-13 vs. prior year) — worth monitoring though overall leverage still low
  • Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) suggest ongoing workforce disruption costs
  • Insider selling: CEO sold ~$1M shares Aug 2026 (narrative) — minor but notable alongside weak guidance
  • Stock down 15-20% from 52-week high but at P/E 21x still not at the 'on-sale stalwart' level Lynch prefers for entry
  • Heavy institutional ownership (HSBC, Legal & General, Deutsche Bank additions noted in narrative) — not a neglected story with undiscovered upside

Stanley Druckenmiller — 🟡 watch · 52/100 · medium confidence

RMD presents a genuinely mixed picture through my forward-looking, momentum-and-liquidity lens. The fundamentals are unambiguously strong in a trailing sense — $5.65B revenue, 33.4% operating margin, $1.65B FCF, near-zero net debt — but my framework rewards the DIRECTION of change, not the level, and that is where the tension lies. On the bullish side: FCF inflected dramatically from $216M in FY2022 to $1.65B in FY2026 (10-K filed 2026-08-13), margins expanded materially, and the balance sheet is pristine (LT debt $399M vs. cash $1.47B per FY2026 10-K). The DCF pegs intrinsic value at $297.54 vs. $228.35 current price — a 30% margin of safety. The OSA addressable market is large and underpenetrated. Institutional accumulation (HSBC, Legal & General, Deutsche Bank per the narrative) post-selloff suggests smart money sees value. AGAINST the thesis, however, are the signals I care about most: (1) The TAPE IS BAD — stock is down 19.8% from its 52-week high and down roughly 15% over the past year; price action is distribution, not accumulation. I do not fight a broken chart. (2) FY2027 guidance DISAPPOINTED — the narrative cites an 'Astral-driven guidance miss.' Negative forward estimate revisions and a guidance miss are exactly the second-derivative-turning-down signal I most fear. The rate of change in earnings growth is decelerating: net income grew 31% FY2024-to-FY2025, then only 8.7% FY2025-to-FY2026 (per fundamentals history). FCF also effectively flat year-over-year ($1.662B FY2025 vs. $1.650B FY2026 per fundamentals). (3) CATALYST IS UNCLEAR OR NEGATIVE — the near-term driver is a ventilator recall and operational headwind, not a positive inflection. The MatrixCare divestiture is capital-return-oriented (buyback) but signals limited high-ROI reinvestment opportunities, not a growth acceleration. (4) The $260M in short-term debt now sitting on balance sheet (FY2026 10-K note 8, up from $10M at FY2025) alongside field safety notification accruals jumping to $45.7M from $4.8M (FY2026 10-K accrued expenses note 7) are near-term financial headwinds. CEO insider selling (~$1M Aug 11, 2026 per narrative) is not disqualifying but directionally unhelpful. The setup lacks the asymmetric, catalyst-confirmed entry I require. This is not a 'put all your eggs in the basket' moment — the tape says wait. I would watch for a guidance revision upward, chart base formation and breakout above the 50/200-day, and resolution of the Astral recall liability before sizing up. The intrinsic value gap is real, but value alone is not my framework — I need the earnings trajectory to re-inflect AND the tape to confirm before concentrating.

Key points

  • FCF inflected from $216M (FY2022) to $1.65B (FY2026) representing a structural profitability transformation — per fundamentals history
  • Operating margin at 33.4% and ROIC at 21.3% signal genuine franchise quality — per FY2026 10-K
  • Near-zero net debt ($1.47B cash vs. $399M LT debt) gives optionality and resilience — per FY2026 10-K balance sheet
  • DCF intrinsic value $297.54 vs. $228.35 price implies ~30% upside — per valuation block
  • Institutional buying (HSBC, Legal & General, Deutsche Bank) in late Aug 2026 signals smart-money value recognition — per narrative
  • MatrixCare divestiture + buyback program signals capital discipline and potential EPS accretion catalyst — per narrative
  • OSA market remains structurally underpenetrated — long-duration secular tailwind intact

Red flags

  • Tape is broken: stock -19.8% from 52w high and -15.5% over trailing year — price action is distribution, contradicting a long thesis
  • FY2027 guidance miss ('Astral-driven') signals negative forward estimate revisions — exactly the second-derivative-negative signal I most fear
  • Net income growth decelerated sharply: +37% FY2024, +37% FY2025, but only +8.7% FY2026 — rate of change clearly slowing
  • FCF essentially flat year-over-year: $1.662B FY2025 vs. $1.650B FY2026 — stall in what was the key bull momentum driver
  • Field safety notification accruals surged from $4.8M to $45.7M (FY2026 10-K note 7) — material near-term cost and liability uncertainty
  • Short-term debt jumped from $10M to $260M (FY2026 10-K note 8) — unusual step-up warrants monitoring
  • CEO sold ~$1M of stock on Aug 11, 2026 per narrative — directionally negative insider signal concurrent with guidance disappointment
  • No clear re-acceleration catalyst identified; capital return (buyback) rather than growth investment suggests management lacks high-conviction organic growth visibility
  • AI/disruption risk: while AI could enhance ResMed's data platform (myAir, AirView ecosystem), it could also enable lower-cost competitors or disintermediate device revenue via software-only diagnostic solutions over a 5-10 year horizon — not imminent but worth flagging for long-duration positioning

Benjamin Graham — 🟡 watch · 52/100 · medium confidence

ResMed is a profitable, well-established, dividend-paying medical device company with a decade of uninterrupted earnings growth — these qualities Benjamin Graham would recognise and respect. However, applying Graham's quantitative value tests rigorously reveals that the stock does not clear the margin-of-safety bar with comfortable room to spare, and several key ratio tests fall short of his conservative thresholds.

EARNINGS STABILITY: Clearly satisfactory. The fundamentals history (Edgar companyfacts) shows net income rising every year from $779M (FY2022) to $1,523M (FY2026), and operating cash flow of $1.81B in FY2026. No losses in the disclosed period. The 3-year revenue CAGR is ~10.2%. Graham would approve of the earnings record.

P/E RATIO: At 21.6x trailing GAAP earnings (price $228.35 / EPS implied ~$10.56), this exceeds Graham's defensive investor ceiling of 15x. It is a meaningful overpayment by his standards. The earnings yield is 5.9%, which exceeds current high-grade bond yields modestly, providing some relative justification, but Graham's absolute 15x cap is not met.

P/B RATIO: At 5.0x book (stated in fundamentals block), this is elevated. Graham's combined P/E × P/B test: 21.6 × 5.0 = 108, versus the 22.5 ceiling he set for defensive investors. This fails badly — implying the stock is pricing in substantial growth that has not yet been demonstrated on an asset-value basis.

NET-NET TEST: Net current assets = current assets $4,325M minus ALL liabilities $2,381M = approximately $1,944M. Divided by 144.25M shares = ~$13.48/share. Price at $228.35 is roughly 17x net current asset value. This is not a net-net situation by any definition.

BALANCE SHEET: Current ratio of 3.1 — Graham's 2.0 minimum is met comfortably. Long-term debt of $399M (10-K 2026-08-13) versus working capital (current assets $4,325M minus current liabilities $1,395M) = $2,930M working capital. LT debt is well below working capital — a criterion Graham explicitly required, and here it passes easily. Total liabilities $2,381M versus current assets $4,325M — current assets exceed total liabilities by a factor of ~1.8x, close to but not quite meeting the 2x standard Graham preferred.

DIVIDEND: Dividend is paid and was increased (per narrative, Q4 FY2026 announcement). The filing history supports an ongoing program. Graham's dividend continuity test is met.

MARGIN OF SAFETY vs DCF: The two-stage DCF puts intrinsic value at ~$297.54/share (base case), with a bear-case of $233. At $228.35, the stock is marginally below the bear-case DCF, which technically implies a sliver of margin of safety. However, Graham was deeply skeptical of DCF-derived intrinsic values — he preferred asset-anchored or earnings-power-based estimates. The DCF relies on a 10.2% FCF growth rate sustained for 5 years then 2.5% terminal growth; Graham would note the terminal value constitutes 79.1% of enterprise value (flagged in valuation block), making this calculation highly sensitive to assumptions he would distrust. By his earnings-power framework, capitalising FY2026 net income of $1.52B at a conservative 12-15x yields $10.5B–$12.8B equity value, or ~$73–$89/share — far below the current price. Even at 15x P/E the 'Graham value' is roughly $158/share, still well below $228.

FIELD SAFETY / RECALL RISK: The 10-K (2026-08-13) discloses accrued field safety notification expenses of $45.7M at June 30, 2026, versus only $4.8M a year earlier — a nearly 10x increase. The narrative references ventilator recall headwinds and an FY2027 guidance miss attributed in part to Astral device issues. Graham would flag this as a near-term earnings-quality concern.

INSIDER BEHAVIOUR: CEO sold ~$1M of stock (narrative, Aug 11, 2026); a director planned additional sales. Not alarming in isolation, but directionally concerning when combined with guidance disappointment.

AI / DISRUPTION: ResMed's core moat — proprietary CPAP/BiPAP hardware, mask ecosystem, and myAir cloud data platform — faces a nuanced AI threat. AI could improve diagnostic workflows (potentially expanding the addressable market for sleep testing), but could also enable lower-cost entrants to replicate device intelligence. The company's software segment (Residential Care Software, being partly divested via MatrixCare sale) shows some strategic flux. Through Graham's lens, technological disruption risk is a qualitative concern but not a near-term earnings impairment; the durable medical device nature of the core business provides some insulation. Not a decisive factor for this lens.

SUMMARY: ResMed is a high-quality, financially sound business — but quality businesses are not automatically bargain purchases. By Graham's hard quantitative standards (P/E <15, P/E×P/B <22.5, price approaching net asset value), RMD fails materially. The balance sheet is strong (current ratio 3.1, LT debt dwarfed by working capital), earnings are stable and growing, and dividends are paid — these are genuine virtues. But the pricing leaves essentially no margin of safety by Graham's asset-based or earnings-multiple standards. A 'watch' rather than 'pass' reflects the quality of the underlying business that would make it interesting at a substantially lower price, while 'avoid' would be too harsh given the financial integrity.

Key points

  • Earnings stability confirmed: net income grew every year FY2022–FY2026 per fundamentals history; no losses in the observable period
  • Dividend paid and increased per Q4 FY2026 announcement; satisfies Graham's continuity criterion
  • Balance sheet passes key tests: current ratio 3.1 (vs Graham's 2.0 floor); long-term debt $399M (10-K 2026-08-13) well below working capital of ~$2.93B
  • Trailing P/E of 21.6x exceeds Graham's 15x defensive ceiling — fails the earnings-multiple test
  • P/E × P/B = 21.6 × 5.0 = 108, far above Graham's 22.5 combined threshold — stock prices in substantial growth
  • Net current asset value (current assets minus ALL liabilities) approximately $13.48/share; stock at $228.35 is ~17x NCAV — not remotely a net-net
  • Graham earnings-power value (15x trailing net income / shares) implies roughly $158/share, a ~30% premium to current price in Graham's favour but still well below what he'd require
  • Field safety notification accrual surged from $4.8M to $45.7M (10-K 2026-08-13) — Astral ventilator recall a near-term earnings headwind
  • DCF bear case $233 is marginally above current price, but DCF is 79.1% terminal value — Graham distrusted such forecast-dependent valuations
  • MatrixCare sale and accelerated buyback announced (narrative); capital return is positive but signals limited high-return reinvestment opportunity internally

Red flags

  • P/E of 21.6x and P/B of 5.0x both violate Graham's absolute defensive investor thresholds
  • P/E × P/B of ~108 is nearly 5x Graham's 22.5 combined ceiling — no margin of safety on asset/earnings basis
  • Field safety notification accrual nearly 10x year-over-year ($4.8M to $45.7M per 10-K 2026-08-13); FY2027 guidance reportedly missed consensus
  • CEO insider sale of ~$1M (narrative, Aug 11, 2026) concurrent with guidance disappointment
  • Terminal value comprises 79.1% of DCF enterprise value — Graham would regard this as speculation dressed in arithmetic
  • FCF margin declined slightly in FY2026 (29.2%) versus FY2025 (32.3%), though still strong in absolute terms

Seth Klarman — 🟡 watch · 52/100 · medium confidence

ResMed is a high-quality medical device franchise with genuinely strong cash generation, but it does not meet the Klarman margin-of-safety standard as a clear buy. The two-stage DCF from the fact base yields an intrinsic value of ~$297/share, implying roughly 30% upside at the $228 current price — a meaningful but not deep discount. The bear-case DCF sensitivity is $233, barely above today's price. That means the downside case provides essentially zero cushion: if the bear scenario materializes (ventilator recall headwinds, FY2027 guidance miss, slower OSA growth), you are paying approximately fair value or worse. Klarman's first principle demands a deliberate discount to a CONSERVATIVE estimate — not the base case. The bear case here offers no margin of safety whatsoever. On hard asset coverage: total assets of ~$8.97B vs. total liabilities of ~$2.38B gives a book equity of ~$6.59B, but goodwill and intangibles are substantial (customer relationships at $484M gross plus developed technology at $396M gross per the 10-Q filed 2026-05-01, plus acquisition premiums embedded in goodwill not fully extracted from available text). Tangible book is materially lower than stated equity — the 'asset floor' is soft, not hard. FCF quality is genuinely excellent: $1.65B FCF on $5.65B revenue (10-K filed 2026-08-13), FCF margin ~29%, operating cash flow $1.81B, capex only $156M, yielding a price-to-FCF of ~20x. Balance sheet is clean: long-term debt only $399M (10-K filed 2026-08-13), cash $1.47B, net cash position of ~$1.07B. Debt-to-equity of 0.06 is fortress-like — this is a genuine positive and removes balance sheet fragility from the red flag list. The catalyst picture is mixed: MatrixCare asset sale with proceeds directed to buybacks (narrative) is a real value-unlocking event, and institutional accumulation post-30% decline from peak ($284.87 high per price data) suggests some technical dislocation. However, this is not a classic Klarman special situation — it's a well-followed, liquid, large-cap S&P 500 component. There is no forced selling, distress, complexity discount, or orphaning that Klarman specifically seeks. The ventilator recall (Astral field safety notification accrual jumped from $4.8M to $45.7M at June 30, 2026 per the 10-K, a nearly 10x increase) is a concrete headwind that creates uncertainty but is not yet quantified in its full earnings impact — this is the most significant new risk in the filings. AI risk is meaningful but not immediate: AI-assisted sleep diagnostics and home monitoring could commoditize parts of ResMed's AirSense ecosystem over a 5-10 year horizon, though ResMed's data network (myAir platform, 15M+ connected devices implied by business model) could be a durable moat if integrated with AI rather than displaced by it. On balance, this is a Watch: the price has come off 20% from peak, FCF yield is acceptable (~5%), the balance sheet is excellent, and there is a nascent catalyst from the MatrixCare sale and buyback. But the margin of safety relative to a genuinely conservative (bear-case) intrinsic value is essentially absent. Klarman would wait for either a deeper price decline (closer to $180-190 where bear case offers real cushion) or greater clarity on the Astral recall financial impact before committing capital. Cash remains the more honest alternative here until the discount widens.

Key points

  • Bear-case DCF sensitivity is $233/share (fact base valuation block), providing virtually zero cushion at current $228 price — Klarman's margin of safety is absent on a conservative valuation basis
  • Balance sheet is genuinely fortress-like: only $399M long-term debt vs $1.47B cash (10-K filed 2026-08-13), net cash ~$1.07B, debt-to-equity 0.06 — removes balance sheet fragility as a red flag
  • FCF of $1.65B (FCF margin 29%, price-to-FCF ~20x) is high quality and sustainable; multi-year trend shows FCF margins expanding from 6% (FY2022) to 29% (FY2026) per fundamentals history
  • Astral field safety notification accrual spiked from $4.8M to $45.7M (10-K filed 2026-08-13) — a near-10x jump that signals a material but not yet fully quantified recall liability creating forward earnings uncertainty
  • MatrixCare asset sale + accelerated buyback (narrative) is a real catalyst, but ResMed is a large-cap, well-followed name — not the orphaned/complex/forced-selling situation Klarman preferentially targets
  • Stock is ~20% below 52-week high of $284.87 — some technical dislocation, but price must decline further or conservative intrinsic value must be established with a wider gap to clear the margin-of-safety bar

Red flags

  • Bear DCF sensitivity of $233 offers near-zero margin of safety at $228 current price — any disappointment on ventilator recall or FY2027 guidance converts this to a value trap
  • Astral recall accrual explosion ($4.8M to $45.7M, per 10-K filed 2026-08-13) combined with masks-with-magnets accrual of $39.7M in field safety notifications — total contingent liability unclear and still preliminary
  • Goodwill and intangibles are substantial (customer relationships $484M gross, developed technology $396M gross per 10-Q filed 2026-05-01); tangible asset floor is materially softer than stated book equity of $6.59B — 'asset backing' is not hard-asset backed
  • CEO insider selling ~$1M of stock (narrative, Aug 11, 2026) concurrent with weak FY2027 guidance is a mild alignment concern in combination with the operational headwinds
  • DCF intrinsic value rests on 10.2% FCF growth assumption (revenue CAGR as proxy) — this is not a Klarman-style conservative estimate; it embeds growth optimism that the ventilator recall and guidance miss call into question
  • No classic special-situation catalyst: not distressed, not spun-off, not forced selling, not index-deleted — mispricing driver is a routine guidance miss, not structural dislocation Klarman preferentially exploits

Paul Singer — 🟡 watch · 52/100 · medium confidence

ResMed is a high-quality, predominantly single-product-category medical device company with genuine operating excellence — 33% operating margins, ~29% FCF margins, ROIC of ~21% (per fundamentals block), and a nearly debt-free balance sheet (long-term debt $399M vs. $1.47B cash per 10-K filed 2026-08-13). This is not a classical Elliott target: it is not a sprawling conglomerate, the balance sheet is not hoarded or overleveraged, and the core Sleep and Breathing Health business appears well-run. However, the MatrixCare divestiture creates a specific, near-term, forceable self-help moment that is worth evaluating. The company has two segments — Sleep and Breathing Health and Residential Care Software. The narrative confirms the MatrixCare asset sale was announced July 8, 2026, with proceeds earmarked for an accelerated share buyback announced September 1, 2026. The Residential Care Software segment (which housed MatrixCare) has been a drag: the 10-K filings show repeated impairments of office-space right-of-use assets within that segment ($4M in FY2024, $2.7M in Q2 FY2026, $2.7M in Q1 FY2026 per the 10-Q filings), and restructuring charges of $21.7M in nine months ended March 2026 for workforce severance. The D&A for Residential Care Software was only $10.8M vs. $112M for Sleep and Breathing Health (10-K 2026-08-13), confirming it is a small, subscale segment. The divestiture is thus clearly value-enhancing and management is already executing it — the self-help gap is partially closed and actively being arbitraged by management itself, which reduces the activist opportunity. The capital allocation record is mixed but improving: ResMed spent ~$335M acquiring Noctrix Health on June 1, 2026 (10-K 2026-08-13), a medical device start-up developing wearable therapeutics in which ResMed previously held a 3% equity stake, immediately after completing the MatrixCare sale. This is a modest bolt-on, not a reckless acquisition spree. Historical FCF was very low in FY2022 ($216M) and has ramped dramatically to $1.65B in FY2026 (fundamentals history block), suggesting prior capital was tied up in working capital/supply-chain normalization rather than destroyed. The governance lever is weak: ResMed is a standard Delaware corporation with a conventional single-class share structure — no dual-class, no identified founding-family control. This means, in theory, a large holder could press for change. However, the board composition, proxy details, and specific director ownership figures are not available in this fact base, preventing a precise entrenchment assessment. The downside floor is solid: at $228/share, the company trades at ~20x price-to-FCF and ~21.6x P/E (fundamentals), with a DCF intrinsic value of $297.54/share (valuation block, base case) implying 30% upside, and a bear-case floor of $233 — nearly at current price. Net cash position ($1.47B cash vs. $659M total debt, implying net cash of ~$810M) provides a genuine floor. The ventilator (Astral) recall and guidance miss are the key near-term risks: the 10-K shows field safety notification expenses of $45.7M accrued at June 30, 2026 vs. $4.8M a year earlier (10-K 2026-08-13, accrued expenses table), confirming a material step-up in recall-related costs. The FY2027 guidance miss attributed to Astral issues (narrative) is a real operational drag with uncertain duration. AI risk: ResMed's core moat is regulatory clearance, clinical data, and the physician/insurer ecosystem for PAP therapy — not easily disintermediated by AI in a 3-10 year horizon. AI could modestly enhance its connected-device platform (AirSense data analytics) but is unlikely to commoditize the hardware/reimbursement moat. This is not a primary risk factor here. The specific activist call would be: (1) complete and accelerate MatrixCare exit, (2) commit to disciplined capital return (buyback + dividend funded by the $1.65B FCF run-rate), (3) avoid further software/diversification acquisitions that dilute the core Sleep franchise multiple, and (4) provide clear Astral recall containment timeline. Worth per share of completing the capital return program properly: roughly $25-40/share of incremental value from a sustained buyback at current prices. What proves it wrong: Astral recall costs metastasize beyond the $45.7M accrual, FY2027 revenue growth stalls materially, or management deploys MatrixCare proceeds into another dilutive software acquisition. The thesis is real but largely self-executing without activist pressure, reducing the premium for an event-driven entry.

Key points

  • Self-help partially in motion: MatrixCare divestiture already announced and proceeds committed to buyback — management is closing the conglomerate discount without activist pressure, reducing the activist premium
  • Net cash balance sheet ($1.47B cash vs. ~$659M total debt per 10-K 2026-08-13) provides genuine downside floor; DCF bear case $233 nearly matches current price of $228.35
  • FCF margin expanded dramatically from 6% (FY2022) to 29% (FY2026) per fundamentals history — underlying business quality is improving, not deteriorating
  • Residential Care Software segment showed persistent impairments ($4M FY2024, $2.7M each in Q1 and Q2 FY2026 per 10-Q filings) confirming it was subscale and correctly being exited
  • No dual-class shares identified; standard Delaware corporation — governance lever is theoretically accessible, but board detail absent from fact base
  • Noctrix Health acquisition ($335M, June 1, 2026, 10-K 2026-08-13) is modest and bolt-on within the sleep/respiratory core; not a red-flag diversification move
  • ROIC of 21.3% and operating margin of 33.4% indicate the core Sleep and Breathing Health business is already run near peer-leading efficiency — the 'gap to a better owner' is narrow for the core

Red flags

  • Astral recall accrual jumped to $45.7M at June 30, 2026 from $4.8M a year earlier (10-K 2026-08-13) — magnitude and duration of this headwind is material and unresolved, directly impacting FY2027 guidance
  • FY2027 guidance miss attributed to ventilator issues (narrative) with no clear containment timeline disclosed in available filings — open-ended operational liability
  • Self-help gap is already being closed by management (MatrixCare sale, buyback, dividend increase), meaning the activist catalyst is substantially priced in with less upside for an event-driven entry
  • CEO sold ~$1M of stock August 11, 2026 (narrative) — minor but directionally negative signal against a backdrop of disappointing guidance
  • Governance details (board composition, director ownership, staggered vs. annual elections) absent from fact base — cannot fully assess entrenchment or shareholder-action rights
  • SGA expense rising: GAAP SGA $1.12B (19.8% of revenue) in FY2026 vs. 19.3% in FY2025 (10-K 2026-08-13) — modest but bears watching as a capital efficiency metric
  • Terminal value represents 79.1% of DCF equity value (valuation block) — intrinsic value highly sensitive to terminal growth assumption; bear case ($233) leaves minimal margin of safety at current price

Walter Schloss — 🔴 avoid · 28/100 · high confidence

ResMed fails the Schloss deep-value test on almost every hard criterion. The anchor metric is price-to-tangible-book, and RMD trades at a severe premium to any reasonable tangible book figure. Total stockholders' equity per the 10-K filed 2026-08-13 is $6.585 billion against a market cap of ~$32.94 billion — that is already a price-to-book of roughly 5x on stated book. But stated book is itself heavily inflated by goodwill and acquired intangibles: the balance sheet shows total assets of $8.966B and total liabilities of $2.381B, yet the asset base includes substantial intangibles from acquisitions (customer relationships, developed technology, goodwill) that Schloss would strip out entirely because they are not independently appraisable hard assets. After removing intangibles and goodwill, tangible book value would be a fraction of stated equity, pushing the tangible price-to-book ratio well into double digits — far outside any Schloss comfort zone. The stock is also not at a multi-year low in the distressed sense Schloss required: it sits at $228.35, roughly 20% below the 52-week high of $284.87, and the 52-week low is $180.27 — this is a 30% decline off peak, not a true multi-year wipeout creating hard-asset bargains. The balance sheet quality is actually good on a leverage basis — long-term debt of only $399M against $1.469B cash (net cash positive per the valuation block: net debt of -$1.07B), so there is no balance-sheet distress. But that merely means the stock doesn't screen as a distressed asset play either — it is a high-quality compounder priced as such, not a Schloss-style statistical bargain. The business model is also heavily intangible-driven: medical devices, software (Residential Care Software segment), recurring SaaS revenues, acquired goodwill. Schloss explicitly avoided complexity and hard-to-appraise intangibles. The Noctrix acquisition (10-K, 2026-08-13: $335M acquisition June 1, 2026) adds further goodwill. Insider alignment is ambiguous at best — the narrative notes CEO sold ~$1M of stock August 11, 2026, and a director planned a sale September 2, 2026. There is no evidence of insider buying in the fact base. Dividends are being paid and increased, which is a partial positive, but Schloss required this as a sign of durability while waiting for a cheap asset base to be recognized — here there is no cheap asset base. The DCF intrinsic value of $297.54/share (30% upside at base case) is plausible as a growth/FCF story, but Schloss did not buy based on DCF projections — he bought hard assets at a discount. The business earns excellent returns (ROIC 21%, FCF margin 29%), which paradoxically means the market will never price it near tangible book. A Schloss name is cheap because it is earning poorly on its assets temporarily; RMD is expensive because it earns superbly and the market knows it.

Key points

  • Price-to-book approximately 5x stated book (market cap $32.94B vs equity $6.585B per 10-K filed 2026-08-13); tangible book after stripping intangibles is far lower, implying double-digit tangible P/B — well outside Schloss criteria
  • Balance sheet is actually conservatively leveraged: long-term debt only $399M, net cash positive ~$1.07B per valuation block, current ratio 3.1x — no distress, but also no cheap hard-asset floor
  • Stock is 20% below 52-week high ($284.87) and 27% above 52-week low ($180.27) — beaten down but not a Schloss-style multi-year wipeout creating a hard-asset bargain
  • Business is intangible-heavy: medical device IP, software platforms, customer relationships, goodwill from acquisitions including $335M Noctrix deal (10-K 2026-08-13) — assets Schloss could not independently appraise
  • Dividend is growing and FCF is strong ($1.65B FCF, 29% margin per fundamentals), which is a partial positive signal of financial durability
  • ROIC of 21% signals the market will rationally price this well above tangible book indefinitely — the opposite dynamic from a Schloss recovery situation

Red flags

  • Severe premium to tangible book value — the single most important Schloss disqualifier
  • Insider selling: CEO sold ~$1M of stock August 11 2026 and director planned sale September 2 2026 per narrative; no insider buying noted in fact base
  • Business complexity: two segments (Sleep and Breathing Health, Residential Care Software), recurring SaaS revenue streams, ongoing acquisitions, equity investment portfolio with unrealized losses — more moving parts than Schloss preferred
  • Thesis depends on intangible assets, brand moat, and growth forecasts rather than verifiable hard assets providing downside protection
  • Field safety notification accrual jumped from $4.8M to $45.7M for one product line (10-K 2026-08-13, Astral devices) — adds execution/recall uncertainty though not a balance sheet threat at current scale
  • AI/disruption risk: AI-enabled diagnostic tools and consumer wearables could commoditize CPAP adherence monitoring and software platforms over a 5-10 year horizon, eroding intangible asset values that are already hard to appraise

Fact base appendix

Price

  • last_close: 228.35
  • as_of: 2026-09-07
  • high_52w: 284.87
  • low_52w: 180.265
  • range_source: provider
  • pct_below_52w_high: -19.84
  • return_1d_pct: 0.0
  • return_52w_pct: -15.47

Fundamentals

  • last_price: 228.35
  • market_cap: 32940017471
  • fifty_two_week_high: 284.87
  • fifty_two_week_low: 180.265
  • beta: 0.7714741
  • currency: USD
  • exchange: NEW YORK STOCK EXCHANGE, INC.
  • sector: Health Care
  • industry: Health Care
  • price_source: finnhub
  • bars: 1
  • entity: ResMed Inc.
  • fiscal_year: 2026
  • revenue: 5653443000
  • revenue_period: 2026-06-30
  • net_income: 1523293000
  • net_income_period: 2026-06-30
  • operating_income: 1886715000
  • operating_income_period: 2026-06-30
  • operating_cash_flow: 1805829000
  • operating_cash_flow_period: 2026-06-30
  • capex: 156285000
  • capex_period: 2026-06-30
  • total_assets: 8965950000
  • total_assets_period: 2026-06-30
  • total_liabilities: 2380557000
  • total_liabilities_period: 2026-06-30
  • current_assets: 4324739000
  • current_assets_period: 2026-06-30
  • current_liabilities: 1395110000
  • current_liabilities_period: 2026-06-30
  • stockholders_equity: 6585393000
  • stockholders_equity_period: 2026-06-30
  • cash_and_equivalents: 1469234000
  • cash_and_equivalents_period: 2026-06-30
  • long_term_debt: 399415000
  • long_term_debt_period: 2026-06-30
  • shares_outstanding: 144252306.0
  • shares_wad: 145723000.0
  • shares_wad_annual: 146054000.0
  • operating_margin: 0.3337
  • net_margin: 0.2694
  • roe: 0.2313
  • debt_to_equity: 0.0607
  • current_ratio: 3.0999
  • roic: 0.2134
  • free_cash_flow: 1649544000
  • fcf_margin: 0.2918
  • pe_ratio: 21.62
  • price_to_fcf: 19.97
  • price_to_sales: 5.83
  • revenue_cagr: 0.1021
  • revenue_cagr_years: 3
  • fundamentals_source: edgar_companyfacts
  • market_cap_source: vendor_corroborated
  • price_to_book: 5.0
  • earnings_yield: 0.0592
  • peg: 2.12

Filings reviewed

  • 8-K (2026-09-01) https://www.sec.gov/Archives/edgar/data/943819/000119312526378487/d530283d8k.htm
  • 8-K (2026-08-17) https://www.sec.gov/Archives/edgar/data/943819/000119312526354154/d292919d8k.htm
  • 10-K (2026-08-13) https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/rmd-20260630.htm
  • 8-K (2026-08-06) https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/d158732d8k.htm
  • 8-K (2026-07-07) https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/d88958d8k.htm
  • 10-Q (2026-05-01) https://www.sec.gov/Archives/edgar/data/943819/000094381926000025/rmd-20260331.htm
  • 8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm
  • 8-K (2026-04-30) https://www.sec.gov/Archives/edgar/data/943819/000119312526197192/d146862d8k.htm
  • 10-Q (2026-01-30) https://www.sec.gov/Archives/edgar/data/943819/000094381926000007/rmd-20251231.htm
  • 10-K (2025-08-08) https://www.sec.gov/Archives/edgar/data/943819/000094381925000035/rmd-20250630.htm
  • 10-K (2024-08-09) https://www.sec.gov/Archives/edgar/data/943819/000094381924000013/rmd-20240630.htm

Other sources

  • [news] OMERS ADMINISTRATION Corp Buys Shares of 22,106 ResMed Inc. $RMD - MarketBeat
  • [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
  • [news] ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
  • [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
  • [news] Deutsche Bank AG Takes Position in ResMed Inc. $RMD - MarketBeat
  • [news] Why ResMed (RMD) Shares Are Falling Today - Yahoo Finance
  • [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
  • [news] ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
  • [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
  • [news] Is ResMed Inc (RMD) a Bargain After 6.3% Drop? GF Value Says Und - GuruFocus
  • [news] ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
  • [news] ResMed stock held at Hold by Needham as MatrixCare sale announced - Investing.com
  • [news] ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion - ChartMill
  • [news] ResMed (NYSE: RMD) counsel surrenders shares for RSU tax withholding - Stock Titan
  • [news] Director at ResMed (NYSE: RMD) plans new 970-share stock sale - Stock Titan
  • [news] ResMed Inc. $RMD Shares Sold by Van ECK Associates Corp - MarketBeat
  • [news] Is It Too Late to Buy ResMed Inc (RMD) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
  • [news] ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
  • [news] ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance
  • [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
  • [news] Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026 - Moomoo
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] Is ResMed Stock a Buy After Its Astral-Driven Guidance Miss? Here’s What Analysts Are Saying - TIKR.com
  • [news] ResMed Stock: Analyst Estimates & Ratings - Yahoo Finance
  • [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
  • [news] BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
  • [news] ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Yahoo Finance
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - marketbeat.com
  • [news] Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - marketbeat.com
  • [news] ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise - Stock Titan
  • [news] Is This the Right Time to Retain Resmed Stock in Your Portfolio? - TradingView
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
  • [news] ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
  • [news] ResMed (NYSE: RMD) plans to use MatrixCare sale cash for fast-track buyback - Stock Titan
  • [news] Resmed Inc Stock (RMD) Moved Down by 3.25% on Sep 1: Facts Behind the Movement - tradingkey.com
  • [news] ResMed Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
  • [news] Hsbc Holdings PLC Buys Shares of 355,518 ResMed Inc. $RMD - MarketBeat
  • [news] 942,614 Shares in ResMed Inc. $RMD Acquired by Legal & General Group Plc - MarketBeat
  • [news] 228,458 Shares in ResMed Inc. $RMD Purchased by American Capital Management Inc. - MarketBeat
  • [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
  • [news] ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
  • [news] Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues? - Yahoo Finance
  • [news] 350,860 Shares in ResMed Inc. $RMD Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
  • [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
  • [news] Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
  • [news] ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
  • [news] Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - marketbeat.com
  • [news] ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
  • [news] How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - Sahm
  • [news] Is ResMed Inc. (RMD) A Good Stock To Buy Now? - Yahoo Finance
  • [news] Is ResMed Stock Underperforming the Dow? - Yahoo Finance
  • [news] ResMed (RMD) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
  • [news] ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% - ChartMill
  • [news] Is ResMed Inc (RMD) Undervalued After Q4 Earnings Miss? EPS at $ - GuruFocus
  • [news] Earnings Flash (RMD) Resmed Inc. Reports Q4 Revenue $1.46B, vs. FactSet Est of $1.46B - marketscreener.com
  • [news] ResMed Inc. (NYSE: RMD) grows FY 2026 revenue to $5,653M and lifts dividend - Stock Titan
  • [news] Resmed raises quarterly dividend 10% to $0.66 per share - Stock Titan
  • [news] Lazard Asset Management LLC Has $734,000 Stock Position in ResMed Inc. $RMD - MarketBeat
  • [news] Nykredit A S Acquires New Position in ResMed Inc. $RMD - MarketBeat
  • [news] ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts - ChartMill
  • [news] ResMed Inc (RMD) Shares Surge 4.2% -- What GF Score of 90 Tells Investors - GuruFocus
  • [news] ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
  • [news] GTS Securities LLC Has $2.05 Million Holdings in ResMed Inc. $RMD - MarketBeat
  • [news] United Capital Financial Advisors LLC Purchases New Holdings in ResMed Inc. $RMD - MarketBeat
  • [news] Resmed Inc (RMD) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
  • [news] Vista Investment Management Invests $920,000 in ResMed Inc. $RMD - MarketBeat
  • [news] 78,381 Shares in ResMed Inc. $RMD Purchased by Quantbot Technologies LP - MarketBeat
  • [news] 87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
  • [news] 41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
  • [news] ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals - Yahoo Finance
  • [news] Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results - simplywall.st
  • [news] ResMed Q4 Earnings Call Highlights - Yahoo Finance
  • [news] Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
  • [news] ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case - TIKR.com
  • [news] The Manufacturers Life Insurance Company Makes New Investment in ResMed Inc. $RMD - MarketBeat
  • [news] Empowered Funds LLC Buys New Shares in ResMed Inc. $RMD - MarketBeat

Data gaps

  • Dataset completeness: 80 of 80 source documents were dropped to fit the prompt budget — the council did not see them; only 5 of 11 filing excerpts contained readable filing text.

Generated 2026-09-07T11:09:41 · est. cost $1.07

What each investor thinks

01

Chuck Akre Quality

pass · 78

ResMed passes the Akre three-legged stool test with meaningful conviction, though one leg — reinvestment runway clarity — carries a question mark from the ventilator recall/guidance miss and the MatrixCare divestiture. Leg 1 (extraordinary business): RMed is a near-monopoly in CPAP/APAP therapy for obstructive sleep apnea (OSA), a chronic, underdiagnosed condition with decades of underpenetration globally. It enjoys strong switching costs (device-physician-patient ecosystems), a recurring consumables revenue stream (masks, accessories), and embedded software via cloud-connected devices. Operating margin of 33.4% and FCF margin of 29.2% (FY2026, per fundamentals) on $5.65B revenue confirm the capital-light, high-margin franchise. ROIC of 21.3% and ROE of 23.1% (fundamentals) are well above cost of capital and achieved WITHOUT financial engineering: debt-to-equity is only 6.1% (long-term debt $399M vs. equity $6.6B per the 10-K filed 2026-08-13). This is a genuine business return, not a leverage artifact. Leg 2 (management quality/integrity): Capital allocation has been rational. Long-term debt was $1.44B in FY2023 (10-K filed 2024-08-09 shows FY2023 long-term debt ~$1.435B) and has been steadily repaid to $399M by FY2026 — demonstrating disciplined balance sheet management. The MatrixCare sale and earmarking proceeds for buyback is consistent with capital return below intrinsic value (stock 20% off 52-week high). Dividend was increased in conjunction with Q4 FY2026 results. Minor concern: CEO sold ~$1M of stock per the narrative (Aug 2026), and there are acquisition and portfolio review related expenses of $11.5M in FY2026 vs. $2M in FY2025 (10-K filed 2026-08-13), plus the Noctrix acquisition for $335M (June 1, 2026) — so M&A activity is increasing. The Noctrix deal price appears reasonable for a wearable therapeutics platform that extends the OSA franchise. Non-GAAP presentation is standard and reconciliations are transparent in the 10-K. No restatements or related-party red flags visible. Field safety notifications (masks with magnets, Astral ventilator component) are disclosed promptly and accrued properly ($45.7M field safety notification expenses in accrued liabilities at June 30, 2026 per 10-K vs. $4.8M prior year) — a meaningful jump that partially explains the FY2027 guidance miss. Integrity bar is met. Leg 3 (reinvestment runway): OSA remains vastly underpenetrated globally — hundreds of millions of undiagnosed patients. The Residential Care Software segment (though MatrixCare is being divested) and the Sleep and Breathing Health segment both present reinvestment opportunities. However, FCF grew from $216M in FY2022 to $1.65B in FY2026 (per history), but FCF was essentially flat YoY between FY2025 ($1.66B) and FY2026 ($1.65B), and FCF margin ticked down from 32.3% to 29.2% — this could reflect Noctrix acquisition costs and field safety costs, or it could indicate early margin pressure. The Astral ventilator recall creates near-term noise. Reinvestment at high rates into OSA device innovation, connected care software, and geographic expansion remains the core thesis — the runway is long if the core franchise holds. Valuation: DCF base case of $297.54/share (per valuation block) vs. current price of $228.35 implies ~30% upside. Bear case is $233 — only modestly above current price, which is the key risk. At P/FCF of ~20x and P/E of ~21.6x on a business compounding FCF at a ~10% 3-year CAGR, this is a reasonable but not cheap price for an Akre-style holding. The PEG of 2.12 is elevated, suggesting the market is paying up for quality. AI risk: ResMed's connected-device platform (cloud-connected CPAPs feeding data to myAir and to physicians) could be enhanced significantly by AI-driven adherence coaching and sleep diagnostics — this is a tailwind, not a threat. AI is unlikely to disintermediate the core hardware/consumables revenue. However, GLP-1 weight-loss drugs (not explicitly in the fact base but a known market risk) could reduce OSA prevalence over time — this is the key unmodeled risk in the DCF. Confidence is medium rather than high because: (1) no earnings call transcript to assess management tone; (2) FY2027 guidance specifics unknown; (3) Astral recall magnitude/duration unclear; (4) GLP-1 impact on TAM not addressed in filings. Overall: two-and-a-half legs are clearly intact; the half-leg hesitation is on reinvestment-at-high-rates visibility given near-term headwinds. Score 78.

02

Warren Buffett Quality

pass · 78

ResMed is a high-quality medical device franchise with durable competitive characteristics that fit squarely within the Buffett quality lens. The business is understandable — it makes CPAP/sleep therapy devices and related masks/accessories for obstructive sleep apnea, plus software for residential care. The economics are excellent: ROIC of 21.3%, ROE of 23.1% (fundamentals block), operating margins of 33.4% (10-K filed 2026-08-13: GAAP revenue $5.65B, operating income $1.89B), and FCF margins expanding dramatically from 6% in FY2022 to ~29-32% by FY2025-2026 (history block). This FCF surge reflects real earnings quality — operating cash flow of $1.81B versus capex of only $156M (fundamentals), yielding ~$1.65B owner earnings. The balance sheet is conservative: long-term debt of only $399M (10-K 2026-08-13), cash of $1.47B, resulting in net cash of approximately $1.07B (valuation block: net debt = -$1.07B). Debt-to-equity of 0.06 (fundamentals) is essentially negligible. Revenue has grown at a 10.2% 3-year CAGR (fundamentals). The moat appears real: ResMed dominates the global CPAP/sleep therapy market with sticky device-and-mask ecosystems, recurring consumable mask revenue, and proprietary cloud-connected device data (AirSense platform) creating switching costs for patients, providers, and payors. The DCF intrinsic value of ~$297/share (valuation block) implies ~30% upside to the current $228.35, with a bear-case of $233 providing modest but real margin of safety. At 21.6x P/E and 20x price-to-FCF, the price is not cheap but is fair for this quality tier — a wonderful business at a fair price. Capital allocation is rational: dividend increase, share buyback from MatrixCare proceeds, and selective tuck-in acquisitions (Noctrix Health for $335M per 10-K 2026-08-13). Near-term headwinds include ventilator recall issues (Astral field safety notification; accrued field safety expenses jumped from $4.8M to $45.7M per 10-K 2026-08-13), which creates FY2027 guidance uncertainty and is a watch item. CEO share sales ($1M, per narrative) and the FY2027 guidance miss are modest red flags but not disqualifying. On AI disruption: AI likely enhances ResMed's moat by improving diagnostic algorithms, patient adherence monitoring, and payors' data requirements — all areas where ResMed's connected-device data advantage deepens. AI is not a near-term commoditizing threat to CPAP hardware or consumable masks.

03

AI & Disruption Referee (Christensen-style) Referee

pass · 78

ResMed's core business is hardware-anchored medical devices (CPAP/BiPAP, ventilators, masks) combined with a cloud-connected data platform (AirSense/myAir/AirView ecosystem) that monitors patient adherence and outcomes. The obsolescence question here is fundamentally different from a pure software or knowledge-work intermediary: the primary 'job' is to physically treat obstructive sleep apnea and respiratory disease by delivering pressurized air through a device strapped to a patient's face. AI cannot replace that physical therapeutic function. There is no disintermediation risk to the core hardware revenue from LLMs or generative AI in any meaningful 3-10 year horizon. The more interesting question is the data and software layer — ResMed's AirView platform monitors 10+ million patients and generates proprietary adherence, efficacy, and physiological data at scale. This proprietary longitudinal dataset is a genuine moat that AI makes MORE valuable, not less: better predictive adherence algorithms, tele-monitoring optimization, payer/provider reporting, and remote care coordination all improve with more data and better models. This is the compounding-moat scenario, not the commoditization scenario. The Residential Care Software segment (now partly exited via MatrixCare sale per the narrative) did carry more AI disruption risk — care coordination software is a knowledge-work workflow product where AI-native competitors (well-funded health-tech startups, or Epic/Oracle bundling) could commoditize. The MatrixCare divestiture (noted in the narrative, July 2026) actually REDUCES that exposure, though the 10-K excerpt confirms the Noctrix acquisition (June 1, 2026 per 10-K filed 2026-08-13) moves ResMed further into wearable therapeutics — a hardware-plus-data direction that AI strengthens rather than threatens. Key AI tailwinds: (1) AI-driven resupply optimization and adherence intervention (ResMed's existing data flywheel gets more valuable); (2) AI-assisted therapy titration reducing in-lab sleep study dependency expands the addressable patient pool (more devices needed, not fewer); (3) Remote patient monitoring reimbursement trends favor connected device makers. Key residual risks: (1) The Residential Care Software segment still exists post-MatrixCare and competes in a space where AI-native entrants and EHR incumbents (Epic, Oracle Health) could bundle workflows more cheaply — this is the segment where hyperscaler/platform capture is a real threat; (2) AI-assisted diagnostic tools (Apple Watch, Whoop, smartphone-based sleep scoring) could theoretically reduce the perceived need for full polysomnography and CPAP prescription pipelines if they become 'good enough' for mild OSA, compressing the addressable market at the margin; (3) Generic/commodity CPAP hardware from Asian manufacturers (already a price pressure vector) could be further enabled by AI-optimized manufacturing and direct-to-consumer channels, eroding ASPs on devices. Management's AI framing: the fact base does not include earnings call transcripts, so direct management commentary on AI strategy is unavailable — this limits confidence. The narrative references 'OSA market growth' broadly but no specific AI strategy language. This is a data gap, not evidence of denial. On balance, ResMed is a medical device company with a strong proprietary data moat that AI amplifies rather than erodes, with the most exposed software segment being divested. The Christensen-style disruption risk is LOW for core device revenue and MODERATE for the remaining software/SaaS segment. The falsifiable bear case: watch for (a) Apple/Samsung/Google launching AI-native sleep apnea screening that captures the mild-OSA market and reduces CPAP prescription rates materially; (b) Epic or Oracle bundling residential care software at near-zero marginal cost, collapsing ResMed's software take-rates; (c) AI-native direct-to-consumer CPAP companies (bypassing traditional DME/prescription channel) gaining share. The falsifiable bull case: (d) ResMed's AirView data enables AI-driven care models that attract new payer contracts or expand into chronic disease management, raising ARPU; (e) AI-assisted auto-titrating devices reduce the need for costly in-lab titration, expanding the diagnosed-and-treated population. Current evidence tilts toward the bull case on the core business.

04

Charlie Munger Quality

pass · 78

ResMed is precisely the kind of business Munger prizes: a durable, understandable franchise with a genuine moat, high returns on capital, and earnings that convert robustly to free cash flow. The company dominates the CPAP/sleep-apnea device market through a combination of proprietary hardware, a cloud-connected data ecosystem (AirView/myAir), and deep payer/physician relationships that create real switching costs. The unit economics are simple: sell a device, attach a recurring mask/consumable stream, and collect data that entrenches the clinical workflow. The moat is identifiable and has been durable across multiple years of data in the fact base.

On returns: ROIC of 21.3% and ROE of 23.1% (fundamentals block) substantially exceed the 8.1% WACC, and this has been sustained across the multi-year history. FCF margins have exploded from 6% in FY2022 to 29% in FY2026 (history table), which is not a one-year artifact — the FY2025 FCF margin was 32.3%. Operating income of $1.89B on $5.65B revenue (33.4% operating margin, 10-K FY2026) is the kind of unit economics Munger respects. Owner earnings — operating cash flow of $1.81B less $156M capex = roughly $1.65B — are real and largely match reported FCF.

Balance sheet is clean. Long-term debt of $399M against $1.47B cash (10-K FY2026) leaves the company in a net cash position of roughly $1.07B. Debt-to-equity is 0.06. This balance sheet survives any plausible downturn.

Accounting quality is acceptable. Non-GAAP adjustments are disclosed and reconciled (10-K FY2026). The main adjustments — acquired intangibles amortization and field safety notification costs — are real charges but disclosed transparently. FCF conversion from net income is strong (FCF of $1.65B vs net income of $1.52B for FY2026), which is the signature of honest earnings. The one note of caution: field safety notification accruals jumped from $4.8M to $45.7M between FY2025 and FY2026 (accrued expenses table, 10-K FY2026) — the Astral ventilator component replacement issue is a real cost and a real operational risk, not a phantom. The masks-with-magnets issue is a separate but smaller liability.

Management capital allocation has been rational: debt was reduced from $1.44B (FY2023) to $399M long-term (FY2026) while FCF grew; dividends were increased; the MatrixCare sale (narrative) and planned buyback suggest willingness to exit non-core assets and return capital rather than empire-build. The Noctrix acquisition at $335M (10-K FY2026) is modest relative to FCF and plausibly adjacent. I note with mild concern that CEO sold ~$1M of stock (narrative, Aug 2026) coinciding with the guidance miss — not disqualifying but worth watching.

Valuation: The two-stage DCF yields $297.54 intrinsic value vs $228.35 market price — roughly 30% upside in the base case. The bear-case DCF is $233, barely above current price, which means at current price the stock is priced near the bear scenario. P/E of 21.6x and price-to-FCF of 20x for a 21%+ ROIC, ~10% revenue CAGR business is not cheap but is not expensive for the quality. A 5% FCF yield on a business reinvesting at 20%+ incremental returns is a reasonable entry. Revenue CAGR of 10.2% (3-year, fundamentals block) used in the DCF is plausible given OSA market underpenetration — estimated diagnosis rates remain low globally.

AI/disruption lens: AI is a tailwind for ResMed, not a threat. Remote patient monitoring, adherence analytics, and device-generated sleep data are areas where ResMed's existing AirView platform already operates. AI could enhance clinical decision support and deepen the data moat. The risk of AI commoditizing hardware is real but modest in the 3-5 year window — FDA clearance requirements and clinical validation create high barriers. The larger AI risk is if a tech giant entered remote monitoring at scale, but ResMed's installed base and payer integrations create substantial switching costs.

Inversion test: How does this go to zero or permanently impair capital? (1) A dominant new therapy (GLP-1 drugs reducing OSA prevalence) could shrink the addressable market — this is the most serious structural risk but OSA severity and comorbidities suggest PAP therapy remains necessary even for patients losing weight; the market likely grows even if patient mix shifts. (2) The Astral/ventilator recall worsens dramatically and generates massive liability — possible but the $45.7M accrual (10-K FY2026) and the company's FCF capacity suggest it is manageable. (3) Regulatory reimbursement changes — always a risk for medical device companies, not unique to ResMed. None of these answers 'yes, capital can be permanently destroyed with high probability.'

What holds the score below 85: (1) FY2027 guidance miss (narrative) creates genuine uncertainty about near-term earnings power — the market is pricing in real risk; (2) the field safety notification cost jump ($45.7M accrual) is a tangible operational issue whose full scope is unclear from the fact base — I am missing the full Q4 call transcript; (3) at 20x FCF the stock is fair but not obviously cheap — the margin of safety is moderate, not wide; (4) GLP-1 drug competition is a genuine long-term uncertainty on the TAM that I cannot fully dismiss.

05

Terry Smith (Fundsmith) Quality

pass · 78

ResMed is exactly the kind of business Fundsmith would scrutinize closely: a dominant medical-device franchise with recurring consumable revenues (masks, accessories), essential healthcare demand tied to obstructive sleep apnea and respiratory care, and demonstrably high returns on invested capital. The quality case is strong but carries some Fundsmith-style reservations around acquisitiveness, non-GAAP reliance, field safety notification charges, and near-term guidance uncertainty from ventilator issues. On balance, the business clears the quality bar comfortably, and the current price offers a meaningful margin of safety relative to the DCF intrinsic value — though not a screaming bargain.

ROCE/ROIC: The fact base reports ROIC of 21.3% and ROE of 23.1% for FY2026 (fundamentals block). Operating margin is 33.4% (FY2026 10-K: GAAP income from operations $1.887B on revenue $5.653B). These are sustained — the FY2025 10-K shows similar margins — placing ResMed well above a 20% ROCE threshold across multiple years. Smith's first test: pass.

Cash conversion: FCF of $1.650B versus net income of $1.523B for FY2026 (fundamentals). FCF margin 29.2%. Free cash flow is tracking above reported net income — textbook quality cash conversion. Capex is light at $156M on $5.65B revenue (~2.8%), confirming asset-light characteristics. Smith's cash-conversion test: pass.

Margins: Operating margin 33.4%, net margin 26.9%, FCF margin 29.2%. These are durable and high. The mask/accessory consumable cycle creates repeat-purchase revenue — highly Fundsmith-friendly. The Sleep and Breathing Health segment drives the core; Residential Care Software (MatrixCare, being divested per narrative) was the more questionable piece and is being shed.

Balance sheet: Debt has been rapidly reduced. Long-term debt fell from $1.435B (FY2023 10-K) to $700M (FY2024) to $660M (FY2025) to $399M (FY2026 fundamentals). Cash stands at $1.469B, giving net cash of approximately $1.07B (valuation block: net_debt = -$1.07B). This is now a net-cash business — a green flag for Smith who fears leverage.

Capital allocation concerns: The 10-K (filed 2026-08-13) discloses the $335M acquisition of Noctrix Health (June 1, 2026), a wearable therapeutics company. Smith is skeptical of serial acquisitions. The narrative also references the VirtuOx acquisition (FY2025) and the MEDIFOX DAN acquisition referenced in earlier filings. There is a pattern of bolt-on M&A which adds goodwill and acquired intangibles (amortization of acquired intangibles was $78M in FY2026 per the 10-K segment note). The company relies partly on non-GAAP metrics to back out these amortization charges and acquisition-related costs — a classic Fundsmith red flag. However, since FCF comfortably exceeds GAAP net income, the cash backing is real; the non-GAAP presentation is more cosmetic than masking a cash-generation problem here.

Field safety notifications: The 10-K (2026-08-13) discloses two active field safety notification accruals — $45.7M for masks-with-magnets and an Astral ventilator component replacement program. These are real costs and the Astral issue is reportedly behind the FY2027 guidance miss (narrative). This is a quality/execution demerit and adds near-term earnings uncertainty.

Valuation: The DCF intrinsic value is $297.54/share versus current price $228.35, implying ~30% upside (valuation block). P/E of 21.6x, price-to-FCF of 20.0x, FCF yield of ~5%. For a business growing revenue at ~10% CAGR (3-year, fundamentals) with 33% operating margins and net-cash balance sheet, a 20x FCF multiple is not cheap but is defensible. Smith would ask: is the reinvestment runway long enough to justify holding? Given global OSA underdiagnosis rates and the recurring consumable stream, yes — though the ventilator recall risk and M&A pattern are modest valuation headwinds.

AI disruption: AI is more enabler than threat for ResMed. The company's AirSense platform already uses cloud connectivity and data analytics for patient adherence and remote monitoring — an AI-augmented moat. AI-driven OSA diagnosis tools (apps, wearables) could theoretically reduce CPAP device volumes long-term, but given that devices and masks are reimbursed through established healthcare channels with regulatory approval requirements, disruption is slow. Near-term AI impact: neutral to mildly positive (better adherence data, stronger physician integration).

Summary: ResMed is a high-quality compounder — strong ROIC, exceptional margins, excellent cash conversion, asset-light, now net-cash — that fits the Fundsmith template well. The demerits (M&A pattern, non-GAAP reliance, field safety notifications, FY2027 guidance uncertainty) prevent a higher score but do not undermine the core quality thesis. The price offers ~30% upside to DCF base case with a bear-case of $233, suggesting limited downside to intrinsic value. A pass, not a high-conviction one.

06

Philip Fisher Growth

pass · 76

ResMed passes the Fisher growth lens on most criteria but with meaningful caveats on near-term execution headwinds. The core franchise — dominant position in CPAP/sleep-disordered breathing devices, a recurring mask/accessory revenue stream, and a growing digital health/SaaS layer — fits Fisher's template of a company with a visible multi-year runway rooted in R&D-driven product expansion and an expanding addressable market (obstructive sleep apnea remains massively underdiagnosed globally). Revenue CAGR of ~10.2% over three years (per fundamentals block) is solid for a medical device company of this scale. FCF conversion has improved dramatically — FCF margin expanded from 6% in FY2022 to ~29-32% in FY2024-2026 (per the historical table in fundamentals), signaling genuine operating leverage rather than financial engineering. Operating margin of 33.4% (fundamentals, FY2026) is best-in-class for the sleep/respiratory segment and indicates strong pricing power and cost discipline. However, Fisher's bar demands candor about headwinds: the Astral ventilator field safety notification, the masks-with-magnets recall costs, and an FY2027 guidance miss (per the narrative) are exactly the kind of operational stumbles Fisher scrutinized for management character. The fact that accrued field safety notification expenses jumped from $4.8M to $45.7M (10-K filed 2026-08-13, Note 7) is a material increase that needs watching. The MatrixCare divestiture is a positive signal — pruning non-core software to refocus on the core sleep/breathing franchise — but using proceeds for buybacks rather than organic reinvestment raises a mild Fisher flag about long-term reinvestment philosophy. R&D spend is not broken out in the excerpts available, which limits confidence. The Noctrix Health acquisition ($335M, completed June 1, 2026 per 10-K filed 2026-08-13) for clinically validated wearable therapeutics is consistent with Fisher's criterion of management seeking new markets before current ones mature. Balance sheet is conservatively leveraged: long-term debt of $399M vs. $1.47B cash (fundamentals, FY2026), D/E of 0.06, giving ample firepower. AI risk is real but manageable — AI could enhance ResMed's digital health data platform (AirView has millions of connected patients) rather than commoditize it, at least over a 3-10 year horizon; the data moat from remote monitoring becomes MORE valuable as AI analytics improve. The primary Fisher risk is the current guidance credibility problem and whether management communicates transparently about recall scope and duration — no transcript was available to assess candor directly, which is a key evidence gap.

07

Michael Mauboussin Quality

pass · 75

ResMed earns a 'pass' through the Mauboussin lens primarily because ROIC clearly exceeds WACC, the moat sources are concrete and mechanistically defensible, and the current price embeds expectations that appear roughly consistent with a conservative-to-base case scenario — not a right-tail demand. The key reservation is near-term uncertainty around the Astral ventilator recall, FY2027 guidance disappointment, and a residual value that constitutes ~79% of the DCF (per the valuation block), meaning the terminal value does enormous lifting and any moat erosion has outsized consequences.

ROIC vs. WACC Scorecard: The fact base shows ROIC of 21.3% (fundamentals block) against a WACC of 8.12% (valuation block), yielding a spread of approximately 1,300 basis points. Operating margin of 33.4% and FCF margin of 29.2% (FY2026, 10-K filed 2026-08-13) confirm this is not a thin-spread, commodity-like business. ROE of 23.1% corroborates. The spread has been widening: FCF margin moved from 6.1% in FY2022 to 32.2% in FY2025 before settling at 29.2% in FY2026 (fundamentals history block), a structurally improving trajectory rather than cyclical luck. However, I must note that part of this FCF improvement likely reflects normalization of working capital and capex post-supply-chain disruption; the base rate says high-ROIC spreads mean-revert, so I weight the persistence question heavily.

Moat Concreteness: Three mechanisms are identifiable from the filing evidence:

  1. Switching costs (high): CPAP/APAP therapy is titrated to individual patients, data is captured on ResMed's AirSense/AirView cloud platform (referenced across 10-K filings), and switching devices disrupts compliance data continuity for physicians and payers. The SaaS/connected-device architecture creates genuine procedural switching costs — not just brand loyalty.
  2. Scale economies and intangibles (moderate-to-wide): The Sleep and Breathing Health segment generates D&A of $112M (FY2026, 10-K) with $5.65B in revenue, suggesting substantial fixed-cost leverage. Patent/IP barriers in sleep diagnostics and respiratory care are standard in medtech; the 10-K references intangible amortization of ~$78M/year implying significant acquired IP, though the useful-life schedule (2–40 years per 10-K, 2026-08-13) is wide.
  3. Regulatory and reimbursement moat (narrow-to-moderate): Third-party reimbursement is noted as a key variable (10-K and 10-Q alike), which cuts both ways — it creates barriers to new entrants (who must navigate the same reimbursement landscape) but also creates payer-concentration risk and pricing exposure. The Residential Care Software segment (now being divested via MatrixCare sale per narrative) added customer-relationship switching costs in care-coordination workflows, though that moat is being exited.

Overall moat rating: Wide, but with a stable-to-slightly-eroding trajectory given: (a) GLP-1 drugs (Ozempic/Wegovy class) as a potential long-run demand headwind for OSA — not quantified in the fact base but a known structural question; (b) Astral recall uncertainty creating near-term volume uncertainty in ventilators (narrative); (c) MatrixCare divestiture removes one switching-cost layer, though it simplifies capital allocation.

Expectations Investing — What's Priced In? The DCF intrinsic value is $297.54/share vs. current price of $228.35 (valuation block), implying ~30% upside at base. The base case uses ~10.2% FCF growth (revenue CAGR) and an 8.12% WACC with 2.5% terminal growth. Working backwards from the current price: at $228.35, the market is roughly pricing in FCF growth closer to 6–7% annually or a somewhat higher discount rate — neither assumption requires heroic optimism. The bear case at $233 (valuation block) is almost exactly the current price, suggesting the market is already pricing in near-bear conditions. For the base case to fail, FCF growth would need to sustain below the revenue CAGR of the past 3 years (10.2%) — plausible given GLP-1 headwinds and recall, but not the median outcome. P/FCF of 19.97x (fundamentals) on a business with 21%+ ROIC and 33% operating margins is not demanding by historical medtech standards. P/E of 21.6x with 27% net margins implies an earnings yield of 5.9% — modestly above the WACC, providing some margin of safety.

Distribution of Outcomes:

  • Bull (25% weight): GLP-1 uptake proves complementary rather than substitutive to CPAP, ventilator recall resolved quickly, MatrixCare sale proceeds accelerate buyback at attractive prices, FCF grows 12–15%, stock reaches $350–400.
  • Base (50% weight): Steady 8–10% revenue/FCF growth, OSA market continues expanding, recall costs manageable (~$45.7M field safety expense already accrued per 10-K 2026-08-13), stock converges toward $280–310.
  • Bear (25% weight): GLP-1 drugs meaningfully reduce new CPAP patient starts over 5 years, ventilator recall drags FY2027 more than anticipated, payer pressure on reimbursement rates, FCF growth decelerates to 3–5%, stock range $170–230.

The fat left tail is GLP-1 structural displacement — the fact base does not quantify this and I cannot assert a number, but it is the single most important outside-view question for the moat's 10-year trajectory.

Capital Allocation: The shift from debt repayment (long-term debt dropped from $1.44B in FY2023 to $399M in FY2026 per 10-K 2026-08-13) to buybacks and dividend growth reflects disciplined capital allocation as the balance sheet healed. The Noctrix Health acquisition ($335M, June 2026 per 10-K 2026-08-13) for wearable sleep therapeutics is early-stage and small relative to FCF — a plausible adjacency bet, not empire-building. MatrixCare divestiture (narrative) removes a subscale SaaS segment that was generating ROU asset impairments and restructuring charges. These moves are consistent with ROIC-focused management, not value-destructive empire-building. Insider selling (CEO ~$1M, per narrative) is minor relative to FCF and not disqualifying.

Skill vs. Luck: The FCF ramp from $216M (FY2022) to $1.65B (FY2026) is partially supply-chain normalization and partially the structural benefit of competitors (Philips) having a major recall that gifted ResMed market share — outside-view, some of this was luck. However, the operating margin expansion from pre-COVID levels to 33%+ suggests genuine scale and operating leverage that is unlikely to fully reverse.

AI and Technology Disruption: AI is potentially both a threat and an opportunity. As a risk: AI-assisted diagnostics could reduce referral pathways that funnel patients to CPAP/APAP therapy (disintermediation of the diagnostic chain). As an opportunity: ResMed's AirView connected platform and patient data assets could be enhanced by AI-driven compliance coaching, early-warning deterioration signals, and physician workflow integration — deepening switching costs. On balance, AI appears modestly net-positive over 3–10 years through the connected-device/data moat, but the GLP-1 question is a larger structural threat than AI displacement specifically.

08

Valuation Referee (Damodaran-style) Referee

pass · 74

ResMed trades at $228.35 against a base DCF intrinsic value of $297.54, implying ~30% upside. The DCF is grounded in defensible inputs: WACC of 8.12% is consistent with RMD's low beta (0.77 per fundamentals), sector positioning in medical devices, and a nearly debt-free balance sheet (long-term debt $399M vs. cash $1.47B, implying net cash per the valuation block of ~$1.07B). Terminal growth of 2.5% is reasonable and below long-run nominal GDP. The base FCF of $1.65B is real and auditable — FY2026 operating cash flow was $1.806B with capex of $156M (10-K filed 2026-08-13). The revenue CAGR proxy for near-term FCF growth at ~10.2% is achievable but not heroic: historical revenue grew from $3.578B (FY2022) to $5.653B (FY2026), a 3-year CAGR of ~10.2% (fundamentals block). ROIC is 21.3% vs. WACC ~8.1% — the spread is substantial and validates that growth here creates, not destroys, value. FCF margin has expanded dramatically from 6.1% (FY2022) to 29.2% (FY2026), suggesting genuine operating leverage rather than financial engineering. The bear DCF case of $233 is essentially at today's price, meaning the margin of safety is thin but present — the stock does NOT require the bull case ($390) to justify; even a conservative base holds ~2% above current. Critical risks to the DCF: (1) The Astral ventilator recall creates an identifiable FY2027 headwind — field safety notification expenses accrued at $45.7M vs. $4.8M the prior year (10-K 2026-08-13, accrued expenses note), signaling a material cost. (2) The 10.2% FCF growth assumption derived from revenue CAGR may overstate near-term FCF growth if recall costs and restructuring ($21.7M in nine months ended March 2026, per 10-Q filed 2026-05-01) persist. (3) Terminal value represents 79.1% of total enterprise value — the model is highly sensitive to terminal growth and WACC, which is structurally typical of a DCF but worth flagging explicitly. (4) The reverse-implied expectations at $228 require roughly 7-8% FCF growth plus stable ~29% FCF margins — achievable given history but not guaranteed given the ventilator headwinds. (5) The Noctrix acquisition ($335M completed June 2026, per 10-K 2026-08-13) and MatrixCare divestiture introduce near-term noise in FCF comparability. On AI disruption: ResMed's CPAP/BiPAP franchise is hardware-centric with strong regulatory moats, proprietary data from connected devices (AirSense platform), and entrenched reimbursement relationships. AI could enhance, not threaten, ResMed's moat by improving diagnostic algorithms and adherence monitoring — this is a modest positive, not a disruption risk on a 3-10 year horizon. The Residential Care Software segment (being divested via MatrixCare) had higher AI-disruption exposure, so the divestiture actually sharpens the AI-resilience of the remaining portfolio. Overall: price sits ~30% below base DCF, ROIC vastly exceeds WACC, FCF is real and growing, debt is minimal. The margin of safety is meaningful but not overwhelming — bear case barely clears current price, demanding confidence in the base assumptions. I score this 74: a clear pass but not a high-conviction slam dunk given near-term guidance miss, recall headwinds, and the high terminal value dependency.

09

Ray Dalio Risk

pass · 72

ResMed is a medical-device compounder with a structurally resilient demand profile that holds up reasonably well across Dalio's four macro regimes, though it is not regime-neutral. The core Sleep and Breathing Health segment addresses obstructive sleep apnea — a chronic, non-discretionary condition with third-party reimbursement buffering end-demand from consumer credit cycles. This is a meaningful differentiator versus purely discretionary or credit-sensitive businesses. The balance sheet is fortress-grade: the 10-K filed 2026-08-13 shows long-term debt of only $399M, cash of $1.47B, and a net cash position (net debt of approximately -$1.07B per the valuation block), debt-to-equity of 0.06, and ROIC of 21%. FCF of $1.65B on $5.65B revenue (29% FCF margin) means the company self-funds entirely through a downturn. The debt maturity profile is NOT alarming — the 10-K shows short-term debt at $260M and long-term debt at $399M as of June 30, 2026, versus $1.47B cash, so refinancing risk is negligible. Interest coverage is extremely high: operating income of $1.89B vs. minimal net interest cost (the filings show interest INCOME of ~$50M in FY2026, not expense). These factors tick most of Dalio's balance-sheet-resilience and self-funding boxes. On regime robustness: in a RISING GROWTH/FALLING INFLATION regime (boom), RMD benefits from volume growth and stable margins. In a FALLING GROWTH/FALLING INFLATION regime (deflationary bust), reimbursed medical devices are among the most durable demand categories — patients continue CPAP therapy regardless of the business cycle, and the company's low debt means no distress risk. In a RISING GROWTH/RISING INFLATION (reflation) regime, RMD has demonstrated pricing power in devices and masks, and its gross margins have been stable-to-expanding. The weakest quadrant is STAGFLATION — rising inflation squeezes real reimbursement rates (Medicare/Medicaid rates are set administratively and may lag inflation), input costs in electronics/components could compress margins if pass-through is constrained, and a slower growth environment could crimp new patient diagnoses. The near-term Astral ventilator recall and FY2027 guidance miss (noted in narrative) are idiosyncratic operational risks, not macro risks, but they do introduce earnings uncertainty. The GLP-1/weight-loss drug narrative (Ozempic-type drugs potentially reducing OSA prevalence) is a structural disruption risk that has weighed on sentiment and is the biggest long-duration bear case — this is not a macro risk in the Dalio sense but it is a demand-durability question. On geographic diversification: RMD has meaningful international revenue (Sleep segment is global; Residential Care Software is more US-concentrated), providing partial FX diversification, though the fact base does not provide precise split by region in this excerpt. FX hedging instruments are disclosed ($16.6M accrued at June 30, 2026 per 10-K). On correlation/diversification value: with beta of 0.77, RMD offers below-market beta and its primary drivers (disease prevalence, reimbursement policy, clinical adoption) are partially uncorrelated to economic cycles — a genuine diversification benefit in a risk-parity context. The DCF base-case intrinsic value of $297.54/share implies 30% upside to current price of $228.35, with a bear-case sensitivity of $233 — a thin bear-case cushion that assumes continued FCF growth. The valuation assumes ~10% FCF growth (revenue CAGR) which could be too optimistic if GLP-1 penetration or recall headwinds are sustained. At ~20x FCF and 21.6x earnings, the stock is not cheaply priced in absolute terms, which means in a regime shift to higher-for-longer rates or multiple compression, there is valuation downside even if fundamentals hold. The PEG of 2.12 is elevated. Overall, for a Dalio-style risk assessment: excellent balance sheet, non-cyclical demand, self-funded, diversified geographically, below-market beta — these are strong positives. Key risks are stagflation margin compression (reimbursement lag), structural GLP-1 disruption to long-run demand, and a valuation that embeds optimistic growth assumptions. Score: 72 — a pass but not a high-conviction allocation.

10

Forensic Short-Seller (Chanos/Einhorn-style) Referee

pass · 72

ResMed passes the forensic screen with modest concerns but no smoking-gun accounting fraud indicators. The core earnings-vs-cash test is actually strong: net income of $1.523B vs. operating cash flow of $1.806B and FCF of $1.650B for FY2026 (10-K filed 2026-08-13) — cash persistently exceeds reported earnings, which is the opposite of the Chanos red flag. The accrual ratio is negative (cash > earnings), the cleanest possible signal on earnings quality. FCF margin has expanded dramatically from 6.1% in FY2022 to 29.2% in FY2026 (fundamentals history). Non-GAAP adjustments exist but are modest: the 10-K reconciliation shows GAAP operating income of ~$1.887B vs. non-GAAP adding back ~$78M amortization of acquired intangibles and ~$50M field safety notification expenses — a manageable and disclosed gap, not a sprawling 'adjusted' fiction. Insider selling is a mild flag: the narrative cites CEO selling ~$1M in stock (Aug 11, 2026) and a director planning a 970-share sale (Sep 2, 2026), but no clustered or large-scale selling pattern is documented in the fact base. Debt structure is favorable: long-term debt has been dramatically reduced from $1.435B (FY2023, per 10-K filed 2024-08-09) to $399M (FY2026, fundamentals), with net cash position of ~$1.07B (valuation block net_debt = -$1.07B). Interest coverage is not a concern. SBC dilution: shares outstanding have actually declined modestly from ~147.5M (FY2024) to ~144.3M (FY2026), confirming buybacks are net accretive, not a treadmill. Three genuine forensic concerns exist: (1) Field safety notification accruals surged from $4.8M (FY2025) to $45.7M (FY2026) per the 10-K accrued expenses note — the Astral ventilator recall is a real and growing liability with uncertain ultimate cost; (2) The $335M Noctrix Health acquisition (June 1, 2026, 10-K) at a 'preliminary' purchase price allocation creates intangible asset uncertainty and potential future goodwill impairment risk; (3) Restructuring charges of $21.7M in the nine months ended March 2026 (10-Q filed 2026-05-01) after $64.2M in FY2024 (10-K filed 2024-08-09) suggest recurring 'one-time' items. The MatrixCare divestiture removes a segment with recurring ROU asset impairments ($2.7M in each of two quarters per 10-Q filings), which is actually accounting hygiene, not a concern. AI disruption risk is moderate: ResMed's core CPAP/respiratory device moat rests on proprietary algorithms, clinician relationships, and regulatory clearances — AI could enhance remote monitoring (already a product feature) but is less likely to disintermediate the hardware/therapy loop than software-only businesses. The kill question: this becomes a short if (a) Astral recall costs escalate materially beyond the $45.7M currently accrued, triggering a guidance reset and cash drain, (b) GLP-1 weight-loss drugs structurally reduce OSA prevalence and device demand at a faster-than-expected pace, or (c) a major restatement or fraud emerges in the Noctrix or other acquisition accounting. None of these are evidenced in the current fact base; the business is generating real cash in excess of reported earnings.

11

Joel Greenblatt Value

watch · 62

ResMed is a high-quality business that scores well on the ROIC axis of the Magic Formula but looks only moderately cheap on the earnings yield axis. Let me work through both inputs rigorously from the fact base.

ROIC (quality axis): Using Greenblatt's preferred denominator of net working capital + net fixed assets. From the 10-K filed 2026-08-13 (period 2026-06-30): current assets = $4,324.7M, current liabilities = $1,395.1M, net working capital = ~$2,929.6M. Net fixed assets (PP&E net) can be estimated from 10-Q filed 2026-05-01 (March 31, 2026 figure of $567M net PP&E) as a proxy — the annual filing excerpt does not give us a standalone net PP&E figure, but the Q3 10-Q shows net PP&E of ~$567M. Adding NWC (~$2,930M) + net PP&E (~$567M) = ~$3,497M tangible capital employed. EBIT (operating income) from fundamentals = $1,886.7M for FY2026. Greenblatt ROIC = $1,887M / $3,497M ≈ 54%. This is exceptional — a genuinely high-quality business. The reported ROIC from fundamentals (21.3%) is lower because it uses a broader equity-based denominator; on tangible capital the returns are far superior. The 33.4% operating margin (10-K filing) and FCF margin of ~29% (fundamentals) confirm real, repeatable cash earnings. Importantly, EBIT converts cleanly to FCF: operating cash flow of $1,806M vs. EBIT of $1,887M is tight, with minimal accrual inflation.

Earnings Yield (cheapness axis): EV = market cap + total debt - excess cash. Market cap = $32,940M. Total debt from 10-K: short-term debt $260M + long-term debt $399.4M = ~$659.4M. Cash = $1,469.2M. EV = $32,940 + $659 - $1,469 = ~$32,130M. EBIT = $1,887M. Earnings yield = $1,887 / $32,130 = 5.87%. This is mediocre — not the 'cheap' half of the Magic Formula. On a pure Greenblatt ranking, 5.9% EBIT/EV would sit in the middling range for the universe, not the top decile. The stock is trading at roughly 17x EV/EBIT, which for a high-quality compounder is fair-to-full, not bargain-priced.

Special Situation Catalyst: The MatrixCare divestiture (announced July 2026 per narrative) and the subsequent accelerated buyback (8-K filed 2026-09-01) are genuine special-situation elements Greenblatt would notice. Portfolio simplification + capital return via buyback when the stock is 20% off its 52-week high ($284.87 per price data vs. $228.35 current) is a real catalyst. However, the sale price of MatrixCare is not disclosed in the fact base, so the magnitude of capital return is uncertain.

Red Flags: (1) The earnings yield is not compelling — this is more 'good business at fair price' than 'good business at bargain price.' (2) The Astral ventilator field safety notification (accrued $45.7M at June 30, 2026 per 10-K vs. $4.8M prior year) is a meaningful charge and represents execution/product risk. (3) FY2027 guidance reportedly disappointed (narrative); the guidance miss and ventilator recall headwind could weigh on near-term EBIT, making current earnings yield even thinner if EBIT normalizes lower. (4) Insider selling noted (CEO sold ~$1M per narrative) — modest but directionally negative. (5) The Noctrix acquisition for $335M (10-K, June 1, 2026 close) is small but adds integration noise. (6) Restructuring charges of $21.7M in nine months ended March 2026 (10-Q filed 2026-05-01) and prior year's $64.2M restructuring suggest ongoing operational flux in Residential Care Software.

AI/Disruption Assessment: ResMed's core CPAP/respiratory device business has a meaningful data moat — AirView cloud platform connecting 10M+ patients creates switching costs and regulatory stickiness. AI-enhanced diagnostics and adherence monitoring could extend rather than erode the moat. However, GLP-1 weight-loss drugs reducing OSA prevalence is a real structural risk to the addressable market over a 5-10 year horizon — this is not directly quantified in the fact base but is a known overhang. AI does not appear to directly commoditize ResMed's hardware/software integration at this stage.

Magic Formula Summary: ROIC ~54% (exceptional, top decile). EBIT/EV ~5.9% (middling, not cheap). Combined ranking: one excellent axis, one mediocre axis. Greenblatt's formula requires both — this is not a clear pass. The special-situation element (MatrixCare sale + buyback) nudges the score upward from a pure formula perspective, but the unknown sale proceeds and ventilator headwinds limit conviction. Score: 62 — watch, not a clear buy.

12

Bruce Greenwald Value

watch · 62

ResMed presents a classic franchise-quality business that clears most Greenwald moat tests, but the market price requires meaningful growth credit that must be scrutinized against the EPV anchor.

EPV Calculation (normalized): Using the 10-K filed 2026-08-13: GAAP operating income FY2026 was $1,886,715,000 on revenue of $5,653,443,000 (33.4% operating margin). To normalize, I must strip genuine one-offs but be conservative: the 10-K excerpt shows field safety notification expenses (Astral recall, masks-with-magnets) accrued at $45.7M at June 30, 2026 vs. $4.8M prior year — a ~$41M incremental charge that is non-recurring in nature. Acquisition/portfolio expenses were $11.5M. Restructuring in FY2026 is referenced in the Q3 10-Q (nine months ended March 31, 2026 had $21.7M of restructuring charges). Adding these back conservatively: normalized EBIT ≈ $1,887M + $45M (field safety accrual increment) + $11.5M (acquisition) + ~$22M (restructuring) ≈ $1,966M. Applying a normalized 21% tax rate (approximated from net income $1,523M / pre-tax income $1,919M from 10-K excerpt ≈ 20.6%) yields NOPAT ≈ $1,563M. The 10-K notes depreciation of $103M and capex of $156M (fundamentals block). Maintenance capex is likely closer to $103M (matching D&A), so add back excess D&A of ~$0 (or a modest ~$50M if roughly half capex is maintenance vs. growth). Distributable earnings ≈ $1,563M + $50M excess = ~$1,613M. At WACC of 8.12% (from the valuation block), EPV ≈ $1,613M / 0.0812 ≈ $19.9B enterprise value. Adding net cash of ~$1.07B (valuation block: net debt = -$1,070M) yields equity EPV ≈ $20.97B, divided by 144.25M shares ≈ EPV per share ~$145. This compares to a current price of $228.35 — market price is ~57% above my EPV estimate. That gap is real and substantial.

Asset Reproduction Value: Tangible assets: PP&E net ~$566M (Q3 10-Q), inventories ~$912M, current assets $4,325M less cash $1,469M ≈ $2,856M non-cash working capital area; total equity $6,585M per fundamentals. Goodwill and intangibles from the balance sheet are substantial but not fully quantified in the excerpts. Total assets $8,966M less total liabilities $2,381M = $6,585M book equity. A competitor would need to reproduce not just the physical plant but: (1) ResMed's 30+ year installed base of CPAP devices in patients' homes with data connectivity — its AirView platform reportedly connects millions of patients (fact base narrative references OSA market and data connectivity moat, though no specific subscriber count is in the filings); (2) physician prescription relationships and insurer reimbursement approvals globally; (3) the regulatory clearances across 140+ markets. Reproducing this from scratch would take a decade and billions in R&D, regulatory filings, and go-to-market spend. I estimate reproduction value conservatively at $10–12B, well below EPV of ~$21B. EPV >> reproduction value — this is a genuine franchise. The moat test passes clearly.

Moat Assessment: The moat rests on three Greenwald-approved pillars: (1) Customer captivity via habit — CPAP therapy requires machine-specific masks and accessories; once a patient is established on a ResMed device with AirSense/AirView data, switching imposes real clinical and logistical friction; (2) Economies of scale within a concentrated niche — the 10-K reports two segments (Sleep and Breathing Health; Residential Care Software), with D&A of $112M in Sleep segment alone, suggesting scale investments competitors cannot easily match; (3) Regulatory/IP moat — patent portfolio and FDA/international clearances represent years of accumulated approval. These are real, not vague brand claims.

Why Not a Full Pass: The price of $228.35 is ~57% above my conservative EPV of ~$145. To justify the current price, the market is embedding substantial growth value. The DCF in the valuation block uses 10.2% FCF growth and a terminal growth of 2.5%, arriving at $297.54/share — but 79% of that value sits in the terminal value (noted in the valuation block: residual_value_pct = 0.791). Per my framework, this is exactly the kind of long-horizon, terminal-value-heavy DCF I distrust. The franchise IS real, so growth inside it does create value — but the FY2027 guidance miss (narrative: 'Astral-driven guidance miss') and ventilator recall headwinds create near-term earnings uncertainty. The field safety accrual jumped from $4.8M to $45.7M for 'Astral' issues alone (10-K, June 30, 2026 accrued expenses). If recall costs escalate or linger, normalized earnings power could be impaired beyond my adjustment. Additionally, the Noctrix acquisition ($335M, June 1, 2026 per 10-K) adds integration risk and modest growth-capex pressure. Insider selling (CEO ~$1M, director sale per narrative) is a minor caution. The MatrixCare divestiture simplifies the business (a positive) but removes one revenue stream.

AI/Disruption Assessment: AI is a net positive for ResMed's franchise over a 3–10 year horizon. The AirView connected-device platform generates proprietary patient-level sleep data that would be extremely difficult to replicate. AI-driven diagnostics and therapy optimization (remote patient monitoring) are likely to deepen customer captivity, not erode it — the data moat compounds. The risk is that AI-powered virtual sleep clinics or wearable alternatives (Noctrix acquisition targets this, suggesting management is aware) could modestly disintermediate traditional CPAP channels. Net assessment: AI strengthens the franchise more than it threatens it, but does not alter the EPV math materially in the near term.

Margin of Safety: At $228, there is NO margin of safety to EPV (~$145). There IS a margin of safety if one credits the franchise's growth at moderate rates — at $228, the market roughly prices in ~5–7% annual earnings growth indefinitely, which is plausible but not certain. For a Greenwald-style value investor, the entry price should be at or below EPV (~$145) for a high-confidence position, or between EPV and a conservatively grown franchise value for a watch posture. Current price is in the 'watch zone' — franchise confirmed, but price already embeds the franchise premium without much safety buffer.

13

Howard Marks Risk

watch · 58

ResMed sits in an interesting middle ground for a Marks-style risk/value assessment. The stock has declined ~30% from its 52-week high of $284.87 to the current $228.35, and the DCF (10-K filed 2026-08-13 and valuation block) suggests a base intrinsic value of ~$297.54, implying roughly 30% upside — a meaningful but not extreme discount. The bear DCF scenario of $233 is only modestly above the current price, which tells me the downside cushion is thin if the bear case materializes. The bull case at $390 requires compounding ~10% FCF growth for years — plausible but not assured given the Astral ventilator recall headwinds and FY2027 guidance disappointment noted in the narrative. On capital structure, ResMed is genuinely low-leverage: long-term debt of ~$399M against $1.47B cash (per 10-K filed 2026-08-13 fundamentals), net cash positive by ~$1.07B, debt-to-equity of 0.06. Interest coverage is not a risk. FCF generation is real — $1.65B in FY2026 (10-K), up from $216M in FY2022, with FCF margins expanding from 6% to 29%. This is a fortress balance sheet that earns high marks on survivability. The risk-of-permanent-loss is genuinely low given the balance sheet and cash generation. However, my framework asks not just about quality but about what is PRICED IN. At a P/E of 21.6x and price-to-FCF of ~20x, the market is not pricing in catastrophe — this is not a deep-value, distressed or out-of-favor situation where the crowd has abandoned the name in panic. The stock is down from a peak, yes, but it remains a $33B market cap medical device leader trading at premium multiples on any absolute basis. The PEG of 2.12 suggests growth expectations remain embedded at a meaningful level. The DCF terminal value represents 79.1% of enterprise value — a warning that most of the value depends on a long-duration earnings stream that requires sustained execution. Near-term headwinds are real: the Astral field safety notification expenses jumped from $4.8M accrued at June 30, 2025 to $45.7M at June 30, 2026 (per 10-K accrued expenses table), signaling a material cost event. FY2027 guidance disappointed. Analyst downgrades (RBC, per narrative) and insider selling by the CEO (~$1M, per narrative) are soft negative signals. The MatrixCare divestiture redirects capital to buybacks rather than growth — defensible but not a signal of abundant organic opportunity. The contrarian case has some validity: institutional accumulation (HSBC, Legal & General, Deutsche Bank, etc., per narrative) suggests sophisticated buyers see value at these levels, and the sentiment has clearly cooled from the peak. But I do not see the revulsion, forced selling, or genuine despair that characterizes the most compelling contrarian entries in my framework. This feels more like a modestly cheap, high-quality business than a deeply mispriced, feared asset. The asymmetry is OK but not exceptional — downside is protected by the balance sheet (the bear DCF is ~$233, barely below today's price), upside to base is ~30%, bull is ~70%. That is a 2:1 skew at best. For my framework, I want wider margins. The ventilator recall uncertainty is the key variable I cannot fully assess: the Astral accrual surge is meaningful, the narrative references ongoing guidance headwinds, but the financial impact magnitude and duration are opaque. That is an unresolved downside risk. On AI disruption: ResMed's moat is in connected device ecosystems, proprietary algorithms for sleep therapy titration, and reimbursement relationships — AI could modestly strengthen their remote monitoring/data analytics capabilities (AirSense ecosystem), but also could enable competitive disruption in diagnosis over a 5-10 year horizon. Not an immediate material threat, but a watch item. Net: A quality business with a clean balance sheet trading at a modest discount to DCF — but not cheap enough, nor feared enough, to clear my threshold for a conviction pass. The bear scenario offers little cushion. Watch and wait for either a deeper discount or resolution of the recall/guidance uncertainty.

14

Peter Lynch Growth

watch · 55

ResMed is a classic stalwart — a large-cap medical device leader in CPAP/sleep therapy with a durable moat, steady double-digit revenue growth (~10% CAGR per 10-K filings), and exceptional cash generation. But as Lynch would frame it: the story is easy to tell (they make machines that help people breathe while they sleep, doctors prescribe them, insurers pay for them, and the installed base generates recurring mask/accessory revenue), yet the valuation is not cheap enough to call a clear buy. The PEG of 2.12 (per fundamentals block) is well above my 1.0 ceiling and even above the 'expensive' 2.0 threshold. Revenue CAGR is 10.2% (3-year, per fundamentals), and while the DCF model projects 10.2% FCF growth, recent EPS growth has been more solid — net income growing from $897M (FY2023) to $1,523M (FY2026, per history block) represents a ~19% CAGR over 3 years — but that pace is partly normalization from COVID supply disruptions and may not sustain. At P/E of 21.6x on what is fundamentally a stalwart growing 10-12%, the Lynch framework says you should pay roughly 10-12x for a stalwart and sell at 30-50% appreciation — not initiate at 21x. The balance sheet is genuinely excellent: debt-to-equity of 0.06, net cash position ($1.47B cash vs. $399M long-term debt per 10-K filed 2026-08-13, plus short-term debt of $260M), ROIC of 21.3%, FCF margin of 29.2% — this is a beautifully run business. The Noctrix acquisition ($335M, June 1, 2026, per 10-K) is small relative to the balance sheet and on-strategy (wearable sleep therapeutics), so no diworsification flag. The MatrixCare divestiture actually reverses prior diworsification. Inventories are flat-to-down year-on-year (10-Q: $911M Mar-2026 vs. $927M Jun-2025) — clean. But three things hold me back from a pass: (1) PEG of 2.12 is simply too high for my discipline regardless of business quality; (2) FY2027 guidance disappointed the market (narrative digest) with ventilator recall headwinds (Astral field safety notification accruals jumped to $45.7M from $4.8M per 10-K Note 7) — this is a real earnings drag; (3) the stock, while down 20% from peak, is not yet at the 'neglected' low-multiple level Lynch loves. The DCF at $297 (30% upside) is encouraging and the bear case at $233 barely covers current price, suggesting limited downside but also limited margin of safety on Lynch's own terms. I'd watch for a further de-rating toward 15-17x earnings before initiating. AI risk is modest-to-positive here: ResMed's cloud-connected devices and AirSense ecosystem generate proprietary sleep-data moats that AI could enhance rather than disrupt; no AI commoditization risk to the hardware/therapy model in a 3-5 year window.

15

Stanley Druckenmiller Risk

watch · 52

RMD presents a genuinely mixed picture through my forward-looking, momentum-and-liquidity lens. The fundamentals are unambiguously strong in a trailing sense — $5.65B revenue, 33.4% operating margin, $1.65B FCF, near-zero net debt — but my framework rewards the DIRECTION of change, not the level, and that is where the tension lies. On the bullish side: FCF inflected dramatically from $216M in FY2022 to $1.65B in FY2026 (10-K filed 2026-08-13), margins expanded materially, and the balance sheet is pristine (LT debt $399M vs. cash $1.47B per FY2026 10-K). The DCF pegs intrinsic value at $297.54 vs. $228.35 current price — a 30% margin of safety. The OSA addressable market is large and underpenetrated. Institutional accumulation (HSBC, Legal & General, Deutsche Bank per the narrative) post-selloff suggests smart money sees value. AGAINST the thesis, however, are the signals I care about most: (1) The TAPE IS BAD — stock is down 19.8% from its 52-week high and down roughly 15% over the past year; price action is distribution, not accumulation. I do not fight a broken chart. (2) FY2027 guidance DISAPPOINTED — the narrative cites an 'Astral-driven guidance miss.' Negative forward estimate revisions and a guidance miss are exactly the second-derivative-turning-down signal I most fear. The rate of change in earnings growth is decelerating: net income grew 31% FY2024-to-FY2025, then only 8.7% FY2025-to-FY2026 (per fundamentals history). FCF also effectively flat year-over-year ($1.662B FY2025 vs. $1.650B FY2026 per fundamentals). (3) CATALYST IS UNCLEAR OR NEGATIVE — the near-term driver is a ventilator recall and operational headwind, not a positive inflection. The MatrixCare divestiture is capital-return-oriented (buyback) but signals limited high-ROI reinvestment opportunities, not a growth acceleration. (4) The $260M in short-term debt now sitting on balance sheet (FY2026 10-K note 8, up from $10M at FY2025) alongside field safety notification accruals jumping to $45.7M from $4.8M (FY2026 10-K accrued expenses note 7) are near-term financial headwinds. CEO insider selling (~$1M Aug 11, 2026 per narrative) is not disqualifying but directionally unhelpful. The setup lacks the asymmetric, catalyst-confirmed entry I require. This is not a 'put all your eggs in the basket' moment — the tape says wait. I would watch for a guidance revision upward, chart base formation and breakout above the 50/200-day, and resolution of the Astral recall liability before sizing up. The intrinsic value gap is real, but value alone is not my framework — I need the earnings trajectory to re-inflect AND the tape to confirm before concentrating.

16

Benjamin Graham Value

watch · 52

ResMed is a profitable, well-established, dividend-paying medical device company with a decade of uninterrupted earnings growth — these qualities Benjamin Graham would recognise and respect. However, applying Graham's quantitative value tests rigorously reveals that the stock does not clear the margin-of-safety bar with comfortable room to spare, and several key ratio tests fall short of his conservative thresholds.

EARNINGS STABILITY: Clearly satisfactory. The fundamentals history (Edgar companyfacts) shows net income rising every year from $779M (FY2022) to $1,523M (FY2026), and operating cash flow of $1.81B in FY2026. No losses in the disclosed period. The 3-year revenue CAGR is ~10.2%. Graham would approve of the earnings record.

P/E RATIO: At 21.6x trailing GAAP earnings (price $228.35 / EPS implied ~$10.56), this exceeds Graham's defensive investor ceiling of 15x. It is a meaningful overpayment by his standards. The earnings yield is 5.9%, which exceeds current high-grade bond yields modestly, providing some relative justification, but Graham's absolute 15x cap is not met.

P/B RATIO: At 5.0x book (stated in fundamentals block), this is elevated. Graham's combined P/E × P/B test: 21.6 × 5.0 = 108, versus the 22.5 ceiling he set for defensive investors. This fails badly — implying the stock is pricing in substantial growth that has not yet been demonstrated on an asset-value basis.

NET-NET TEST: Net current assets = current assets $4,325M minus ALL liabilities $2,381M = approximately $1,944M. Divided by 144.25M shares = ~$13.48/share. Price at $228.35 is roughly 17x net current asset value. This is not a net-net situation by any definition.

BALANCE SHEET: Current ratio of 3.1 — Graham's 2.0 minimum is met comfortably. Long-term debt of $399M (10-K 2026-08-13) versus working capital (current assets $4,325M minus current liabilities $1,395M) = $2,930M working capital. LT debt is well below working capital — a criterion Graham explicitly required, and here it passes easily. Total liabilities $2,381M versus current assets $4,325M — current assets exceed total liabilities by a factor of ~1.8x, close to but not quite meeting the 2x standard Graham preferred.

DIVIDEND: Dividend is paid and was increased (per narrative, Q4 FY2026 announcement). The filing history supports an ongoing program. Graham's dividend continuity test is met.

MARGIN OF SAFETY vs DCF: The two-stage DCF puts intrinsic value at ~$297.54/share (base case), with a bear-case of $233. At $228.35, the stock is marginally below the bear-case DCF, which technically implies a sliver of margin of safety. However, Graham was deeply skeptical of DCF-derived intrinsic values — he preferred asset-anchored or earnings-power-based estimates. The DCF relies on a 10.2% FCF growth rate sustained for 5 years then 2.5% terminal growth; Graham would note the terminal value constitutes 79.1% of enterprise value (flagged in valuation block), making this calculation highly sensitive to assumptions he would distrust. By his earnings-power framework, capitalising FY2026 net income of $1.52B at a conservative 12-15x yields $10.5B–$12.8B equity value, or ~$73–$89/share — far below the current price. Even at 15x P/E the 'Graham value' is roughly $158/share, still well below $228.

FIELD SAFETY / RECALL RISK: The 10-K (2026-08-13) discloses accrued field safety notification expenses of $45.7M at June 30, 2026, versus only $4.8M a year earlier — a nearly 10x increase. The narrative references ventilator recall headwinds and an FY2027 guidance miss attributed in part to Astral device issues. Graham would flag this as a near-term earnings-quality concern.

INSIDER BEHAVIOUR: CEO sold ~$1M of stock (narrative, Aug 11, 2026); a director planned additional sales. Not alarming in isolation, but directionally concerning when combined with guidance disappointment.

AI / DISRUPTION: ResMed's core moat — proprietary CPAP/BiPAP hardware, mask ecosystem, and myAir cloud data platform — faces a nuanced AI threat. AI could improve diagnostic workflows (potentially expanding the addressable market for sleep testing), but could also enable lower-cost entrants to replicate device intelligence. The company's software segment (Residential Care Software, being partly divested via MatrixCare sale) shows some strategic flux. Through Graham's lens, technological disruption risk is a qualitative concern but not a near-term earnings impairment; the durable medical device nature of the core business provides some insulation. Not a decisive factor for this lens.

SUMMARY: ResMed is a high-quality, financially sound business — but quality businesses are not automatically bargain purchases. By Graham's hard quantitative standards (P/E <15, P/E×P/B <22.5, price approaching net asset value), RMD fails materially. The balance sheet is strong (current ratio 3.1, LT debt dwarfed by working capital), earnings are stable and growing, and dividends are paid — these are genuine virtues. But the pricing leaves essentially no margin of safety by Graham's asset-based or earnings-multiple standards. A 'watch' rather than 'pass' reflects the quality of the underlying business that would make it interesting at a substantially lower price, while 'avoid' would be too harsh given the financial integrity.

17

Seth Klarman Value

watch · 52

ResMed is a high-quality medical device franchise with genuinely strong cash generation, but it does not meet the Klarman margin-of-safety standard as a clear buy. The two-stage DCF from the fact base yields an intrinsic value of ~$297/share, implying roughly 30% upside at the $228 current price — a meaningful but not deep discount. The bear-case DCF sensitivity is $233, barely above today's price. That means the downside case provides essentially zero cushion: if the bear scenario materializes (ventilator recall headwinds, FY2027 guidance miss, slower OSA growth), you are paying approximately fair value or worse. Klarman's first principle demands a deliberate discount to a CONSERVATIVE estimate — not the base case. The bear case here offers no margin of safety whatsoever. On hard asset coverage: total assets of ~$8.97B vs. total liabilities of ~$2.38B gives a book equity of ~$6.59B, but goodwill and intangibles are substantial (customer relationships at $484M gross plus developed technology at $396M gross per the 10-Q filed 2026-05-01, plus acquisition premiums embedded in goodwill not fully extracted from available text). Tangible book is materially lower than stated equity — the 'asset floor' is soft, not hard. FCF quality is genuinely excellent: $1.65B FCF on $5.65B revenue (10-K filed 2026-08-13), FCF margin ~29%, operating cash flow $1.81B, capex only $156M, yielding a price-to-FCF of ~20x. Balance sheet is clean: long-term debt only $399M (10-K filed 2026-08-13), cash $1.47B, net cash position of ~$1.07B. Debt-to-equity of 0.06 is fortress-like — this is a genuine positive and removes balance sheet fragility from the red flag list. The catalyst picture is mixed: MatrixCare asset sale with proceeds directed to buybacks (narrative) is a real value-unlocking event, and institutional accumulation post-30% decline from peak ($284.87 high per price data) suggests some technical dislocation. However, this is not a classic Klarman special situation — it's a well-followed, liquid, large-cap S&P 500 component. There is no forced selling, distress, complexity discount, or orphaning that Klarman specifically seeks. The ventilator recall (Astral field safety notification accrual jumped from $4.8M to $45.7M at June 30, 2026 per the 10-K, a nearly 10x increase) is a concrete headwind that creates uncertainty but is not yet quantified in its full earnings impact — this is the most significant new risk in the filings. AI risk is meaningful but not immediate: AI-assisted sleep diagnostics and home monitoring could commoditize parts of ResMed's AirSense ecosystem over a 5-10 year horizon, though ResMed's data network (myAir platform, 15M+ connected devices implied by business model) could be a durable moat if integrated with AI rather than displaced by it. On balance, this is a Watch: the price has come off 20% from peak, FCF yield is acceptable (~5%), the balance sheet is excellent, and there is a nascent catalyst from the MatrixCare sale and buyback. But the margin of safety relative to a genuinely conservative (bear-case) intrinsic value is essentially absent. Klarman would wait for either a deeper price decline (closer to $180-190 where bear case offers real cushion) or greater clarity on the Astral recall financial impact before committing capital. Cash remains the more honest alternative here until the discount widens.

18

Paul Singer Value

watch · 52

ResMed is a high-quality, predominantly single-product-category medical device company with genuine operating excellence — 33% operating margins, ~29% FCF margins, ROIC of ~21% (per fundamentals block), and a nearly debt-free balance sheet (long-term debt $399M vs. $1.47B cash per 10-K filed 2026-08-13). This is not a classical Elliott target: it is not a sprawling conglomerate, the balance sheet is not hoarded or overleveraged, and the core Sleep and Breathing Health business appears well-run. However, the MatrixCare divestiture creates a specific, near-term, forceable self-help moment that is worth evaluating. The company has two segments — Sleep and Breathing Health and Residential Care Software. The narrative confirms the MatrixCare asset sale was announced July 8, 2026, with proceeds earmarked for an accelerated share buyback announced September 1, 2026. The Residential Care Software segment (which housed MatrixCare) has been a drag: the 10-K filings show repeated impairments of office-space right-of-use assets within that segment ($4M in FY2024, $2.7M in Q2 FY2026, $2.7M in Q1 FY2026 per the 10-Q filings), and restructuring charges of $21.7M in nine months ended March 2026 for workforce severance. The D&A for Residential Care Software was only $10.8M vs. $112M for Sleep and Breathing Health (10-K 2026-08-13), confirming it is a small, subscale segment. The divestiture is thus clearly value-enhancing and management is already executing it — the self-help gap is partially closed and actively being arbitraged by management itself, which reduces the activist opportunity. The capital allocation record is mixed but improving: ResMed spent ~$335M acquiring Noctrix Health on June 1, 2026 (10-K 2026-08-13), a medical device start-up developing wearable therapeutics in which ResMed previously held a 3% equity stake, immediately after completing the MatrixCare sale. This is a modest bolt-on, not a reckless acquisition spree. Historical FCF was very low in FY2022 ($216M) and has ramped dramatically to $1.65B in FY2026 (fundamentals history block), suggesting prior capital was tied up in working capital/supply-chain normalization rather than destroyed. The governance lever is weak: ResMed is a standard Delaware corporation with a conventional single-class share structure — no dual-class, no identified founding-family control. This means, in theory, a large holder could press for change. However, the board composition, proxy details, and specific director ownership figures are not available in this fact base, preventing a precise entrenchment assessment. The downside floor is solid: at $228/share, the company trades at ~20x price-to-FCF and ~21.6x P/E (fundamentals), with a DCF intrinsic value of $297.54/share (valuation block, base case) implying 30% upside, and a bear-case floor of $233 — nearly at current price. Net cash position ($1.47B cash vs. $659M total debt, implying net cash of ~$810M) provides a genuine floor. The ventilator (Astral) recall and guidance miss are the key near-term risks: the 10-K shows field safety notification expenses of $45.7M accrued at June 30, 2026 vs. $4.8M a year earlier (10-K 2026-08-13, accrued expenses table), confirming a material step-up in recall-related costs. The FY2027 guidance miss attributed to Astral issues (narrative) is a real operational drag with uncertain duration. AI risk: ResMed's core moat is regulatory clearance, clinical data, and the physician/insurer ecosystem for PAP therapy — not easily disintermediated by AI in a 3-10 year horizon. AI could modestly enhance its connected-device platform (AirSense data analytics) but is unlikely to commoditize the hardware/reimbursement moat. This is not a primary risk factor here. The specific activist call would be: (1) complete and accelerate MatrixCare exit, (2) commit to disciplined capital return (buyback + dividend funded by the $1.65B FCF run-rate), (3) avoid further software/diversification acquisitions that dilute the core Sleep franchise multiple, and (4) provide clear Astral recall containment timeline. Worth per share of completing the capital return program properly: roughly $25-40/share of incremental value from a sustained buyback at current prices. What proves it wrong: Astral recall costs metastasize beyond the $45.7M accrual, FY2027 revenue growth stalls materially, or management deploys MatrixCare proceeds into another dilutive software acquisition. The thesis is real but largely self-executing without activist pressure, reducing the premium for an event-driven entry.

19

Walter Schloss Value

avoid · 28

ResMed fails the Schloss deep-value test on almost every hard criterion. The anchor metric is price-to-tangible-book, and RMD trades at a severe premium to any reasonable tangible book figure. Total stockholders' equity per the 10-K filed 2026-08-13 is $6.585 billion against a market cap of ~$32.94 billion — that is already a price-to-book of roughly 5x on stated book. But stated book is itself heavily inflated by goodwill and acquired intangibles: the balance sheet shows total assets of $8.966B and total liabilities of $2.381B, yet the asset base includes substantial intangibles from acquisitions (customer relationships, developed technology, goodwill) that Schloss would strip out entirely because they are not independently appraisable hard assets. After removing intangibles and goodwill, tangible book value would be a fraction of stated equity, pushing the tangible price-to-book ratio well into double digits — far outside any Schloss comfort zone. The stock is also not at a multi-year low in the distressed sense Schloss required: it sits at $228.35, roughly 20% below the 52-week high of $284.87, and the 52-week low is $180.27 — this is a 30% decline off peak, not a true multi-year wipeout creating hard-asset bargains. The balance sheet quality is actually good on a leverage basis — long-term debt of only $399M against $1.469B cash (net cash positive per the valuation block: net debt of -$1.07B), so there is no balance-sheet distress. But that merely means the stock doesn't screen as a distressed asset play either — it is a high-quality compounder priced as such, not a Schloss-style statistical bargain. The business model is also heavily intangible-driven: medical devices, software (Residential Care Software segment), recurring SaaS revenues, acquired goodwill. Schloss explicitly avoided complexity and hard-to-appraise intangibles. The Noctrix acquisition (10-K, 2026-08-13: $335M acquisition June 1, 2026) adds further goodwill. Insider alignment is ambiguous at best — the narrative notes CEO sold ~$1M of stock August 11, 2026, and a director planned a sale September 2, 2026. There is no evidence of insider buying in the fact base. Dividends are being paid and increased, which is a partial positive, but Schloss required this as a sign of durability while waiting for a cheap asset base to be recognized — here there is no cheap asset base. The DCF intrinsic value of $297.54/share (30% upside at base case) is plausible as a growth/FCF story, but Schloss did not buy based on DCF projections — he bought hard assets at a discount. The business earns excellent returns (ROIC 21%, FCF margin 29%), which paradoxically means the market will never price it near tangible book. A Schloss name is cheap because it is earning poorly on its assets temporarily; RMD is expensive because it earns superbly and the market knows it.

Want this on a name you own?Send a ticker; we convene the full council on it.

Request Analysis →